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ABSTRACT 
Rubella virus (RUBV) is a significant human pathogen. RUBV infection takes an enormous toll 
due to congenital rubella syndrome (CRS), a constellation of birth defects including blindness, hearing 
defects and mental retardation. Little is known about RUBV-induced teratogenesis due to the absence of 
useful models. This research is now enabled by the availability of human embryonic stem cells (hESCs) 
and hESC-derived precursor cell lines. Human neural progenitor cells (hNPCs) serve as a particularly rel-
evant model due to the symptoms and complications of CRS related to neural system development. The 
overarching question addressed in this dissertation is: what is the mechanism underlying the development 
of neurological abnormalities seen in CRS? In this context, we investigated the cellular responses of 
hNPCs to RUBV infection comprehensively by: 1) assessing susceptibility of the cells to RUBV infection; 
2) analyzing the effect of infection on cell proliferation; and 3) examining  the impact of RUBV infection 
on differentiation of hNPCs into neuronal and astroglial lineages . We found that hNPCs are susceptible 
to RUBV infection and that the percentage of infected cells closely mimics CRS in which few cells har-
bor virus. The virus was able to persist in culture for up to one month without significant alteration of cell 
morphology and stemness marker expression. In addition, RUBV infection moderately attenuated the pro-
liferation of undifferentiated hNPCs by triggering cell cycle arrest, but not apoptosis or other cell death 
events commonly seen upon virus infection. This lack of apoptosis appeared to be due in part to virus-
induced anti-apoptotic suppression.  Interestingly, the virus only had a marginal effect on the induction of 
cell differentiation into both neuronal and astroglial phenotypes. In fact, RUBV infection promoted ter-
minal differentiation of the culture due to depletion of precursor cells. With differentiation, viral replica-
tion was suppressed. We thus propose a model for RUBV-induced neurological defects in which the virus 
acts by depleting precursor cell pools. The results of this study provide clues for elucidating the mecha-
nisms of RUBV teratogenicity at the cellular level and serves as a potential reference study for elucidating 
mechanisms of teratogenesis induced by other infectious agents. 
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CHAPTER 1 : GENERAL INTRODUCTION 
1.1 RUBELLA VIRUS CLASSIFICATION AND RELATED VIRUSES 
Rubella virus (RUBV) is the sole member of the genus Rubivirus in the family Togaviridae [1]. 
This family includes animal viruses with ribonucleic acid (RNA) genomes of positive-polarity (mRNA 
sense) of ~10,000 nt in length. Togaviruses have small round virions that consist of a quasispherical nu-
cleocapsid surrounded by a lipid bilayer envelope. All members of this family replicate in the host cell 
cytoplasm within a membranous replication complex (RC) derived from host structures and do not inte-
grate into the genome of the host.  
The other 26 members of the Togaviridae family, such as the well studied Sindbis virus (SINV), 
Semliki forest virus (SFV), Chikungunya virus (CHIKV), Venezuelan equine encephalitis virus (VEEV), 
and Ross River virus (RRV), all belong to the genus Alphavirus [2]. Alphaviruses are classified into Old 
World and New World viruses dependent on their geographical distribution. Diseases symptoms can 
range from rash and fever with Old World viruses to encephalitis with New World viruses. The alpha-
virus and rubivirus genera mainly differ in following two respects.  First, all alphaviruses are arthropod 
(mosquito)-borne and infect humans, mammals, and birds.  RUBV does not circulate through arthropods 
and humans are the only host.  Secondly, the alphavirus and rubivirus genera share no homology at either 
the nucleotide or amino acid level and exhibit no antigenic cross reactivity. However, due to the similari-
ties in their genomic coding strategies and replication cycles between the two genera of Togaviridae, im-
portant parallels may be drawn between RUBV and the alphaviruses. SINV, for example, causes rash and 
fever in humans but age-dependent encephalitis in mice, therefore serving as a model to study viral en-
cephalitis induced by viruses in the Togaviridae family [3, 4]. Another example is SFV, which  infects 
developing fetuses in mice and is used as a model to study viral teratogenic effects due to its broad tro-
pism [5]. However, unlike RUBV, which replicates slowly and asynchronously in host cells, most alpha-
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viruses replicate quickly and induce a lytic cycle. This has to be taken into consideration in  comparative 
virology studies. 
1.2 RUBELLA VIRUS STRUCTURE, LIFE CYCLE, AND CODING STRATEGY 
In electron micrographs rubella virions generally appear round with a mean diameter of 70 nm 
(Figure 1.1).The virion is surrounded by an envelope derived from  host lipid membranes. Embedded in 
this envelope are two viral glycoproteins, E1 (58 kDa) and E2 (44-52 kDa), which can be resolved as 
spikes on the surface of the envelope. The quasispherical   core inside the envelope is made up of the viral 
capsid protein, C (34 kDa), in the form of disulfide-linked homodimers. The viral RNA genome contained 
within the core is considered as an integral component of the core structure [6]. 
RUBV has a 5'-capped and 3'-poly (A)-tailed RNA genome of almost 10 kb in length. The genome 
has a G+C content of 69%, which is among the highest of all of the RNA viruses identified to date. The 
genome is comprised of two polycistronic open reading frames (ORFs) separated by a nontranslated re-
gion [7]. The 5' ORF encodes two nonstructural replicase proteins, P150 and P90, which are proteolytical-
ly processed from one precursor called P200. The 3' ORF encodes three proteins, E1, E2 and C, that form 
the virion structure and are similarly processed from a single precursor, but translated from  a subgenomic 
RNA that consists of sequences from the 3' terminal third of the genome RNA (Figure 1.2) [8].    
The RUBV life cycle begins with the attachment of the virion to the host cell; this process is  rapid  
with adhesion occurring anywhere from 30 minutes to 3 hours post-infection [9]. The only known RUBV 
receptor is myelin oligodendrocyte glycoprotein (MOG) [10]. Next, the virus enters the cell through low 
pH-mediated endocytosis.  Release of the viral genetic material into the cytoplasm is thought to be trig-
gered by low pH-mediated conformational changes to the viral glycoproteins that allow the fusion of the 
viral and endosomal membranes. Once the RUBV genetic material has been released, replication of the 
genome begins. During viral replication, the genomic RNA serves as the mRNA for the nonstructural pro-
tein precursor and as the template for the synthesis of a full-length negative-polarity RNA strand. The 
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minus strand in turns acts as the template for the transcription of both the genomic and subgenomic RNAs, 
with the subgenomic RNA serving as the mRNA for the translation of structural proteins. The replication 
process was thought to take place in replication complexes (RCs), vacuoles which form on the surface of 
viral-modified endosomes and lysosomes. The converted organelles, known as “cytopathic vacuoles”, 
recruit other cellular structures such as the rough endoplasmic reticulum (RER), Golgi, and mitochondria 
to the site of replication, thus providing the RCs with all the energy, ribosomes, and protein processing 
required for successful replication [11]. Following the replication of the genome RNA and synthesis of 
the structural proteins, the RNA and capsid protein coalesce to form capsids.  Following this encapsida-
tion process, de novo virions are formed by budding of the capsid through membranes of the Golgi in 
which the glycoproteins have accumulated. Virions are eventually released from the cell via the exocytot-
ic pathway (Figure 1.3). 
In terms of kinetics, both the genomic and subgenomic RNA are detectable at the end of the viral 
latent period of 12-24 hours, with the viral structural proteins appearing 4 hours later. Peak virus produc-
tion usually occurs during the period from 36 to 48 hours post infection (h.p.i) in permissive cell lines 
such as Vero and BHK/21. Infection of culture cells is asynchronous (meaning that the cells in the culture 
do not become infected at the same time), even when high multiplicities of infection (MOIs) are used, and 
relatively noncytopathic [12]. 
As noted above, SINV shares a similar virus life cycle with RUBV. The viral 11.7 kb RNA ge-
nome serves as an mRNA for the nonstructural polyproteins P123 and P1234. The structural proteins, 
capsid, E1, and E2 are translated from a subgenomic RNA. E2 is synthesized as a precursor, pE2 that is 
cleaved to E2 and E3 late in replication to produce the mature E2 necessary for virions to be infectious. 
Heterodimers of E1 and E2 trimerize to form the spikes of the mature virion.  Virion formation is by  
budding of the capsid through the cytoplasmic  membrane [13].  In contrast to RUBV, SINV replication is 
rapid (completed within 24 hours in permissive cell lines), high titer (100 X titers achieved by RUBV), 
and lytic in nature. 
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1.3 RUBELLA: A BRIEF OVERVIEW 
RUBV is the causative agent of the disease rubella. The disease was initially recognized by two 
German physicians, Bergen and Orlow in 1752 and 1758, respectively [14]. It was not until 1866 that the 
then “German Measles” was termed rubella by Scottish physician Veale, who further elaborated on its 
clinical characteristics [15]. The cornerstone for rubella as a disease of significance, rather than a benign 
illness, was the discovery of its role in causing congenital birth defects. This was achieved in 1940 by 
Australian ophthalmologist Norman Gregg, who observed that there was resounding evidence of  preg-
nant mothers with rubella transmitting congenital defects to her offspring, including cataracts, deafness, 
small size, low birth weight, and heart defects [16]. The term congenital rubella syndrome (CRS) was 
given to describe the collection of birth defects caused by RUBV. 
Rubella is endemic worldwide, with regular seasonal peaks occurring in the spring months in tem-
perate climates. Before the introduction of vaccine, epidemics of rubella occurred at the interval of 6 to 9 
years in the United States.  Rubella and CRS became nationally notifiable disease in 1966. The largest 
annual total of cases of rubella in US was in 1969, when 57,686 cases were reported. Following vaccine 
licensure in 1969, rubella incidence declined rapidly in the United States and the reported cases since the 
1990s are mostly among the foreign-born and unvaccinated Hispanics and Latin Americans, with  elimi-
nation of indigenous rubella in the United States achieved in 2004 [17-19]. However, given that there is 
no treatment for CRS, rubella is still a major concern in most developing countries where vaccination is 
rarely provided [20, 21]. 
Rubella vaccination is accomplished by parenteral injection of live attenuated rubella strains grown 
in human diploid fibroblast cells [22]. The first rubella vaccine was the HPV-77 strain, licensed in 1969, 
seven years after the isolation of the virus [23].  Today, with the exception of Japan, the vaccine in use is 
the RA 27/3 virus [24], which was attenuated and produced in cultures of fetal human diploid fibroblast 
cells  during the early 1960s in the Stanley Plotkin laboratory [25]. The immunogenicity of the RA 27/3 
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virus is high, leading to seroconversion in close to 100% of vaccinees [26]. It is important to note that RA 
27/3 is available in combination with measles, mumps and  varicella vaccines  .The current vaccination 
strategy utilizes the measles-mumps-rubella (MMR) vaccine with one dose at 12-15 months of age and a 
second at 5-10 years of age [27]. However, despite  vaccination programs it is believed that 10% to 20% 
of post pubescent individuals are still susceptible to rubella in developed countries and up to 68% are sus-
ceptible in developing countries, allowing for the continued transmission of RUBV  among women of  
reproductive age , the group at risk [28-30]. The addition of the rubella vaccine to their 2008 initiatives  
by the Global Alliance for Vaccines and Immunization (GAVI) further emphasized rubella and  CRS as 
major public health issues worldwide and further asserts the importance of the study of this virus [31].  
1.4 RUBELLA: THE DISEASE 
1.4.1 Acute infection 
RUBV  is transmitted by the respiratory route, resulting in mild disease (acute or acquired rubella) 
that typically exhibits  in symptoms such as  rash, low-grade fever, lymphadenopathy, and conjunctivitis 
[29]. The disease has a general incubation period of 12 to 22 days before the onset of rash. The virus rep-
licates first in the nasopharynx and then in regional lymph nodes, resulting in viremia 7 days before the 
rash. A second round of viremia is thought to be generated from virus replication in target organs such as 
the spleen and distant lymph nodes [32]. Immune responses such as generation of neutralizing antibodies, 
cessation of viremia, and appearance of transformed lymphocytes can be seen 2 to 3 days after the onset 
of rash [33]. The end of the disease state occurs with the resolution of the rash. Complications of rubella 
such as arthralgia, thrombocytopenia, encephalopathy, and hemorrhagic manifestations are not common, 
but occur more often in adults than in children [34, 35]. The most devastating effect of RUBV infection is 
CRS, which is caused by the infection of the placenta and fetus during viremia.  
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1.4.2 Congenital Rubella Syndrome 
While infection with RUBV only causes mild disease when contracted postnatally, it can cause se-
vere birth defects in a developing fetus during pregnancy. The term congenital rubella syndrome (CRS) is 
defined by South and Sever to denote any combination of the complications  known to result from gesta-
tional rubella [36]. 
The range of defects, before and after birth, caused by RUBV  infection has been well documented 
and they almost exclusively result from infection in the first trimester [37].The main defects associated 
with CRS are deafness, cataracts, cardiovascular defects, particularly patent ductus arteriosus, and CNS 
damage including  to mental retardation. Neonatal manifestations that result from infection include a wide 
range of transient symptoms, but growth retardation and failure to thrive are the most severe. Postnatal 
defects, which were found by monitoring of CRS survivors for up to 50 years, include  insulin-dependent 
diabetes, thyroid dysfunction, and a rare neurodegenerative disorder- progressive-rubella panencephalitis 
(or PRP) [38, 39]. The incidence of above mentioned defects  are: intrauterine growth retardation such as 
microcephaly (62%), cardiac disease (52%), deafness (48%), cartaracts (18%), and mental deficiency (5%) 
[33].Despite the difference in the frequency of each type of defect, two common features of CRS fetuses 
are reduced size of affected organs and angiopathy of early placental and embryonic tissues. Microscopic 
analysis of aborted RUBV infected fetuses revealed cellular damage in multiple sites, with non-
inflammatory necrosis being common in the eyes, heart, brain, and ears [40, 41]. 
The two most important features of CRS from a virological point of view are as follows. First, the 
efficiency of fetal infection and degree of severity of CRS symptoms are most pronounced when infection 
occurs during early pregnancy. During the first trimester of pregnancy, the rate of fetal infection ap-
proaches 80% and most of the infants exhibit symptoms. The risk of fetal infection and the severity of 
congenital abnormalities decreases after first trimester; after 17 weeks gestation the risk of developing 
any defects is low (25-35%)[9, 42-44]. This is partially due to changes in the placenta during second tri-
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mester which allows sufficient transfer of maternal RUBV-specific IgG antibodies to the fetus [41]. 
Meanwhile, fetal IgG as well as alpha-interferon (IFN) is readily detectable in the sera of midgestational 
RUBV- infected fetuses, implying that fetus starts producing its own immune responses after the first tri-
mester to combat RUBV infection [45, 46]. The second important feature is the persistence of RUBV in 
CRS patients, making congenital rubella a contagious disease. Children born after exposure to RUBV  in 
utero continue to shed virus in the nasopharynx and urine for months after birth and the virus has been 
shown to persist in human tissues for several years [47]. In one case, RUBV  was cultured from cataract 
material as late as three years after birth [48]. In vitro study of RUBV  carrier cultures derived from con-
genitally infected abortuses  also demonstrated recovery of the virus in most organs including brain, 
which rarely can be infected due to the presence of blood-brain barrier [49]. Serological testing has 
demonstrated persistence of RUBV antibody in congenitally infected patients and many have elevated 
titers for over twenty years [50, 51]. Therefore, the persistence of RUBV infection may play a significant 
role in the development of late onset manifestations of CRS [52]. 
Currently there is no cure for CRS.  RUBV has long been recognized as teratogen [53] and fur-
thermore was among the initial  group of infectious teratogen that were categorized as  TORCH agents 
(toxoplasmosis, other virus such as varicella zoster virus and syphillis, rubella, cytomegalovirus, and her-
pes simplex virus)  a medical acronym for a set of perinatal infections that lead to severe fetal anomalies 
and even fetal death [54, 55]. Of these, RUBV was the most efficient in terms of incidence of defects fol-
lowing maternal infection.  Early on, RUBV was  one of the best model systems to study viral teratogene-
sis due to sufficient numbers of aborted CRS fetal specimens and such studies  date back to early 
1940s[56].  However, with the decline of the disease after institution of vaccination programs ~1970, such 
studies ceased. Despite the elimination or near elimination of rubella and CRS in developed countries, the 
fact that the incidence of CRS remains very high in developing countries emphasizes the continued im-
portance of the study of RUBV-induced teratogenicity.  Additionally, there are likely common mecha-
nisms that RUBV shares with other teratogenic agents..  
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1.4.3 Teratogenesis of rubella: mechanistic studies 
Following congenital RUBV infection, the explicit pathways leading to teratogenesis remain to be 
elucidated. While the consequences of CRS are well documented, exactly how the virus causes this dra-
matic effect has been the subject of much speculation. In fact, the study of RUBV as a teratogen can be 
dated back to late 1960s when scientists examined clinical specimens, which were still available, and used 
different animal models to simulate CRS, without success [57, 58]. Recently with advanced techniques, 
insights into RUBV-induced teratogenicity at the cellular level have been gained. Several hypotheses 
have been posed by the findings of this research, based both on the virus’ replication and ability to estab-
lish persistence in culture cells, which mimics the persistent infection established by the virus in the in-
fected fetus. The major hypotheses are summarized as follows: 
(a) Noncytopathic RUBV infection of selected embryonic cell types upsets the delicate balance of 
proliferation and differentiation with a profound effect on organogenesis. RUBV generally establishes a 
chronic nonlytic infection in the fetus and has the potential to infect any organ [59]. In vivo, examination 
of RUBV-induced cataractous eye lenses from first-trimester fetuses revealed lens development was re-
tarded [40].A recent clinical study of CRS patients with motor deficiencies revealed the most serious mo-
tor deficits are associated with first 4 weeks of gestation, when the structures that will be involved in a 
particular motor activity are in their most crucial stage of organization and differentiation [60]. In vitro, 
RUBV multiplication has been demonstrated in murine embryonic cells, human embryo derived cultures 
as well as human fibroblasts [5, 49, 61-63].  Human mesenchymal stem cells derived from embryonic 
cells persistently infected with RUBV display an altered responsiveness to the growth-promoting proper-
ties of epidermal growth factors as well as a decreased capacity for collagen synthesis, a sign of abnormal 
differentiation [64]. Therefore, RUBV infection may contribute to the development of CRS by affecting 
cell differentiation and the following organogenesis.   
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(b) RUBV infection in early fetal cells, including progenitor cells, is able to cause a cell-growth in-
hibition, by slowing down or halting the cell cycle. A constant feature of CRS is fetal growth retardation, 
perhaps due to reduced or slower cell division in infected cells [36, 65]. A number of in vitro studies have 
shown that the RUBV  infected cells divide more slowly than do uninfected cells [7, 66]. Cell strains de-
rived from different fetal human organs, although demonstrated no sign of cell death and morphological 
changes, exhibited tissue specific responses to RUBV. Those diploid cells derived from human fetal lung, 
kidney or pituitary ceased  growth within a few passages; while this effect is inapparent in skin and mus-
cle, a high percentage of chromosome breakage was observed [61, 63, 67]. In vitro growth inhibition has 
been attributed to a protein present in the culture fluid which inhibited mitosis [68].Moreover, it has been 
reported that the  RUBV nonstructural protein P90 associated with the cellular citron-K kinase, potential-
ly causing cell cycle aberrations [69, 70]. “Clones of infected cells” isolated from CRS abortuses indicat-
ed that only 1 in 10
3
 to 10
5
 of cells from the infected fetal organs harbored the virus and these infected 
cells always clustered in infected organs.  Thus, the growth retardation effect of RUBV infection is re-
stricted so that infected fetus can still be born and serve as a vector for spread of the virus [52].  
(c) Destruction of formed organs seen in CRS is partially due to cell death such as apoptosis and 
necrosis. Microscopic analysis of aborted infected fetuses revealed non-inflammatory necrosis being 
common in the structure of the eyes, heart, brain, and ears [71, 72]. Cell necrosis may occur at the time of 
initial infection or at a later stage in development. For this to happen the virus still has to gain entry into 
susceptible cells, but the damage may not occur until later due to growth of virus which has persisted in 
infected cells [33]. High multiplicity RUBV infection induces apoptosis in many types of cells, including 
Vero, BHK21 and RK13, although there are discrepancies among the proposed mechanisms of induction 
among these studies [73-77]. Moreover, multiplication of RUBV induced apoptosis in both rat neural and 
glial cells, both of which are representative of terminally differentiated cells [78-80]. It has been proposed 
that during congenital rubella infection, RUBV destroys precursor cells by induction of apoptosis [76] 
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Thus, inhibition of cell growth and cell death, alone or in concert, could be contribute to the pathogenesis 
of CRS. 
(d) In addition to these direct effects of RUBV replication in host tissue, there is evidence that per-
inatal and also postnatal damage is, at least in part, immune mediated. Pathological signs in infants who 
die at some interval after birth usually include mononuclear inflammatory infiltrates in one or more or-
gans, particularly the lung and brain [81]. Although in vitro studies have shown that RUBV is a poor in-
ducer of IFN compared to other teratogenic viruses, a substantially higher amount of IFN is detected in 
placenta during midgestational stage [36, 82, 83].A cytokine storm model has also been proposed recent 
years considering the failure of multiple organs in CRS infants [84].Circulating immune complexes con-
taining RUBV antigens are found in the serum of nearly half of all infants with CRS and there is an in-
creased likelihood of finding rubella-specific immune complexes in the serum of CRS children with ac-
tive clinical problems [85]. In addition, immune mediated responses have long been considered involved 
in the pathogenesis of late-onset complications. A molecular mimicry between RUBV peptides with cel-
lular myelin oligodendrocyte glycoprotein is thought to contribute development of neurological anomalies 
seen in mice infected with RUBV  
(e) Persistent RUBV infection in the developing fetus contributes to the CRS symptoms both at 
birth and late onset. A number of studies have investigated the cellular effects of a persistent RUBV in-
fection in tissue culture, a persistence that can be correlated to persistent fetal infection by RUBV [64, 86]. 
RUBV persistence is maintained without a proviral DNA intermediate, as seen in latent retroviral infec-
tions, even in the presence of neutralizing antibodies in the culture medium, which also correlates with 
persistence in the infected fetus from late in gestation when the fetus develops the ability to make anti-
bodies [87]. Joklik  proposed several mechanisms which could play a role in the maintenance of persistent 
virus infections [88]. These included the presence of endogenous interferon, defective interfering (DI) 
particles, and temperature-sensitive (ts) mutants. These mechanisms have been examined in an attempt to 
explain persistent RUBV infections. 
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 (f) The ongoing RUBV replication can impact normal host cell function, notably, mitochondrial 
abnormalities and disruption of the host cell cytoskeleton [8, 89, 90]. The mitochondrial dysfunction is 
proposed because RUBV replicates in close association with the mitochondria [91, 92].  Mitochondria are 
also related to cell death since they contain and release proteins that are an integral part of the apoptotic 
cascade. As for the cytoskeleton, infection with RUBV has a profound effect on the organization of actin 
in both Vero and BHK21 cells. Actin microfilaments were observed to disintegrate progressively into 
amorphous aggregates as the infection proceeds [8, 89]. In addition, the observation of actin assembly 
inhibition in RUBV infected cells strongly suggests that attenuated mitosis as well as abnormal size of 
RUBV-infected cells could cause some of the pathology of CRS [93]. 
Apparently, the mechanism underlying RUBV teratogenesis is likely to be multifactorial and the 
routes are not limited to above discussed aspects, since many other cellular events that could be affected 
by RUBV infection still remain unknown in both precursor and differentiated cell lines. A summary of 
the pathogenesis of maternal and congenital rubella is provided (Figure. 1.4). 
1.5 NEUROLOGICAL ASPECTS OF RUBELLA VIRUS 
RUBV was one of the first viruses demonstrated to cause congenital anomalies after gestational 
exposure, and, more than 50 years since this discovery; it remains a model for viral teratogenic effects on 
the central nervous system  [16, 94]. Of particular relevance to psychiatric disorders, CRS  has clear de-
velopmental manifestations involving the nervous system, including hearing defects, mental retardation, 
ventriculomegaly, encephalitis, cataracts, and childhood psychiatric disorders such as schizophrenia, au-
tism, separation anxiety, and impaired social relations [95]. Relating to the CNS, sequelae of RUBV in-
fection include three distinct neurological syndromes: a post-infectious encephalitis following acute infec-
tion (acute encephalitis and Guillian Barr Syndrome), a spectrum of neurological manifestations follow-
ing congenital infection (microcephaly, mental retardation, schizophrenia, etc.) and a rare neurodegenera-
tive disorder following either postnatal and perinatal infection, progressive rubella panencephalitis (PRP) 
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[78, 96, 97]. Although virus invasion and replication in the brain has been demonstrated in CRS and ap-
pears to account for the majority of neurological lesions observed , the pathogenesis of these other syn-
dromes is incompletely understood [33, 98, 99]. The following paragraphs will describe each syndrome in 
detail. 
1.5.1 Postacute Rubella encephalitis 
Although post-acute rubella encephalitis is relatively  rare (1 in 5,000-10,000 cases), prior to the 
advent of vaccination programs, rubella was a leading cause of encephalitis among children [100]. The 
average onset of encephalitis is 4 days after the appearance of a rubella rash; in fatal cases, death usually 
ensues within 3 days. In fatal cases, autopsy reveals diffuse nonspecific neural degeneration, edema, the 
presence of perivascular lymphocytes, but neither demyelination nor pronounced inflammatory damage 
[101]. The presence of rubella antibodies has been demonstrated in most patients; however, positive de-
tection of virus by PCR has been rarely successful [102, 103]. Therefore, it is generally thought that the 
pathogenesis is immunological in nature, either due to a hypersensitive reaction or to a molecular mimicry 
between RUBV and host antigens that triggers an autoimmune response [103, 104].However, all of these 
hypotheses are contradictory to the lack of inflammation in most cases. Thus, the pathogenesis of post-
acute rubella encephalitis is unresolved. In addition to encephalitis, acute RUBV  infection has occasion-
ally been associated with cases of Guillain-Barre syndrome [105]. 
1.5.2 CRS associated neurological anomalies 
It is estimated that as many as 80% of CRS patients exhibit neurological disorders, which can be 
devastating in the most severe forms. Microcephaly, motor deficits, mental retardation, autism and schiz-
ophrenia are commonly encountered with development of affected individuals [94]. CRS brain examina-
tions exhibit rare gross structural malformations. The most notable lesions are: (a) vascular abnormalities 
including focal destructions of blood vessels, defects of internal elastic laminia, deposition of granular 
material and endothelial proliferations; (b) reduced cortical width with enlarged ventricles; (c) necrosis in 
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white matter with decreased number of oligodendrocytes [36, 40, 65]. Inflammatory  changes in the brain 
were described as minimal at the most [106]. RUBV has been recovered from CSF and brain tissue of 
infants with  clinical CRS , strongly indicating a direct involvement of the virus in CNS complications 
[60]. As far as how the virus induces damage in brain, different mechanisms have been proposed. The 
microcephaly in CRS infants would be consistent with the concept that the virus can infect the neuroepi-
thelium and reduce cell proliferation. Despite a wealth of experimental evidence showing RUBV induces 
mitotic arrest  (see part 1.4.3), cultures of CRS brain derived cells also display poor growth and stop to 
proliferating within 3 passages [98]. RUBV triggered apoptosis of neuronal cells, especially oligodendro-
cytes, has been shown in multiple studies using a rat model [80, 107]. In human cell culture, the virus se-
lectively and heavily infects astrocytes, but such specificity has not been described in vivo [108]. Since 
the primary time in gestation when  RUBV exhibits profound teratogenicity (i.e first trimester) coincides 
with organogenesis in the developing fetus, another favored hypothesis is that alterations induced in in-
fected fetal progenitor cells ultimately affects organ development.  This idea is further supported by the 
recently developed “schizophrenia hypothesis” after a strong correlation was observed between infection 
by a number of viruses, both congenital and peripheral, and the development of late onset psychiatric dis-
eases [96, 97]. The schizophrenia hypothesis states that schizophrenia results from a disruption in pro-
grammed maturation of the brain in prenatal and early neonatal life [109]. Therefore, susceptibility of fe-
tal progenitor cells to RUBV infection should be investigated. However, one should not ignore that vascu-
lar damage may also play a role in the overall pathogenesis of CRS. Additionally, the involvement of vi-
ral persistence may be implicated as infants who exhibit prolonged persistence do not fare as well medi-
cally as those who clear the virus.  
1.5.3 Progressive Rubella Panecepahlitis 
Progressive rubella panecephalitis (PRP) was first described by Weil et al., in 1975 as a chronic, in-
flammatory, and progressive CNS disorder associated with either delayed reaction to congenital rubella or 
acute postnatal rubella infection [110]. PRP is universally fatal and only a few cases have been reported 
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[111, 112]. Patients usually develop PRP in their second decade of life, undergoing a period of several 
years of a protracted clinical course consisting of intellectual deterioration, seizure, myoclonues, cerebella 
ataxia, and cortical spinal tract signs. Laboratory tests revealed high titers of rubella antibodies in serum 
and CSF and the occurrence of oligoclonal CSF IgG, suggesting a local production of immunoglobulin in 
the CNS [113, 114].  The neuropathological investigation showed meningeal and perivascular plasma 
cells and lymphocytes, gliosis, and glial nodules as well as diffuse neuronal loss. Inclusion bodies and/or 
virus structures, as seen in subacute sclerosing panencephalitis (SSPE), a disease associated with measles 
virus, or other virus infections of the CNS, were not detected. In contrast to SSPE, amorphous deposits 
similar to those seen in children dying with  PRP were present in the blood vessel walls throughout dif-
ferent regions of brain [111, 115]. In vitro characterization of PRP brain derived cell cultures showed very 
few cells were RUBV  positive although isolation of infectious RUBV  could be achieved [98]. Related to 
these observations, it has been hypothesized that PRP is caused by a systemic persistent virus infection 
and somehow pathogenesis is concentrated in the brain, mostly by immunopatholgocial mechanism. Con-
sidering the similarities in the symptoms of SSPE, which is caused by measles viruses, one parallel hy-
pothesis of the PRP pathogenesis is that RUBV present in the brain is in the form of defective virus. 
However, considering the different coding strategies and replication cycles between RUBV and measles, 
this hypothesis is less favored. Also, as PRP shares similarities with multiple sclerosis (MS), a progres-
sive autoimmune disease, the molecular mimicry mechanism may apply in the developing of such disease. 
It has been proposed that RUBV induces the death of oligodendrocytes and those dead cells would release 
otherwise sequestered myelin proteins that would serve as a trigger for such an immune attack. Due to the 
slow progressive properties of PRP, RUBV was added to the growing list of “slow virus” infections of the 
CNS [116].  
Kemper et.,al proposed two mechanism involved in CRS encephalopathy: one, an inhibition of cell 
replication affecting the number of oligodendrocyte and glial cells; the other is the non-specific effect of 
delayed maturation conceivably due to the persistence of the  viral infection [117].  It is necessary to reit-
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erate here that RUBV, although eradicated in most developing countries, remains to be one of the best 
models to study teratogen induced CNS complications. Despite different mechanisms proposed, including 
immunological ones, it is still of great importance to examine how the virus affects authentic neuronal 
cells during development. 
1.6 HUMAN EMBRYONIC STEM CELL DEREIVED PROGENITOR CELLS AS A MODEL 
Laboratory models have an important role in identifying agents  with teratogenic potential,  sup-
porting or refuting the biological plausibility of teratogenic associations identified in human studies, and 
determining mechanisms of abnormal development [118]. The key processes that control development 
appear to be very highly conserved across species. Therefore, human teratogens have traditionally been 
studied by establishing animal models.  There have been many attempts to develop animal models for 
CRS despite that fact that humans are the only host to RUBV. Birth  defects following congenital RUBV  
infection only identified  in limited studies using animal models such as rats, rabbits and monkeys [119-
121].  Other studies using the same models did not successfully reproduce  these defects [122-
125].Therefore, unlike most human teratogens, animal models of CRS are not particularly useful and have 
not contributed significantly to the understanding of the pathogenesis of the defects. Alternative models 
that well mimic human fetal development are needed for the future study of the mechanisms of pathogen-
esis of CRS. 
Human embryonic stem cells (hESCs) are pluripotent stem cells derived from the inner cell mass of 
a blastocyst, an early-stage embryo [126]. They are distinguished by two distinctive properties: their plu-
ripotency, which means they have the potential to differentiate into other cell types, and their ability to 
self-renewal, which means they can replicate indefinitely [127]. hESCs and their derived progenitor cells 
are now  used widely in clinical therapies (such as human genetic disorders), cosmetics development , and 
most relevant to our discussion, as a laboratory model for various types of studies including viral terato-
genicity research [128-130]. 
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Neuroepithelial stem cells or neural progenitor cells (NPCs) are self-renewing multipotent cells 
that can differentiate into neurons, oligodendrocytes, and astrocytes, the three main types of cells compos-
ing the CNS [131]. Neurons transmit information through action potentials and neurotransmitters; astro-
cytes and oligodendrocytes, which are collectively called glial cells, play important roles of their own in 
the CNS in addition to providing a critical role in the support of optimal neuronal functioning and surviv-
al, such as providing the myelin sheath. NPCs naturally exist during development and also in the mature 
CNS. Very early in mammalian development, the CNS begins to develop with the induction of the neu-
roectoderm, which forms the neural plates and then folds to give rise to the neural tube. In humans, this 
process is estimated to occur in the 3
rd
 to 4
th
 week of gestation. Within these primitive neural structures, 
NPCs exist. From then on, NPCs undergo either symmetric division to expand their pools or asymmetric 
division to generate more restricted progenitors that eventually give rise to neuronal and glial cells (Fig-
ure. 1.5)[132]. It was believed that once CNS was complete, it was incapable of mitotic divisions to gen-
erate new brain cells due to the mitotic incapability of neurons.  However, there is now well-established 
evidence that multipotent NPCs do exist in the mature mammalian CNS and that they play a role in neu-
roregeneration [133]. Important cell signaling pathways involved in temporal events during neural differ-
entiation are the  WNT, BMP, FGF, and RA pathways[134]. Besides mimicking the development of the 
CNS, another feature that makes hNPC’s a good model for the study of teratogenicity is the controllable 
and quantifiable cell differentiation of this cell type that can be induced in vitro. (a) Spontaneous hNPC 
differentiation can be easily achieved by removing growth factors such as EGF and bFGF provided in 
basal culturing medium, whereas directed differentiation requires additional culturing supplements, such 
as cillinary neurotrophic factor (CNTF) for the derivation of astroglial and 3T3 for the derivation of pure 
oligodedrocytes. The differentiation process usually takes about 14-21 days [135-137].  (b) A typical way 
to quantify the differentiation of progenitor, as well as stem, cells is by examining the expression of intra-
cellular as well as cell surface markers to identify specific types of cells [138]. To monitor the differentia-
tion stages of hNPCs, different cell markers may be used (Figure. 1.6), for example, Nestin, CD133 and 
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SOX2, which have a high level expression in undifferentiated progenitors cells but not in terminally dif-
ferentiated neurons  [135].  Many markers can be used to detect specific  differentiation, e.g. A2B5 is an  
early astroglial lineage marker, beta-tubulin-III (Tuj-1) and neurofilament-M (NF-M) are markers in  ter-
minally differentiated neurons, and GFAP and MOG serve as markers for astrocytes and oligodendrocytes, 
respectively [136, 137]. Additional quantification methods may also be used, including microscopic anal-
ysis of morphological changes as well as transcriptional profiling. 
 There are three sources of human neural progenitors: neural tissues from fetuses, immortalized cell 
lines, and hESCs. hESC-derived NPCs have advantages over the other two in that: there are no concerns 
about  tumorigenesis and genetic instability ; the  outcomes are  consistent and do not depend on the ges-
tational age of the  cells as with those isolated from fetal tissue ; and hESC- derived hNPCs exhibit  no 
decrease in plasticity during passaging [132]. Laboratory generation of hESC- derived hNPCs can be 
achieved using either an embryoid body model or adherent culture model, the latter ensures a more ho-
mogenous  hNPC population. Although cultured hNPCs do not require mouse embryonic feeder (MEF) 
like hESCs do, other factors are still required to maintain proper growth and self-renewal including a 
proper extracellular matrix  which can be provided by laminin or Matrigel and supplying nutrient and mi-
totic factors such as basal fibroblast growth factors (bFGF) [132]. 
Recently hNPCs have been developed commercially as a model to study developmental neurotoxi-
city and teratogenicity [139]. The model we utilized in this study, hNP1 (ArunA Biomedical), are an 
hNPC line derived from the NIH-approved H9 human embryonic stem cell line, which has a normal fe-
male (46XX) karyotype [126]. hNP1 cells express the NPC markers nestin and SOX2. According to the 
supplier, hNP1 cells also differentiate into multiple neuronal subtypes, including cholinergic, dopaminer-
gic, and GABAnergic neurons, glia, and oligodendrocytyes, and maintain a stable karyotype for at least 
10 passages. hNP1 cells have not been immortalized or otherwise transformed, and therefore the potential 
caveats of transformation are not at an issue when using these cells. They also grow as a monolayer with-
out fibroblast support. hNP1 cells have been successfully used in radiation sensitivity testing, neurotoxici-
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ty screening, neurophysiology, tissue engineering, and translational medicine [135, 140-145]. Thus, there 
is every reason to expect hNPC/hNP1 could be used as a model for studying neurodegenerative diseases 
and the vast majority of CNS abnormalities, including those caused by RUBV infection in CRS.    
1.7 VIRUS INFECTION OF PROGENITOR CELLS: REVIEW OF PREVIOUS WORKS 
Viral infections in the prenatal and perinatal period are a common cause of brain malfunctions. Be-
sides the immediate neurological dysfunctions, virus infections may critically affect CNS development 
that culminates in long-term sequelae such as cognitive deficits. Most of these neurotropic viruses are 
most damaging at a critical stage when the brain is in a dynamic stage of development. As one of the mi-
totically active populations in the postnatal brain, hNPCs have emerged as the potential targets of neuro-
tropic viruses. Numerous studies have focused on how viruses affect such cell populations and review of 
this work is relevant in terms of  how RUBV infection causes neural anomalies during development [146]. 
Teratogenic viruses such as cytomegalovirus (CMV), human immunodeficiency viruses (HIV), Borna 
disease viruses (BDV), and Coxsackie virus, were among the first to be used in hNPC infection studies 
(see Table 1.3 for detail). Human cytomegalovirus (HCMV), a DNA virus belonging to Herpesvirus 
family, is currently the second most common cause of congenital brain deficiencies (after Down's syn-
drome) and a detailed comparison of the teratogenic aspects of HCMV and RUBV infection is summa-
rized in Table 1.1. HCMV is highly tropic to hNPCs, even in the adult brain, particularly in the subven-
tricular zone (SVZ) [147]. In vitro study showed that hNPCs are highly susceptible to virus infection; 
however, cells were not dead following infection but rather displayed slowed proliferation [148-150]. A 
similar impact on hNPCs proliferation is seen with BDV, HIV, and Japanese encephalitis virus (JEV), 
where virus infection results in insignificant cell death but promotes cell quiescence [151-153]. Therefore, 
hNPCs are resistant to virus induced cell death. The only exceptions were Coxsackie virus and a SINV 
vector expressing HIV-gp120, both of which induced significant cell death [120]. The effect of virus in-
fection on hNPC multipotency or differentiation potential varies. HIV-1 infection promotes hNPCs to 
prematurely and preferentially differentiate into astrocytes in vivo and in vitro after a long-term infection 
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[154, 155]. BDV, on the other hand, significantly impairs hNPC neurogenesis instead of gliogenesis [151]. 
Contradictory results have been found with HCMV: in one study, the virus inhibited hNPC neuronal dif-
ferentiation by triggering cell death while in another the virus induced premature differentiation of hNPC 
[119, 149]. The difference in these results may be caused by different sources of hNPCs used in each 
study. It is worth pointing out, however, that these other studies were done using hNPCs derived directly 
from aborted human fetuses and thus our use of hNPCs derived from hESCs is novel. 
Hepatitis B virus (HBV), another classical teratogenic virus, triggers hepatic encephalopapthy as a 
result of liver failure at late-decades of infected individuals. These neurological anomalies result from an 
increased level of toxic chemicals in the blood (such as ammonia) released from hepatocytes that are in-
capable of metabolizing the waste products. Small molecule toxins interfere with neuronal transmission 
and glial cell osmotic pressure within the brain and nervous system, thus resulting in abnormal psycho-
motor behaviors.  However, it is intriguing why HBV does not trigger CNS defects in the fetus during 
pregnancy? It was proposed that HBV does not have the ability to crosses blood-brainbarrier of fetus, or 
alternatively, does not have access to brain/nervous cells due to lack of proper cell surface receptors [156]. 
It was reported that the hepatitis B vaccine induced CNS inflammation and demyelination. A molecular 
mimicry mechanism between MBP and hepatitis B antigen was suggested as an explanation of the onset 
of disease. However, the correlation between the HBV vaccine and demyelination is still debatable [157]. 
As for RUBV, teratogenic studies related to CNS malfunctions have been limited to few studies. 
Hearne et al., showed RUBV has activated replication when the blastocyst came to the embryonic stages 
in mouse; however, the virus titer achieved is only moderate and no cytopathic effects (CPE) were ob-
served [5]. Noncytolytic infections of RUBV have also been reported in human embryos where infected 
cells demonstrated strong growth attenuation and became insensitive to the addition of growth factor to 
the medium [62, 64, 66, 67, 158, 159]. Studies focused on CNS malfunctions have only been carried out 
in mature neuronal culture. RUBV replication in glial cells, especially oligodendrocytes, has been report-
ed extensively in a rat model, which showed a varied teratogenic response to RUBV infection [78-80, 
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107]. The only human study reported that RUBV replicated selectively and heavily in astrocytes, however, 
this is not seen in vivo [36, 108]. Research on the topic was done either on terminally differentiated neu-
ronal and glial cultures or primary embryonic cultures (see Table 1.2 for detail). None of the experiments 
were carried out on the intermediate progenitor stages where the virus could exert the most damage. Thus, 
it is necessary to investigate the susceptibility of hNPCs to RUBV infection as well as its neurotoxicity to 
the same population. 
Besides RUBV, many other viruses in Togaviridae family are teratogenic, such as Semliki forest 
viruses (SFV). In addition, SINV causes age-dependent encephalitis in mice and therefore is a very useful 
model to study viral encephalitis for the family [3, 4]. Viruses with such properties can be used as a con-
trol in this study. SINV infection to NPCs has been characterized:  Undifferentiated murine NPCs were 
permissive for SINV and susceptible to virus-induced cell death. With differentiation, cells exhibited re-
duced virus replication and became progressively resistant to virus-induced cell death, resulting in pro-
longed virus replication [160, 161]. Mechanisms governing pathologenic outcome and extent of SINV 
replication in human cells are not  sufficiently characterized [162]. 
1.8 RESEACH OVERVIEW 
This dissertation is focused on the study the mechanism behind the development of CRS. Currently 
there are three type of models utilized in our lab to address this issue: (i) hESC derived progenitor cells 
including hNPC and human mesenchymal progenitors (hMPro) as a model to study the effect of RUBV 
on the development of different organs and tissues in the fetus; (ii) human lung epithelial cells (A549) as 
a model to characterize innate cellular responses to acute RUBV infection in mature individuals; (iii) a 
RUBV-replicon harboring Vero cell line (925-IN) as a model to study viral persistence. Three seemingly 
separate models unite together in the sense that all contribute to a more complete picture of how RUBV 
impacts the human body from embryo to fetuses to the developed individual.  Work has been carried out 
on all three systems during research towards the PhD. This dissertation  only describes the hNPC studies, 
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with the 925-IN studies, which have been completed [163].  The A549 studies are currently being written 
up for publication by another author.  
The overarching question addressed in this dissertation is what is the mechanism underlying the 
development of neurological abnormalities seen in CRS? By using hNPCs as a model cell line, we ap-
proached the question with respect to neurogenesis. Based on previous studies, the general hypothesis is 
that infection of neural progenitor cells by RUBV leads to the disruption of the proliferation and differen-
tiation of these cells, which is a primary mechanism underlying the development of CRS. 
Since none of the previous research has been done on virus infection of hESC- derived hNPCs, and 
we thus approached the project in a comprehensive manner .Project I, Cellular responses to RUBV in-
fection in hNPCs. The susceptibility of hNPCs to RUBV infection and the virus effect on properties of 
undifferentiated hNPCs is described in Chapter 2. Virus effect on undifferentiated hNPC proliferation, 
with a focus on whether and how RUBV induces cell death and growth attenuation, is presented in Chap-
ter 3. One advantage of using hNPCs as a model is that the cells can into all three lineages of cells that 
compose adult CNS system and thus the effect of RUBV infection on hNPCs differentiation into both 
neuronal and glial cells were studied and are reported in Chapter 4. In project II, Cellular responses to 
SINV infection in hNPCs, we utilize SINV, a model Togavirus for viral encephalitis studies, as a control 
model for RUBV studies.  Studies on this project are reported in Chapter 5. 
The significance of studying cellular responses to RUBV infection in hNPCs is threefold: (a) this is 
the first time RUBV infection has been studied in stem and precursor cells which mimic the stage at 
which is critical to CRS development; (b) the result of this study provides direct clues for elucidating the 
cellular mechanisms of RUBV-induced teratogenicity during the progression of CRS , and (c) the project  
serves as reference study with the potential to inform  corresponding research in the stem cell infection 
field and possibly provide unifying mechanisms of teratogenesis induced by infectious agent.
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Table 1.1 Teratogenesis of HCMV and RUBV 
Fact HCMV  RUBV 
Incidence of disease 5-10% microcephaly, periventricular calcification [164], 
Optic nerve pathology [165] (most common 
cause of birth defect ) 
 
10% subclinical congenital infection, but will subse-
quently develop brain disorders including mental 
retardation, sensorineural hearing loss, visual de-
fects, seizure and epilepsy (reviewed in [147]) 
5-10% microcephaly, mental retardation periventricular 
calcification, Optic nerve pathology (most common 
cause of birth defect ), hearing loss 
10% subclinical congenital infection, but will subse-
quently develop brain disorders including mental retar-
dation, psychomotor retardation, visual defects, seizure 
and epilepsy. Progressive Rubella Panencephalitis (PRP, 
very rare) 
Transmission Contact with body fluid of person who are infected with 
virus [56], Congenital 
Respiratory route; body fluid? 
Congenital 
Fetal infection Rate 
Risk of develop disease af-
ter congenital infection 
50% (at first trimester) 
The riskof fetal transmission appears to increase with 
gestational age,but neurological outcomes are more se-
vere when infectionoccurs during the first trimester[166] 
80% (at first trimester) 
Most severe at first trimester of pregnancy with de-
creased likelihood of developing congenital disease 
thereafter, no sequelae after 16 weeks of gestation. 
Immune responses Adaptive: IgG;  
The presence of maternalantibodies has been shown to 
be associated with a decreasedincidence of CMV and 
with improved neurological outcomesin the setting of 
congenital infection 
Innate: Robust CD8+ cell but few CD4+ 
Mild inflammation agents 
Adaptive: IgG, IgM 
Rubella specific immune complexes present in CRS 
patients  
Innate: Both CD8+ and CD4+ 
Mononuclear inflammatory infiltration in brain  
Inflammation in acute encephalitis and PRP but not 
CRS brain [167] 
Mild Inflammation agent 
Pathology in brain   
Isolation of virus CSF, brain CSF, brain 
Acute infection White matter abnormalities, necrosis, gliosis  Diffuse non-specific neural degeneration, 
No sign of demyelination and inflammation (or delayed 
myelination process) 
Chronic lesions 1. Atrophy(volumeloss),parenchymal and ependy-
malcysts, 
2. Structural brain abnormalities 
3. Abnormal periventricular hyper/hypoechogenicity, 
ventricular adhesions, cystic formation around the 
ventricles, ependymal protrusions; vascular necrosis 
Atrophy (due to reduced cell number) 
Free of morphological malformations 
Abnormal in blood vessels: focal destruction of veins 
and arteries, patchy defects of the internal elastic lamin, 
deposition of granular material, endothelial prolifera-
tion; vascular necrosis. 
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4. White matter gliosis,  
5. Cortical malformations? 
6. Cranial calcifications 
Whiter matter necrosis, oliodendroglial cell depletion 
Reduced cortical gray matter 
Calcification?  
*In PRP: destruction of white matter, loss of myelin, 
sever gliosis 
Cell type infected Preferentially infect cells in VZ and SVZ Preferentially infection epithelial cells 
Proposed mechanism of 
teratogenic effects[168] 
1) Virus penetrated the placenta and infected fetus 
2) A cytopathic infection to cells within infected fetuses. 
3) Clones of differentiating cell s may be destroyed, and 
this may have either a direct or indirect effect on devel-
oping tissues and organs. 
4) The indirect effect may be exerted through interfer-
ence with cellular interactions during development. 
1) Virus penetrated the placenta and infected fetus 
2) A systemic infection of the fetus occurs with most 
types of cells are persistently infected 
3) Teratogenesis is induced by inhibition of cell division 
and/or differentiation in cells involved in morphogenesis 
and organogenesis as well as by cell lysis.  
4) Immune tolerance my facilitate viral persistency 
Mechanisms HCMV RUBV 
Molecular Viriology DNA virus, Herpesviridae Family RNA virus, Togaviridae Family 
Persistent infection Latency 
Reinfection & reactivation 
Yes 
Life-long latency and Periodical reactivation 
Yes 
No 
Receptor [169] EGFR, IL10RA MOG  
Cell type infected in vitro(2) Neural progenitors (Highly susceptible)  [170] 
In differentiated glial but not neuron 
Astrocyte  
Rarely show replication in neuron   
Rarely show replication in oligodendrocytes[171] 
Brain microvascular epithelial cells 
Does not replication in ES cells [172] 
PBML  
Not known 
Astrocyte, microglia [108];  
No replication in rat neuron  
Poor replication in rat oligodendrocytes[78, 107] 
Embryonic vascular epithelial cells [173] 
Infect mouse embryo[5] Embryonic cells derived from 
abortuses 
PBML [174] 
Effect to cells   
Chromosome injury Yes Chromosomal breakage [175] Yes Chromosomal abnormalities & breakage [61, 176, 
177] 
Cell death & apoptosis Induce apoptosis in hNPCs [178] 
Induce apoptosis during differentiation into neuron and 
glial cell 
Encode anti-apoptotic genes UL37 and UL38; [179, 
180] 
Inhibit apoptosis in astrocyte [148] 
Induce apoptosis in many cell types but not embryonic 
lineages 
Rubella capsid (C) is anti-apoptotic 
Inhibit chemical induced apoptosis in A549 [75] 
Does not induce apoptosis in fibroblast [66] 
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Cell cycle progression Inhibit cell DNA synthesis in hNPCs, fibroblast [148, 
178, 181] 
Inhibit cell proliferation in primary fetal organ derived 
cell lines, selected fibroblast [61-63, 68] 
Cytokine mediated damages Yes  Not known yet 
Altered fetal& embryonic 
gene expression 
Premature differentiation of hNPCs [149] 
 
Altered gene expression in human fetal fibroblast [182] 
Impaired differentiation Inhibit neuronal and glial differentiation [178, 181] 
(Controversial) premature differentiation 
Altered differentiation seen in mesenchymal stem cells 
[64] 
(hMPro, our lab unpublished data) 
Cell migration attachment hNPC aberrant migration [183]  
Postsynaptic density FYN Citron kinase 
Gene related Schizophrenia susceptibility gene: Several genes may affect pathogen virulence, while the pathogens in turn may 
affect genes and processes relevant to the neurophysiology of schizophrenia. For such genes, the strength of associ-
ation in genetic studies is likely to be conditioned by the presence of the pathogen, which varies in different popula-
tions at different times, a factor that may explain the heterogeneity that plagues such studies.[169]Me : in this study 
CMV varies from RUBV in the genes related to schizophrenia, there are few overlaps in the associated genes be-
tween two viruses 
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Table 1.2 In vitro studies of RUBV infection in embryonic, fetal and neuronal cultures. 
Lineage Cell source/type Virus strain Result of RUBV infection Reference 
Embryo/ 
Fetal 
Human fibroblast isolate from 2-4 
month abortuses 
West Point, 
Marshall, M-
33, RW 
Growth inhibition, stopped grow after several passages 
No morphological changes 
Differential responses from different organs from same em-
bryo 
[61, 63] 
Human embryonic lung cell  Found to carrying rubella virus [62] 
Rubella carrier culture from infants  Virtuallyeverycell in the carrier populationwas found to be-
producing virus 
[49] 
Human diploid fibroblast (WI-38)  Produce a protein that slows mitosis [68, 184] 
Human embryonic mesenchymal 
cells 
 Altered cell growth and differentiation 
Reduced collagen synthesis and alkaline phosphates content 
Decreased responsiveness to growth factor EGF 
[64] 
Human embryonic cell  Support RUBV growth, no cytolytic effects observed [67] 
Human fetus cells Judith, HPV-
77, RA27/3, 
Cenderhill 
RUBV induce much less interferon than Sendai virus did 
Lung produce much higher interferon than other organ 
[82] 
Human embryonic and fetal rat 
bones 
 Growth regardation 
No histological abnormalities observed 
Increased 35S uptake, indicating a a disorder of mucopolysac-
charide syntheses 
[159] 
Mouse embryos  RUBV infect zona-free blastocysts resulted in a productive 
but non-cytolytic RUBV did not multiply in inner cell mass 
cells isolated from embryos at the blastocyst stage, although 
SFV did multiply in such cells. 
[5] 
Human embryonal fibroblast  Chromosomal alternation [158] 
Human embryonic fibroblast (HEF) Gilchrist (GIL), 
Cordoba (COR) 
RUBV induce apoptosis in normal-term placeta chorionic 
villi explants (CVE) and human monolayer of cytotropho-
blasts (CTB) but not induce apoptosis in primary human em-
bryo fibroblasts (HEF) 
[66] 
Human primary fetal fibroblast COR Gene analysis showed an increased anti-apoptotic and de-
creased pro-apoptotic gene following RUBV infection to 
HEF 
Upregulation of interferon related genes was seen in both 
fetal and adult cells 
[182] 
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Neuronal 
cell cul-
ture 
Primary rat neural cell culture Therien RUBV multiplied to low titer and produced a partial cy-
topahtic effect in rat glial cell cultures. A similar effect was 
produced following infection of myelinating neural cell cul-
ture but virus replication could not detect. 
[107] 
Primary human fetal brain culture Therien, 1B2 
RA27/3, 
Cendehill 
RUBV achieved high titer in the culture 
Astrocyte and microglial are highly susceptible to RUBV 
infection 
Only 5% oligodendrocyte were infected with RUBV 
Occasional neurons expressing viral antigen were seen 
[108] 
Rat mixed glial cutlure Therien; 
RA27/3 
RUBV induces apoptosis in oligodendrocytes in rat glial cell 
cultures 
[78] 
Rat glial cells 2872R Restricted replication in immature glial (RG) but reactivated 
in replication in mature glial culture after treatmet of dB-
cAMP  
[80, 185] 
Rat mixed neuron/glial cutlure Therien The virus causes disruption of cultures of pure glial cells, but 
there is no evidence of virus multiplication or cytopathic ef-
fect in pure neuron cultures. The cytopathic effect in mixed 
neuron/glial cell cultures is concluded to be glial cell mediat-
ed. 
[79] 
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Table 1.3 Characteristics features of neurotropic viruses and their effects on the hNPCs 
Name Virus family Genome Effect on hNPCs Long term neurologi-
cal deficits 
Reference 
Cytomegalovirus 
(CMV) 
Beta herpes-
viruses 
DNA  Highly susceptible to virus infection 
Attenuate cell proliferation (controversial on apoptosis or 
not) 
Impede neuronal and glial differentiation by trigger apoptosis 
Both differentiated neuron and glial susceptible to infection 
Neuron is slightly refractory to the effect of virus 
(rare) induce premature and abnormal differentiation of 
hNPCs 
Developmental brain 
defects, encephalitis, 
hearing loss, psycho-
motor deficits. 
[148, 150, 
178, 181, 
186-190] 
Review in 
[147] 
[149] 
Varicella-Zoster 
Virus (VZV) 
Alpha her-
pesviruses 
DNA Support virus infection, support persistent infection for two 
month 
Low-level infectious VZV produced 
No CPE even in derived neurons (express viral transcripts 
and antigen) 
Replicate in sensory neurons derived from iPSCs  
Meningoencephalitis, 
myelopathy, cascu-
lopathwy and retinits 
[191-195] 
Herpes simplex 
virus 
Alpha her-
pesviruses 
DNA hNPCs were susceptible to virus infection 
Increased cell proliferation in SOX2 and Nestin + population 
at first 5 days after infection but decreased cell proliferation 
to overall population after 15 days after infection 
No CPE develop 
Developmental brain 
defects, behavioral 
changes, hallucina-
tion, amnesia, hypo-
mania 
[196, 197] 
HIV-1 Retrovirus (+) 
RNA 
Single 
stranded 
Support a restricted virus replication but can be maintained 
by addition of TNF-α 
HIV/gp120 attenuate cell proliferation by promote quies-
cence 
Transient activation of virus production of differentiation of 
HIV-infected progenitor cells to astrocyte 
HIV infected macrophage promote induce astrocytic differen-
tiation of hNPCs 
Long –term HIV infection led to upregulation of GFAP and 
altered cell morphology 
Developmental brain 
defects, learning and 
memory deficits, be-
havioral disturbance 
[152, 154, 
155, 198-
201] 
Coxsackie virus 
B3 
Enterovirus (+) 
RNA  
Single 
Highly susceptible to virus infection 
Induce CPE and eventually cell death 
Virus replication reduced along differentiation 
Meningitis, intellectu-
al disability, Scholas-
tic performance defi-
[153, 202-
204] 
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stranded Altered progenitor cell differentiation 
Autophagy associated with cell-type specific susceptibility 
cits, schizophrenia 
Japanese En-
cephalitis virus 
Flavivirus (+) 
RNA  
Single 
stranded 
Support JEV replication (104 pfu/ml) 
Inhibit cell proliferation by arresting cell cycle but not trig-
gering cell death 
Decreased virus load during differentiation into neuron 
Impair neuronal and astroglial differentiation by altering the 
expression of transcription factors involved in differentiation 
(JAK/STAT and AKT pathway) 
Developed immunogenicity following infection (MHC-1, IL-
2 production) 
Behavioral problem, 
learning deficits, 
speech problem 
[205-208] 
Borna Disease 
Virus 
Bornavirus (-) RNA 
Single 
stranded 
Highly susceptible to virus infection 
Persist in hNPCs without altering undifferentiated phenotype 
and proliferation 
Impair neuronal differentiation by induce apoptosis of newly 
generated neuron 
Does not alter glial differentiation although virus actively 
replicated in cells 
Impair pERK1/2 pathway during neuronal differentiation 
Learning deficits, 
schizophrenia, autism, 
mood disorders 
[151, 209] 
Sindbis virus Alphavirus (+) 
RNA  
Single 
stranded 
Highly susceptible to virus infection 
Induce CPE and eventually cell death 
Disorenintation, atax-
ia, mental depression, 
convulsions 
[161, 210] 
(also in 
this study) 
JC virus Polyomavirus DNA hNPCs can be nonproductively infected by virus, while hu-
man oligodendrocyte progenitors (hOPCs) support efficient 
replication of the virus 
Virus reactivate during differentiation into astrocyte 
 
Progressive multifocal 
leukoencephalopathy 
(PML) 
[211, 212] 
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Figure 1.1 Cryo-electron micrograph of rubella virion. 
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Figure 1.2 Schematic representation of the RUBV genome, translation and processing strategy of 
the RUBV nonstructural and structural proteins. 
Reference [9].
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Figure 1.3 Schematic representation of the RUBV replication cycle.
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Figure 1.4 Proposed pathogenesis of congenital rubella. 
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Figure 1.5 Embryonic neural development and the timing of NPC differentiation. 
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Figure 1.6 Embryonic neural stem cell (NSC and/or NPC) pathway in vitro and major markers for 
identification of each cell type before and after differentiation. 
[Modified from Sigma-Aldrich website http://www.sigmaaldrich.com/life-science/cell-biology/cell-
biology ]
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CHAPTER 2 : CHARACTERIZATION OF RUBV INFECTION OF HUMAN NEURAL PRO-
GENITOR CELLS  
2.1 INTRODUCTION 
Several cell lines have been utilized to study RUBV replication as well as its pathogenesis in vitro 
including Vero, BHK21, RK13 , human embryonic fibroblasts (HEF), and human lung epithelial carci-
noma cells (A549). These in vitro models support robust RUBV replication and induce various types of 
cell responses. However, none of them accurately mimic the development of the fetus and therefore CRS 
pathogenesis remains a mystery. RUBV has a broad tropism for different types of tissues within the hu-
man body. The virus disseminates widely in the developing embryo and fetal tissue, establishing a chron-
ic and generally nonlytic infection. Analyses of RUBV-infected specimens obtained during the first tri-
mester showed that virus can be isolated from most organs of abortuses, including the central nervous 
system. Multiple studies have shown that RUBV causes CPE in oligodendrocytes, a subtype of neural 
cells [107, 213-215]. In addition, our preliminary data in which a similar WA09 derived progenitor cell 
line, human embryonic mesenchymal stem cells (hMPro) was found to be infectable by RUBV supports 
the notion of hNPC susceptibility to RUBV infection. In fact, hNPCs have been demonstrated as a reser-
voir for numerous neurotropic viruses in vitro and in vivo, with various outcomes after infection (see Ta-
ble 1.3 for detail). Some of the viruses, such as HCMV and JEV, induce apoptosis in proliferating hNPCs, 
while others such as BDV persist in the cells without altering their morphology until cells are induced to 
differentiate. This study sought to determine the susceptibility of hNPCs to RUBV infection. We exam-
ined whether cells were capable of supporting the full viral cycle from entry into the cells to replication 
and propagation. We found that RUBV was able to enter ~10% of cells within the population and that 
hNPCs support a  modest level of replication by  the virus (10
3
-10
4
pfu/ml) compared to that in cell lines 
in which the virus replicates efficiently, such as Vero (10
6
 to 10
7 
pfu/ml). In addition, RUBV and its repli-
cation have little impact on proliferating hNPCs, including their cell morphology and stemness marker 
expression, although the expression of proliferation marker Ki-67 was down-regulated at the transcrip-
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tional level. Taken together, our results support the idea that hNPCs are susceptible to RUBV infection 
and that the percentage of infected cells closely mimics the pathology of CRS where few cells were found 
infected within affected tissue. This finding also sets the basis for the following studies in this dissertation 
in which virus impact on hNPC proliferation and differentiation will be analyzed. 
2.2 MATERIAL AND METHODS 
2.2.1 Cell culture 
hNP1™ Neural Progenitor cells (hNPC’s) (ArunA Biomedical) derived from  WA09 hESCs were 
cultured in Matrigel™ (BD Bioscience) coated tissue culture dishes. Cells were maintained in complete 
neural expansion medium composed of AB2™ medium supplemented with 1x ANS™ (ArunA Biomedi-
cal Inc), 20 ng/ml Leukemia Inhibitory Factor (LIF, Millipore), 2 mM L- Glutamine, 0.5 U/ml penicillin, 
0.5 U/ml streptomycin (both from Invitrogen), 20 ng/ml basal human fibroblast growth factor (bFGF, 
Millipore) at 37ºC and 5% CO2. Culture medium was changed every other day and hNP1 cells were pas-
saged every 3–4 days using either a cell scraper or manual pipetting. For all the experiments described 
below, passage 6-10 cells were used. For Matrigel coating, the coating solution was made by diluting 
Matrigel 200-fold in ice-cold Dulbecco’s modified Eagle medium (DMEM, Cellgro) and then applied to 
culture dishes in an amount according to the size of the dish (1 ml for a 35 mm
2
 plate, 2 ml for a 60 mm
2
 
plate and 3 ml for a 100 mm
2
 plate). Coated dishes were left at room temperature for 15minutes to 1 hour 
and coating medium was removed completely from plate prior to use. Pre-cooled tubes, pipettes and mi-
cropipette tips were required for manipulation of Matrigel.  For cryo-preservation, cells were suspended at 
a concentration of 2×10
6
 cell/ml in AB2 complete neural expansion medium and then the same amount of 
20% DMSO (Sigma) in expansion medium was added to make a final 1×10
6
 cell/ml in 10% DMSO AB2 
complete neural expansion medium. 
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African green monkey kidney cells (Vero) used for preparing RUBV stock were maintained in 
DMEM containing 5% fetal bovine serum (FBS; Atlanta Biotech) and gentamycin (10 µg/ml; Gibco) at 
35ºC and 5% CO2. 
2.2.2 Virus stock preparation and infection 
To prepare RUBV stock, 80% confluent Vero cells were infected with the RUBV laboratory 
adapted strain F-Therien at a multiplicity of infection (m.o.i) of 1. Culture medium was collected at 3 
days post infection (d.p.i) when CPE was obvious in the culture. Cell-free (clarified) virus stock was pre-
pared by collecting supernatant of such medium after high speed centrifugation. Each batch of virus stock 
was titered by plaque assay to calculate its infectivity. Medium for mock infection was similarly prepared 
from the non-infected Vero cells. hNPCs were infected as follows: after the removal of culture media, 
cells were washed once with phosphate buffered saline (PBS) with calcium and magnesium (KCl 
2.68mM, KH2PO4 1.47mM, NaCl 136.89 mM, Na2HPO4 8.1mM, CaCl2 0.9mM, MgCl2 0.49mM) and 
infected with RUBV stock at the appropriate m.o.i. The plates were incubated at 37°C for one hour to 
allow adsorption. The inoculum was removed and replaced by complete neural expansion medium sup-
plemented with growth factors. Culture medium was collected at appropriate times to test for the presence 
of virus by standard plaque assay on Vero cells. 
2.2.3 RUBV growth curve characterization (infection strategy and plaque assay) 
To characterize RUBV growth kinetics, hNP1 cells at 60-70% confluency were infected with 
RUBV at an m.o.i of either 0.1 or 10, and the medium was changed and collected on a daily basis for 10 
days. For long-term characterization, mock and RUBV-infected cells were passaged every 7-10 days for 
30 days. The amount of infectious RUBV in the medium collected from infected hNP1 cells was titered 
by plaque assay. For plaque assay, serial ten-fold dilutions of RUBV were inoculated onto semi-confluent 
Vero cell monolayers. After adsorption (1h, 35°C), the inoculum was removed and the cells were overlaid 
with MEM containing 0.7% plaque agarose (Miles) and incubated for 7 days at 35°C. Plaques were visu-
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alized by staining the monolayer with crystal violet fixing solution (1% crystal violet, 3.7% formaldehyde, 
1% Methanol in PBS) after removal of the agar overlay.  
2.2.4 Virus genome detection by reverse-transcription PCR (RT-PCR) and quantitative reverse-
transcription PCR (qRT-PCR) 
Total RNA was extracted from mock and RUBV- infected hNPCs by using TRIzol reagent (Mo-
lecular Research Center. Inc) according to the manufacturer’s instructions. Isolated RNA was quantified 
with a Nano Drop spectrophotometer (Thermo scientific) and 500 ng of RNA was reverse transcribed 
with Super-Script II reverse transcriptase (Invitrogen Life Technologies), using oligo dT (Invitrogen) as a 
primer to amplify all mRNAs or 3’-E1/808reverse primer (5’-TTTTTTTTTCTATACAGCAAC-3’; T9 
followed by the complement of nt 9751–9762 of the RUBV genome) to specifically amplify RUBV RNA.  
cDNA was used to perform real-time PCR with a Prism 7500 Fast Real-Time PCR System using SYBR 
green PCR master mix (Applied Bioscience) in a 20µl reaction mixture. For PCR, samples were held for 
5 min at 95°C and then subjected to 30 amplification cycles consisting of incubation at 95°C for 30 sec, 
56°C for 30 sec, and 72°C for 2min, with a final extension step at 72°C for 7 min. Primers used for viral 
genome detection were: Forward: F8812  (5’-CAACACGCCGCACGGACAAC-3’) and Reverse: R9140 
(5’-ACTCCACATACGCGCTGGAC-3’), this pair of primers amplified a region within the RUBV E1 
gene. Primers for hNPC gene expression profiling are listed in Table 4.1.  
2.2.5 Live-cell morphology changes 
Cell morphology changes were monitored on an inverted Nikon TMS-F microscope (using a 20× 
objective). Non-infected and infected cells were monitored in parallel. Cell morphology and the presence 
or absence of CPE was compared. 
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2.2.6 Immunofluorecent assay (IFA) 
Standard immunocyto-fluorescence was performed. hNPCs grown on coated glass-coverslips (80% 
confluence) were fixed with 4% paraformaldehyde (Electron Microscopy Sciences) in PBS for 10 
minutes at room temperature, rinsed twice with PBS and then permeabilized with 0.2% TritonX-100 di-
luted in PBS for 5-7 min. Primary antibodies were incubated in 3% FBS diluted in PBS for 1.5-2 hours at 
room temperature, washed twice with PBS and incubated for 1 hr at room temperature with secondary 
antibodies in 0.1% FBS. After rinsing, cell nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI; 
0.1g/ml; Invitrogen).hNPCs have poor attachment properties on glass coverslips coated with Matrigel, 
therefore, all reagents mentioned above were pre-warmed to room temperature prior to usage. Primary 
antibodies used were directed against nestin (a neural stem marker; 1:450 dilution; Neuromics), E2 (a 
RUBV-envelope protein, 1:100 dilution, Epitomics) and β-tubulin (cytoskeleton marker, 1:200 dilution, 
Abcam). Secondary antibodies were anti-rabbit/mouse Alexa Fluor 488 and anti-rabbit/mouse Alexa Flu-
or 594 (1: 2000-4000 dilution; Molecular Probes-Invitrogen Life Technologies). Fluorescence images 
were acquired on a Zeiss Axioplan-epifluorescence wide-field microscope and processed with Axio-
Vision software. For each condition within the same experiment, at least 3 fields of view were analyzed.  
2.2.7 Flow cytometry 
The percentage of cells expressing virus antigens or lineage specific markers was determined by 
flow cytometry. hNPCs were harvested and washed twice with 2%FBS/PBS (staining buffer) and then 
fixed with  BD Cytofix/Cytoperm solution according to the manufacturer’s instructions (BD Bioscience) 
in aliquots of 100,000 cells in replicate for each antigen. Each aliquot was stained with one or two of the 
selected cell marker antibodies for 1 hr on ice. Antibodies used were: anti-RUBV E2; anti-nestin, anti-
SOX2 (either conjugated with appropriate fluorescent dye or in conjunction with a separate dye-
conjugated secondary antibody), all obtained from BD Pharmingen. Cells were then washed twice with 
staining buffer and then labeled with secondary antibody for 45 min to 1.5hr, if appropriate. Cells stained 
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with isotype controls (mouse IgG APC, rat IgM PE, or mouse IgG FITC (BD Pharmingen) were used as 
controls. Flow cytometry was performed using a BD LSR Fortessa or FACS Canto, both from BD Bio-
science and available in the Department of Biology Core Facility at Georgia State University. Forward 
and side-scatter plots were used to exclude dead cells and debris from the histogram analysis. Data analy-
sis was performed using FACS Diva software (BD Bioscience). The percentage of cells expressing fluo-
rescence intensity greater than the control cells was calculated using the FlowJo program (Tree Star, Inc., 
Ashland, Oregon). 
2.2.8 Western Blot 
Cells were lysed in 500 µl lysis buffer (10 mM Tris (pH 8.0), 150 mM NaCl, 1% Triton X-100, 0.5% 
sodium deoxycholate, 0.1% SDS and 1× protease inhibitor cocktail (EDTA-free, Roche)) at  appropriate 
time points. After clearing insoluble debris by high-speed centrifugation (10 min at 16000 g in an Eppen-
dorf tabletop #5415D centrifuge), lysates were adjusted to 1× with the addition of 5X SDS-sample buffer 
(250 mM Tris-HCl pH 6.8, 20 mM DTT, 10% SDS, 0.2% bromophenol blue, 50% glycerol) and heat-
denatured by boiling for 5min. Each lysate was loaded onto a 10% or 12%  SDS-PAGE gel, resolved and 
transferred to nitrocellulose membrane (Whatman) using 1X transfer buffer (100 ml 10X transfer buffer 
(250 mM Tris, 192 M glycine), 200 ml methanol, and 700 ml deionized water) and a mini-Protean II ap-
paratus (BioRad) at 100V for 1 hour. Blots were blocked in Tris-buffered saline (TBS: 25mM Tris, 
150mM NaCl,2mM KCl, pH7.4) containing 5% non-fat dry milk for 1 hour, washed once with TBS, fol-
lowed by incubation with the primary antibody overnight at 4°C. After washing with TBS 3 times, the 
blots were incubated for 2 hours with alkaline phosphatase-conjugated anti-rabbit or anti-mouse antibody 
(1:5000 dilution; Promega). After 3 washes with TBS, the blot was reacted with NBT/BCIP (Roche) di-
luted in 10 ml alkaline phosphatase buffer (100 mM Tris, 100 mM NaCl, 50 mM MgCl2-6H20, pH 9.8) 
for color development. Primary antibodies used in this assay were anti-GAPDH (1:5000 dilution; Abcam), 
anti-NF-kB p65 (1:200 dilution; Santa Cruz); anti-phospho-STAT3 (1:200 dilution; Cell Signaling), anti-
phospho-IRF3 (1:1000 dilution; Eptomics) and anti-cleaved-caspase 3 (1:1000; Cell Signaling). 
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2.3 RESULTS 
2.3.1 hNPCs are permissive for RUBV infection 
We assessed the ability of hNPCs to support the full RUBV viral life cycle, from entry at the cell 
surface to release of newly formed virionx. First, to test the permissiveness of hNPCs for RUBV infection, 
we plated hNPCs onto Matrigel-coated plates and infected them at an m.o.i of 0.1 or 10pfu/cell. The ca-
pacity of RUBV to enter, to replicate, and to disseminate in hNPCs were evaluated by immunofluores-
cence on days 1, 2, 4 and 6 following infection using an antibody directed towards the viral envelope pro-
tein E2. At an m.o.i of 0.1, E2 positive cells were minimally demonstrable throughout the infection time 
course (data not shown). However, at an m.o.i of 10, E2 positive cells were readily detectable, ranging 
from 5%±1.5% to 11.5%±3.3% during the infection time course (Figure.2.1A and C). E2 protein was 
distributed in perinuclear regions inside the cells, which is consistent with other cell lines infected by 
RUBV, but later spread to the whole cell. The infected hNPCs also expressed capsid protein, another 
marker of permissiveness for infection (Figure.2.1B). Presence of viral antigen inside cells, albeit a small 
number (~10%), confirmed that RUBV could gain access into hNPCs. The number of E2 positive cells 
increased significantly from day 1 to day 2 but not later, suggesting that RUBV replicated but was re-
stricted in its dissemination (Figure.2.1C). 
2.3.2 Infected hNPCs support a modest-level of replication of RUBV 
To further evaluate the susceptibility of hNPCs to RUBV infection, we also examined the intracel-
lular production of virus RNA and extracellular production of virus. First, intracellular viral RNA in 
hNPCs and its temporal changes post- infection were assessed by real-time qRT-PCR and RT-PCR at 
early and late times of infection. Control and RUBV infected (m.o.i of 10) cells were collected at days 1, 
2, 4, and 6 after infection. Viral RNA levels, as tested by real-time qRT-PCR, increased moderately from 
day 1 to day 4 post infection, a good indication of RUBV replication in cell culture after infection. How-
ever, further accumulation of virus RNA was not demonstrated after 4 days of infection, which may be 
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concomitant with the inability of the virus to spread beyond 5-10% of the cells. (Figure.2.2.A). hNPCs 
failed to eliminate RUBV as viral genome was still detectable after 10 days of infection even by semi-
quantitative RT-PCR (Figure 2.2.B). To evaluate extracellular virus yield, hNPCs were infected with ei-
ther a high m.o.i. (10) or a low m.o.i. (0.1) and culture medium was changed daily so that amount of 
progeny virus produced each day could be determined. The extracellular virus titer obtained by plaque 
assay showed a similar trend as intracellular virus yield: although there was an increase in the virus titer 
from days 1 to day 4 post infection, daily virus production was not increased thereafter and a constant but 
modest level (10
3
-10
4
pfu/ml) of progeny virus was released from the culture daily through 10 d.p.i (Fig-
ure.2.3). This pattern was not related to initial virus input as hNPCs infected with m.o.i of 0.1 of RUBV 
showed a similar virus growth curve as those infected with a m.o.i of 10. Taken together, this indicates 
that RUBV had a limited capacity to replicate, possibly related to the low percentage of infected cells, but 
was able to persistently infect hNPCs. 
2.3.3 RUBV undergoes genetic modifications during infection in hNPCs 
To characterize the mechanism of RUBV persistence in hNPCs, we compared the plaques of 
RUBV produced from infected hNPCs to RUBV produced from the standard cell line, Vero, since the 
shape and size of a virus plaque often indicates if there were significant mutations within a persistent 
population compared to original stock and mutations often contribute to virus persistence in culture [216]. 
Although both samples of virus were able to form plaques with smooth edges, a smaller plaque size was 
observed by the RUBV produced from infected hNPCs compared to those propagated from Vero cells 
(Figure.2.4.A and B), suggesting extensive genetic modification and selection events occurred during in-
fection of the hNPCs. The smaller plaque size of RUBV also suggested replication-limited mutants were 
selected in the hNPCs, which possibly explained the ability of the virus to persist without adversely af-
fecting the infected cells. RUBV infected  
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2.3.4 RUBV infected hNPCs did not develop CPE 
We also monitored morphological changes using light-microscopy to assess the development of cy-
topathic effect (CPE) in RUBV infected hNPCs (data not shown). Vero and hNPCs were infected in par-
allel. CPE developed in infected Vero cells at 3-4 days post infection evidenced by detachment of cells 
from the monolayers (so called :"floaters") , while RUBV infected hNPC cultures and uninfected cells 
both appeared healthy 10 days post infection. Four weeks after infection, more than 90% cells still stained 
positive with anti-Nestin and SOX2 antibody (Figure. 2.6 D). Since Nestin and SOX2 are two important 
markers for multipotency, this result indicated that RUBV did not alter the stemness. 
2.3.5 RUBV infected cells exhibit hNPC stemness marker 
Finally, considering the nonhomogeneous nature of hNP1 cells [137],we wanted to verify that 
RUBV infected cells in hNPC cultures were authentic neural progenitors instead of other lineages. Dou-
ble staining of the infected culture at an early time points (4 and 6 d.p.i) showed that viral antigen E2 col-
ocalized with the stemness marker Nestin which is present in neural progenitor populations (Figure 2.5A).  
Among E2 negative cells, ~90% were found to be Nestin positive, while among E2 staining positive cells, 
~100% were found to be Nestin positive, indicating that RUBV preferentially infects the neural progeni-
tor population (Figure 2.5B). Therefore, we demonstrated that RUBV infected cells within the hNPC cul-
ture were authentic progenitors and not other lineages. Also, RUBV infection did not alter the expression 
of cellular stemness markers in the hNPCs during early infection. 
2.3.6 Influence of long-term RUBV infection on biological features of hNPCs 
To investigate whether RUBV persistence in hNPCs has the potential to cause biological changes 
in the neural progenitor cell population, RUBV virus production, cell morphology, lineage specific mark-
er expression and CPE were compared in long term RUBV-infected and uninfected hNPCs. 
Intracellular and extracellular virus yield 
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hNPCs were infected at either a high m.o.i (10) or a low m.o.i (0.1) as described above and further 
subcultured, with an average of one passage a week for up to one month. Culture medium was collected 
every other day to determine the amount of virus shedding from the culture. Infectious virus was present 
in culture fluid for up to one month, especially in the cells infected with a high m.o.i., demonstrating that 
RUBV established a persistent infection in hNPCs (Figure.2.6.A). The decrease in virus titer during time 
course was likely due to either the loss of infected cells during passaging or to the cells becoming too old 
and no longer able to support virus replication. Although extracellular virus production was not detectable  
after 27 days following an infection at an m.o.i. of 0.1, intracellular viral RNA was still readily detectable 
by more sensitive techniques, such as RT-PCR (Figure.2.6.B).Taking this into consideration, RUBV in-
deed was able to persist in hNPCs long term. 
Cell morphology changes 
Previous studies have shown that RUBV alters cell morphology in persistently infected cultures 
[93].We next examined if this is the case in hNPCs. After 2 to 3 subcultures following RUBV infection 
(m.o.i of 10), hNPCs were double stained with anti-E2 antibody to detect RUBV infected cells and anti-
Tubulin antibody to highlight the hNPC's cytoskeleton system. Cell morphology was first compared be-
tween infected cells (E2 positive) and neighboring cells (E2 negative) within infected culture, with no 
detectable difference seen between these two groups (Figure.2.6.C). We then wondered if the entire in-
fected culture underwent morphological changes compared to uninfected cultures. Therefore, we com-
pared the cell morphology between individual cells within uninfected and RUBV-infected cultures. Ran-
dom cells were selected and no significant alteration of cell morphology was observed between the two 
cultures (Figure 2.6.D). At later passages, it was not unusual to observe cells with a different morphology. 
However, this was observed in both infected and uninfected cultures, and therefore was not due to RUBV 
infection but rather to natural differentiation occurring in hNPCs grown on matrigel-coated plates. Quan-
tification of morphological properties showed that the median cell body area and cell process /dimensions 
of long-term RUBV infected progenitor populations (21 days after infection) did not differ significantly 
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from cells in uninfected  populations (data not shown). Therefore, although RUBV persisted in hNPCs 
long-term, the virus did not induce morphological changes to individual infected cells as well the whole 
population. 
Stemness and lineage specific marker expression 
To determine whether RUBV infection altered expression of cellular markers in the hNPCs, the 
expression of stemness as well as lineage specific markers was examined at both the protein and RNA 
level. At 27 days post-infection, expression of two stemness markers, Nestin and SOX2 (markers that are 
constantly expressed by proliferating hNPCs; literature from ArunA Biomedical), between RUBV infect-
ed and uninfected hNPC cultures was examined. As expected, RUBV infection did not alter the percent-
age of cells expressing Nestin or SOX2. Quantification of the number of cells displaying these markers by 
flow cytometry showed that expression did not vary in response to RUBV infection either at a high m.o.i 
(10) or a low m.o.i. (0.1). These data showed that 87%±1.2% of uninfected hNPCs were Nestin positive 
versus 84%±1.5% Nestin positive following RUBV infection. Similar results were obtained when the 
expression of the SOX2 marker was examined (84.3% of the uninfected hNPCs vs. 83% positive follow-
ing viral infection Figure 2.6.E). Mean fluorescence intensity for these markers also remained unaltered 
during infection. The percentage of Nestin and SOX2 positive hNPCs after long-term culture was gener-
ally lower than those hNPCs at early passages (85% of hNPCs cultured for long term vs. >90% of hNPCs 
at passage 6-8), confirming the morphological observations. Thus, the immature state of hNPCs was af-
fected by serial passaging on matrigel-coated plates, but no alteration of the undifferentiated phenotype, 
based on morphology or expression of Nestin level, was observed in relation to RUBV infection. 
At the end of the infection time course, 30 d.p.i, real-time qRT-PCR was used to investigate the 
changes in hNPCs multipotency (stemness) as well as lineage specific marker mRNA levels after RUBV 
infection (Figure.2.6.F). A wide spectrum of cellular markers were tested, including one pluripotency 
marker (Oct3/4), four classical multipotency markers (Nestin, SOX2, Pax6 and Musashi-1), one early 
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neuron/glial specific marker (Olig2), two neuronal specific markers(Map2 and Tuj-1 (β-tubulin-III), one 
astrocyte specific marker (Gfap) and a proliferation marker Ki-67. Compared to uninfected hNPCs that 
had been cultured for same period of time, RUBV-infected hNPCs did not have significant up-regulation 
or down-regulation in the expression of either multipotency as well as lineage specific genes. However, 
the mRNA level of Ki-67 was down-regulated ~7 fold in RUBV infected cultures compared to the unin-
fected cultures, indicating that proliferation of hNPCs may be attenuated upon virus infection. This was 
further verified at protein level by flow cytometry quantitation (shown in Chapter 4). Together, this data 
suggested that RUBV did not alter hNPCs multipotency as well as lineage specific marker expression up-
on infection, and instead, may impact cell proliferation in the long-term. 
Cytopathic effect 
CPE was examined at every passage during the long-term infection course using light-microscopy. 
RUBV infection induced no cytopathic effect to hNPCs cultures, either at early or late passage (data not 
shown) 
2.4 DISCUSSION 
As summarized in the Introduction, RUBV remains the most efficient  infectious agent with respect 
to induction of  fetal neurodevelopmental detects, including microcephaly, mental retardation, encephali-
tis, cerebral palsy, autism, schizophrenia, and sensorineural deafness [94]. The mechanisms underlying 
such congenital disorders are still unclear. Since the primary time in gestation when RUBV exhibits pro-
found teratogenicity,  i.e. the first trimester coincides with organogenesis in the developing fetus, it was 
proposed that RUBV interferes with the maturation of fetus by  upsetting the delicate balance of the pro-
liferation as well as the differentiation of embryonic and progenitor cells  during early stages of gestation 
[101]. Such a notion  is further supported by the observations that RUBV successfully infects selective 
neuronal cell cultures in vitro [5], but the underlying mechanism is unclear, especially considering the 
lack of suitable human cell culture models. In this study, we took advantage of the availability of human 
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embryonic stem cell derived neural progenitor cells to investigate the effect of RUBV on the fetal nervous 
system development processes to gain insight into the mechanisms of teratogenicity. Furthermore, we 
wanted to test RUBV infection of hESC’s and hESC-derived precursor cells to determine its utility as 
such a model system. 
To this end, we first investigated the susceptibility of hNPCs to RUBV infection, which means 
ability of hNPCs to support the full RUBV viral life cycle, from entry at the cell surface to release of 
newly formed virion. The ability of RUBV to infect hNPC's was demonstrated by a roughly 1-log in-
crease in virus titer, which represents extracellular virus production, over the infection time course, albeit 
at 1-2 log lower levels than produced in permissive Vero cells.  Additionally, qRT-PCR analysis of intra-
cellular viral genome has shown a similar increase over the time course. We found that only 10~20% of 
the cells in infected cultures exhibited RUBV-E2 antigen  and the percentage of antigen positive cells did 
not significantly increase over time, indicating RUBV had limited access to the progenitor cells. Infec-
tious virion production as well as viral nucleic acid was readily detectable in hNPCs even through 30 days 
after infection, suggested hNPCs did not clear RUBV and the virus was able to persist in the culture for at 
least one month. Together, hNPCs were susceptible to but supported a restricted replication and dissemi-
nation of RUBV. 
Nevertheless, the limited  nature of RUBV infection in hNPCs shown here correlated well with the 
situation in  CRS : RUBV can be readily isolated from most organs of aborted CRS fetuses, including the 
CNS, however only very low numbers of cells were actually infected (in the range of 1 in 10
3
 to 1 in 
10
5
cells) [49, 63]. Also, RUBV produced a similar titer in primary human fetal fibroblasts as in hNPCs 
[61, 182]. Persistent viral infection, similarly, is also a hallmark of CRS: cell cultures derived from organs 
from abortuses are persistently infected with RUBV and most CRS infants excrete viruses for up to 6 
months after birth [52, 62].  Thus, we believe RUBV infection of hNPCs well mimics the real situation in 
CRS and therefore it was worthwhile to look at how RUBV further impacts properties of hNPCs includ-
ing cell morphology, cell attachment, proliferation and differentiation. 
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RUBV has limited access to hNPCs.  In this regard, it is important to note that RUBV infection of 
even permissive cell lines is asynchronous for unknown reasons.  In Vero cells, 90% of the cells are in-
fected, but not until 48 hpi [12]; in the recently characterized infection of A549 cells, roughly 50% of the 
cells are eventually infected (Y. Zhou, personal communication). The first possible explanation for this is 
lack of RUBV-receptors on hNPCs’ cell surface to support robust viral entry. RUBV, like most enveloped 
mammalian viruses,  utilizes receptor-mediated endocytosis to enter targeted cells [217]. The only known 
RUBV receptor, MOG, was  not expressed in the hNPC cultures in our study (data not shown) [10]. MOG 
is a marker for mature oligodendrocytes and therefore we would expected no  expression in  undifferenti-
ated hNPCs [218]. It is thus likely that RUBV enters cells through interaction with other receptors that 
not yet been identified and that are not uniformly expressed on cells in hNPC cultures. Second, it has been 
postulated that embryonic stem/progenitor cells have intrinsic restrictive factors or lack cellular factors 
required for virus replication [219]. A good example of such intrinsic factors is cell surface charge. In our 
study, we tried using polybrene, a small chemical that neutralizes the charge repulsion between virions 
and sialic acid on the cell surface. Briefly, we use a mixture of viruses (m.o.i. of 10) and increasing 
amounts of polybrene for infection and quantified the number of viral antigen positive cells two days after 
infection. However, adding polybrene did not succeed in increasing the numbers of infected cells [220] 
(data not shown). In addition, since adding polybrene is considered to be a manipulation of cell culture, 
we did use this chemical in our following studies that requires the cells in their natural status. 
Restricted virus replication in hESCs and their derived cell lines has been shown with other viruses. 
Varicella-Zoster Virus (VZV) and human herpesvirus 8 (HHV-8 or KSHV), both Herpes viruses, are un-
able to infected hESCs cultured on mitotically inhibited feeder cells. This restriction remains even after  
bypassing of viral entry by transfection the viral DNA into cells [219]. Epstein - Barr virus (EBV), a Her-
pes virus, demonstrated a limited expression of viral genes in B Cells derived from murine ESCs and this 
was attributed to aberrant splicing and premature termination of EBNA mRNAs within the infected cells. 
Similarly, HCMV establishes a latent or latent-like infection in hESCs as the virus enters hESCs but does 
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not initiate a lytic infection as usual [221]. RNA viruses, for example influenza A virus, were able to enter 
mouse ESCs  and express some viral proteins, but the replication cycle was incomplete and no infectious 
virus was produced [128].Moreover, induced pluripotent stem cells (iPS) derived from human fibroblasts 
were shown not to be susceptible to HCMV infection, which usually exhibit efficient infection in hNPCs 
[222]. Thus, the hESCs and its derived embryonic progenitors appear to have some intrinsic resistance to 
virus infection. 
On the other hand, the apparent inability of RUBV to establish a robust productive infection in 
hNPCs is in striking contrast to some of the other teratogenic and/or neurovirulent viruses where a fully 
permissive of hNPCs to infection was seen. Viruses that produce  a robust infection in  hNPCs in vitro 
range  from the positive strand RNA virus West Nile virus to DNA viruses such as HCMV and HSV[4, 
119, 124, 148] (for a full list of virus see Table 1.3). We also showed that our hNPC cultures were fully 
susceptible to SINV. One possible explanation to this difference is the sources of cells utilized in the 
study. Most other studies used hNPCs derived from aborted fetuses or immortalized hNPC cell lines. Al-
ternatively, considering its slow progression in neurological disease, RUBV simply does not develop a 
typical pathology in hNPCs as other teratogenic viruses do. In fact, RUBV, together with measles virus, 
JC virus, HIV and HTLV, were categorized as slow viruses as they have a long period of incubation time 
before the onset of neurological disease symptoms.[112]. Conversely, there is a great difference in hNPCs 
cell susceptibility between RUBV and HCMV, which also teratogenic and induces similar congenital neu-
rological deficits. All of this suggests a distinct response from the host to RUBV infection during the ear-
ly stages of embryonic development in comparison with other viruses. 
Interestingly, although RUBV did not efficiently infect hNPCs, it showed a potential to establish a 
persistent infection in hNPCs. Virus nucleic acid was still readily evident in cultures that initially infected 
with either a high or low m.o.i after 30 days of infection, indicating the failure of hNPCs to eliminate 
RUBV in the long term. This type of persistence (minimum  virus production) has been previously 
demonstrated in our lab study using permissive  Vero cells, either infected with virus [87]or stably trans-
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fected with a RUBV replicon (a construct lacking the structural proteins)[163]. In the former case, the 
virus persisted even in the presence of antiviral antibody that inhibited cell to cell virus spread.  In the 
latter case, in presence of high doses IFN, the replicon still persisted despite suppression of gene expres-
sion. It is possible that RUBV persistence in hNPCs plays a role in progression of neurological disorders 
associated with CRS. In fact, our observation of a limited number of cells being  infected with RUBV in 
hNPC culture coincides with the  “clonal expansion” hypothesis which postulated that viral persistence 
contributes to the self-limited chronic infection seen in CRS [223]. Meanwhile, we should also take into 
account  the possibility of reactivation of RUBV replication at later stages of development or after birth, 
since this has been demonstrated in HIV-1 infection to hNPCs: the virus production was undetectable af-
ter 10 days but could be stimulated by the addition of tumor necrosis factor alpha (TNF-α)[198]. A transi-
ent instead of persistent infection mechanism was postulated recently to provide a plausible alternative 
mechanism that could explain many of the inconsistencies in MS and PRP research, where evidence of 
the presence of RUBV in PRP and MS brains are debatable[98, 104, 110, 111, 113-115, 224, 225]. How-
ever, this model cannot provide information on the factors initiating the disease, and both the triggering 
and relapse phase it proposes requires long-term viral residency. It should be noted that result of viral 
persistence on  CNS developmentseems to be host dependent. Although it is known from CRS  that 
RUBV  can persist in human tissue  and has an affinity to the CNS both in CRS and following acute 
infection, no unique neuropathological features are known which would explain the development of a 
progressive neurological disorder. It seems that once a virus which has a tendency to persistence enters 
the CNS, a disease process may start which in its clinical/pathological features is more host than virus 
dependent [226]. 
For the mechanism underlying establishment of persistence in hNPCs, it is possible that RUBV un-
dergoes genetic modifications during replication as we observed a reduced virus plaque size in RUBV 
produced in hNPCs compared to stock RUBV. A similar plaque-size mutant was observed in a the study 
of RUBV persistence  in human breast cells (MCF-7)[86].It is also possible that  defective interfering (DI) 
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RNAs  were generated as was shown in persistently infected Vero cells[87], however, this needs to be 
confirmed.  Our lab previously demonstrated that DI particles  appeared to play no role in the slow, non-
cytopathic replication of the virus [12]Alternatively, viral proteins possibly  play a role in persistence in-
stead of genetic modification. It has been suggested that RUBV capsid protein plays a role in stabilizing 
viral RNA therefore supported a long-term residence of RUBV genome in host cytoplasm[163] (Heather 
Mousa, unpublished data).  The capsid protein is also anti-apoptotic [75], which would preserve infected 
cells. 
RUBV did not alter the cell morphology or induce CPE in infected hNPCs. This is consistent pre-
vious studies with RUBV in which human and murine embryonic cells infected with RUBV showed no 
apparent abnormalities [53, 61, 62, 66]. The non-cytopathic effect nature of RUBV is also seen in vivo in 
brain autopsies of PRP patients [36]. Although disintegration of actin-filament has been demonstrated in 
BHK-21 cells and an elongated cell shape was observed in A549 cells after RUBV infection, however, 
neither of these cells were embryonic and therefore do not represent the authentic  situations  congenital 
infection[89].  
RUBV also did not alter the expression of stemness and lineage marker of proliferating hNPCs, in-
dicating that RUBV did not change the multipotency of such cells upon infection. This is in contrast with 
the hMPro studies, where the virus down-regulated the expression CD73 in the cells (Y. Zhou, un-
published data). Therefore, the result of RUBV infection to the stemness of progenitor cells seems to be 
lineage specific. The lack of apparent change in cell marker and cell morphology in hNPC upon RUBV 
infection could possibly due to low percentile of virus being infected in hNPC culture. However, this 
could also be attributed to the non-cytolytic nature of the virus regardless of the permissiveness of the cell 
culture used in the study. In a recent study, human fetal endothelial cells (HUVEC) were shown highly 
permissive to RUBV infection (90%~100% of cells were infected), but  there was no changes in cell mor-
phology as well as global protein synthesis [221]. Not limited to RUBV, BDV infection proceeds without 
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an overt pathogenic effect in hNPCs, impairing neither their cell morphology nor their undifferentiated 
phenotype [151, 209]. 
Thus, in this section we showed that RUBV infected hNPCs and confirmed our plans to explore 
this model system. However, there is a recently developing caveat. The RUBV strain F-Therein was em-
ployed throughout this study. F-Therein is a derivative of a wild type (wt) clinical strain, Therein, which 
was  selected for large plaques and high virus yield and plaque purified in Vero cells [227]. The virus 
strain was chosen in our study because of its robust  replication rate in Vero and other cell lines routinely 
used in RUBV in vitro studies as well as because it is our standard lab strain. However, in a recent study 
in HUVECs, capillary endothelial cells with are thought to be a target organ during RUBV infection, it 
was shown that fresh clinical isolates induced a much higher rate of infection (90-100%) than did lab 
adapted strains, such as F-Therien (similar results have been obtained with HCMV)[228, 229].  This pub-
lication came out after our study was completed and the authors refused to share their clinical viruses with 
us until after their study appeared and an MTA executed.  Considering their findings, it would be of great 
interest to infect hNPCs with fresh clinical isolates to see if characteristics of the infection, in particular 
the percentage of infected cells, would be affected. 
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Figure 2.1 Viral antigen detection and percentage of infected cell determination by indirect immu-
noflorescent assay. 
(A) The susceptibility of hNPCs to RUBV infection was analyzed with an antibody directed toward the 
viral envelope protein E2.  At day 1, 2, 4, and 6 days post infection (d.p.i) (m.o.i=10), cells were fixed, 
permeabilized, and analyzed by fluorescence microscopy. Perinuclear distribution of viral antigen was 
shown in higher magnification (upper left panel in RUBV 1d.p.i). Anti-E2 antibody (red) detected RUBV 
antigen and Hoechest stain (blue) detected nuclei. Bars, 10µm. (B) Immunofluorescece staining of infect-
ed cells with anti-RUBV-Capsid at 100x magnification. Hoechest stain (blue) was used to detect nuclei. 
Bars, 10µm.(C) Based on E2 immunostaining, the percentage of infected hNPCs was determined. At least 
200 cells from three different fields were counted at each time point. Each time point was repeated at least 
twice. Error bars represent SDs.
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Figure 2.2 Viral RNA detection at early and late times of infection. 
(A) hNPCs were infected with RUBV at an m.o.i of 10, and intracellular RNA was extracted at days 1,2,4, 
and 6 post infection. Intracellular viral RNA levels were assessed by real-time qRT-PCR. Each experi-
ment was done in triplicate and repeated at least twice. Representative data from one experiment are 
shown. The viral RNA levels were normalized to GAPDH mRNA in the same sample and are shown as 
fold change over the amount of viral RNA in non-infected control (NC). (B) RT-PCR against RUBV E1 
gene (1110bp) after 10days of infection (cells from the growth curve experiment), showing positive am-
plification of viral nucleic acid at infection of m.o.i.'s of both 10 .and 0.1. This experiment was repeated 
three times and a representative gel is shown.  
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Figure 2.3 RUBV growth curve in proliferating hNPCs. 
Undifferentiated hNPCs (passage 6-10) were seeded in plates and infected with RUBV at an m.o.i. of ei-
ther 10 or 0.1 on the next day. For 10 days, the medium was changed and collected daily for titering the 
amount of virus produced daily. Each data point is the average of duplicate titration from three experi-
ments. Error bars represent SDs.  
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Figure 2.4 Plaque size comparison between stock RUBV and hNPCs produced RUBV. 
hNPCs were infected with RUBV at an m.o.i of 1, which is the moi used to produce stock RUBV in Vero 
cells. Virus was collected at day 3 post infection and then titered by standard plaque assay together with 
original stock RUBV. (A) Image of plaques produced by stock RUBV and virus grown in hNPCs (B) 
Quantification of plaque size. This experiment was repeated 3 times and the error bars represent SDs. *, 
statistical significance compared to the stock control was determined at a 95% confidence interval 
(P<0.05).
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Figure 2.5 Infected cells display the hNPC stemness marker Nestin. 
(A)hNPCs (passage 6-10) were infected with RUBV at an m.o.i of 10. At day 3 post infection, cells were 
fixed, permeabilized, and analyzed by immunofluorescence microscopy. Anti-E2 antibody (red) detected 
RUBV E2 antigen, anti-Nestin (green) detected Nestin protein, and Hoechst stain (blue) detected nuclei. 
Arrows denote colocalization of E2 viral antigen and stemness markers Nestin present on hNPCs. Bars, 
10µm. (B) Enumeration of Nestin positive cells by immunofluorescence staining. The percentage of Nes-
tin positive cells within the whole population and within the RUBV infected (E2 positive) population was 
determined. Error bars indicate SDs . 
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Figure 2.6 RUBV persists in hNPCs without altering their morphology and undifferentiated pheno-
type. 
(A) hNPCs (passage 6-10) were infected with RUBV at an moi of  10   or 0.1  and subcultured as denoted 
by the arrows . Extracellular virus yield was determined by plaque assay on Vero cells. Each data point is 
the average of duplicate titration from at least two experiments. Error bar represent SDs. (B) RT-PCR 
against RUBV E1 gene (1110bp) after 27days of infection (cells from the growth curve exp), showing 
positive amplification of viral nucleic acid after infection with both m.o.i.'s . This experiment was repeat-
ed three times. (C,D) At day 21 post infection, cells were fixed, permeabilized, and then cell morphology 
was analyzed by immunostaining with anti-tubulin antibody (green) together with anti-E2 antibody (red) 
to detect infected cells and Hoechest stain (blue) to visualize nuclei. Cell morphologies were compared 
between infected cells and neighboring uninfected cell within the infected culture (C), or individual cells 
in the uninfected culture with those in the infected culture (D). Bars, 10µm. (E) Expression of stemness 
marker Nestin and SOX2 were examined at day 27 post infection by flow cytometry. Error bars represent 
SD from at least two independent experiments.(F) RNA isolated from control and RUBV infected hNPCs 
at day 30 post infection were used to perform real-time qRT-PCR of various stemness and differentiation 
genes. Each experiment were done in triplicate and repeated at least twice, and representative data from 
one experiment are shown. The gene expression level was normalized to GAPDH mRNA in the same 
sample and was shown as fold change over the amount in the uninfected control at same time point. Error 
bars represent SDs. *, statistical significance compared to the control (P<0.05).
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CHAPTER 3 : RUBV ATTENUATES HUMAN NEURAL PROGENITOR CELL GROWTH BY 
MITOTIC INHIBITION INSTEAD OF TRIGGERING CELL DEATH 
3.1 INTRODUCTION 
RUBV-induced fetal damage is hypothesized to be multi-factorial, resulting from a combination of 
virus-induced effects [22].  A constant feature of CRS is fetal growth retardation, which has been specu-
lated to be due to reduced or slower cell division [36].Microscopic analyses of aborted infected fetuses 
revealed cellular damage in multiple sites, with noninflammatory characteristics being common in the 
structures of the eyes, heart, brain, and ears [40]. Additionally, as previously stated, RUBV replication did 
result in  cytopathic effect on neural lineage cells and was reported to  induce apoptosis in those cells[78]. 
In vitro studies are similarly controversial: RUBV was reported to induce apoptosis in Vero, BHK, human 
normal-term placenta chorionic villi explants (CVE) and in monolayers of cytotrophoblasts (CTB), but 
does not induce apoptosis in primary human embryo fibroblast (HEF) cultures. Hobman et.,al reported 
recently that RUBV infection caused resistance to staurosporine (ST) induced apoptosis in A549 cells[75]. 
RUBV nonstructural protein P90 was also reported to bind to the cell division regulators RB and Citron-
Kinase [69], adding difficulties in finding reasons behind retarded growth of CRS infants.  
Therefore, in this part of the study, the effect of RUBV infection on hNPC cell proliferation and 
division was analyzed, first on a population level by cell counting and EdU incorporation assay. We 
found a modest effect on hNPC proliferation, but cell death (the presence of floaters) was not induced 
upon virus infection. Since few cells were infected in the hNPC population, we then investigated how 
virus impacts hNPCs proliferation at a single cell level mostly by double-immunofluorescence staining of 
virus antigen and desired cell markers. We showed that RUBV attenuated cell growth by introducing cell 
mitotic inhibition instead of apoptosis, a mechanism suggested previously by others [61, 64, 66-69, 159, 
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230]. Finally, a cellular inflammatory response in the form of infammatory cytokines was not induced by 
RUBV infection, possibly explaining in part the lack of an apoptotic response. 
3.2 MATERIAL AND METHODS 
3.2.1 Cell culture 
hNPCs were maintained as previously described in Chapter2 and  for all experiments passage 6-10 
cells were used. Human adenocarcinomic alveolar basal epithelial cells (A549) were used as a control and 
were maintained in Ham's F-12, Kaign's modification (Cellgro), 10% Fetal Bovine Serum (Atlanta Bio-
Tech), and 100 unit/ml Pen-Strep (Invitrogen) at 37ºC and 5% CO2. 
3.2.2 Cell growth curve characterization 
To obtain a cell growth curve in the absence or presence of RUBV infection, a standard cell count-
ing experiment was performed in which 50,000-100,000  hNPCs were plated onto each well of a 24 well 
plate, infected with RUBV at m.o.i of 10 pfu/cell the next day, and the medium was changed every day 
for 10 days. Every day, one well of the mock infected and RUBV infected cells were counted for total cell 
number present in well (including floating cells present in medium). To do so, the cells were scraped from 
the well and counted manually using a hemocytometer under a light microscope. 
3.2.3 EdU incorporation assay 
A Click it
TM 
Alexa Fluor-547 EdU incorporation kit (Invitrogen) was used to assess the cell prolif-
eration rate according to the instructions of the manufacturer.EdU (5-ethynyl-2’-deoxyuridine) is a novel 
alternative for the standard BrdU (5-bromo-2’-deoxyuridine) assay to directly measure active DNA syn-
thesis or S-phase synthesis of the cell cycle. EdU is a nucleoside analog of thymidine and is incorporated 
into DNA during active DNA synthesis. Detection of EdU is based on a click reaction, which is a copper 
(I) catalyzed reaction between an azide and an alkyne. Briefly, cells in monolayers were first pulsed with 
10µM EdU for 2 hours. Cells (1×10
6
 per 50µL) were fixed with BD Fix/Perm buffer (BD Bioscience) and 
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washed twice with PBS-1% FBS and then permeabilized with BD Perm/Wash buffer (1:10 diluted in de-
ionized water). After the fixation/permeabilization process, cells were treated with Click it
TM
 reaction 
mixture for 30-45 minutes to expose incorporated EdU for detection. Samples were washed twice with 
Perm/Wash buffer before analysis using flow cytometry as described in Chapter 2. 
3.2.4 Apoptosis assays 
Multiple assays were used to detect apoptotic events in hNPC cultures. (a) For the assessment of 
viral induced cell apoptosis, active-caspase-3/RUBV-E2 double staining was performed according to 
standard immunofluorescence assay (IFA) protocol (see Chapter 2). A monolayer of hNPC was seeded 
onto a coverslip and infected with RUBV at a m.o.i of 10 the next day.  Cells were fixed and analyzed at 
days 1, 2, 4 and 6 post infection. Primary antibodies used in this assay were anti-active-caspase-3 (1:500; 
Cell Signaling) and anti-RUBV-E2 (1:100; Eptomics). For image analysis, the number of active caspase-
3positive cells, number of E2 positive cells, and number of active-caspase-3 and E2 positive (double posi-
tive) cells over number of total cells in same field was compared between mock-infected and RUBV-
infected cells. (b)  A terminal deoxynucleotidyltransferase-dUTP nick end labeling (TUNEL) assay car-
ried out using the Click –it TM TUNEL Alexa Fluor Imaging Assay kit (Molecular Probes, Inc), in ac-
cordance with the manufacturer’s instructions. (c) To assess number of apoptotic cells in a whole cell 
population, cells were scraped and resuspended at a concentration of 1×10
6
 cells/100µl, followed by 
standard flow cytometry analysis as described in Chapter 2. Antibody used in this part of study was BD 
Horizon
s
 V450 anti- active Caspase 3 antibody (5µl/aliquot). 
3.2.5 Cell death assay by propidium iodide staining 
For assessment of total cell death in uninfected and infected cultures, uninfected control and RUBV 
infected hNPCs at different d.p.i (2, 4, 6, 8, and 10 d.p.i) were detached and collected in 1% FBS/PBS. 
Then 500 µl of each sample (1× 10
6
cells) was incubated with 1 µl of propidium iodide (PI) (1mg/mL; 
Invitrogen) in the dark for 30 min at room temperature. After a wash with 1% FBS/PBS, the samples 
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were analyzed by cell sorting using a BD LSR Fortessa. Data analysis was performed using FACS Diva 
software (BD Bioscience).  
3.2.6 Proliferation assays 
Ki-67 and RUBV-capsid double staining was performed to assess the effect of RUBV infection on 
the hNPC cell cycle. Briefly, hNPCs were seeded onto coverslips and were infected at an m.o.i of 
10pfu/cell with RUBV the next day. Cells were fixed at day 2, 6, and 8 post infection. Standard immuno-
fluorescence assay (see Chapter 2) was performed to detect proliferating cells as well as viral antigen pos-
itive cells. Antibodies used in this study were anti-Ki-67 (1:150; BD Bioscience) and anti-RUBV-capsid 
(1:100; Eptomics). For image analysis, the number of Ki-67 positive cells, the number of capsid positive 
cells, and the number of Ki-67 and capsid positive (double positive) cells over number of total number of 
cells in same field was compared between the mock infected and RUBV infected cultures. Ki-67 gene 
expression was also assessed by qPCR as described in Chapter 2.  
3.2.7 Image processing by Cell Profiler 
Image quantification was performed using the Cell Profiler (http://www.cellprofiler.org/) software 
(Broad Institute). Pipeline was used to identify the number of objects per image (primary object) and then 
number of positive cells under each fluorescent color (secondary object). The percentage of positive cells 
was calculated by overlaying identified secondary objects with the primary object. More specifically, 
CellProfiler allows for the automatic calculation of cell number via nuclei extraction and quantification. 
An optimized cell outline is then generated for each nucleus based on the intensity and distribution of pe-
ri-nuclear-immunostaining. Individual frame wise thresholds for overall immunostain intensity and im-
munostain intensity/cell area were then established on the basis of a consensus selection of representative 
cells considered to be either immune-positive or negative. Application of these thresholds across the en-
tire frame then allowed for the automatic quantification of positive and negative cells. 
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3.3 RESULTS 
3.3.1 RUBV slightly decreases hNPC proliferation 
One signature of the CRS fetus is reduced organ size and total cell number[101]. In vitro studies 
have also had shown RUBV attenuates cell proliferation in various cell models (see Table 1.2 for detail). 
Therefore, we investigated if RUBV infection could affect proliferation in our hNPC model. First, total 
cell number in the absence or presence of RUBV was counted and compared from day 1 to day 10 post 
infection. Virus infected hNPC cultures exhibited attenuated cell growth from day 7 post infection and a 
5-7% reduction of total cell number was observed at 10 days post infection (Figure.3.1). However, this 
difference was not statistically significant. EdU incorporation assays of cells helped to further determine 
the proliferative potential of hNPCs; an exact quantification of the number of proliferating cells was de-
termined by calculating EdU incorporation using flow cytometry. After a single pulse of EdU, the hNPCs 
were collected and EdU positive cells were detected by FACS. Consistent with the cell counting results, 
upon RUBV infection there was a detectable, but not significant, reduction in EdU positive cells com-
pared to uninfected control(Figure.3.2. A, B and C).To further illustrate this marginal effect and to serve 
as a control for overall technique, we also infected A549 cells, for which RUBV is known to significantly 
disturb cell proliferation (Yumei Zhou, et.al., unpublished data) (Figure.3.2.A.B and D). The percentage 
of EdU positive cells in infected A549 cultures were significantly reduced by almost 2-fold compared to 
that of the uninfected control. 
Therefore, we concluded that the effect of RUBV infection on the undifferentiated hNPC prolifera-
tion was slight at best. The detectable, but statistically insignificant, effect of RUBV on cell proliferation 
could due to the low percentage of infected cells present in the culture. Thus, it was still worth it to inves-
tigate the mechanisms behind this attenuation effect, especially at the single infected cell level. The re-
duction in the total cell number observed in infected the culture, in comparison to uninfected cultures, 
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could be a consequence of inhibition of cell cycle progress and/or induction of cell death and/or other 
nonclassicalcytopathic effect. 
3.3.2 RUBV did not induce apoptosis and other cell death events in infected hNPCs 
We first investigated whether the diminished propagation of RUBV-infected hNPCs was due to 
RUBV induced cell death. Apoptosis, a typical cell death event that can  be induced by virus infections, 
including RUBV [76], was detected by the expression of activated-caspase 3. At early infection time 
points (from day 1 to day 6), cells were double stained with anti-RUBV-E2 antibody and anti-active-
caspase 3 antibody so that not only apoptotic cells within whole hNPC pool, but apoptotic cells within 
infected population could be identified (Figure 3.3.A). RUBV infection did not increase the percentage of 
active-caspase 3 positive cells at the total population level or within RUB V infected cell population. The 
lack of overlapping signal between E2 and active-caspase 3 in infected hNPCs, together with the observa-
tion that the percentage of apoptotic cells within the RUBV infected (E2 positive) population is lower 
than what is seen in the overall hNPC pool, indicates that RUBV may actually  block apoptosis, as has 
been shown by other investigators in other cell lines [66, 75] (Figure. 3.3 A and B). Expression of active 
caspase 3 was likewise not elevated at later times of infection (10 d.p.i), as examined by Western Blot 
(Figure.3.3.C). This is also virus load independent as cultures infected with moi's of both 10 and 0.1 did 
not exhibit elevated caspase 3 expression. When we also performed TUNEL and active-caspase 3 flow 
cytometry to test the whole population for  programmed cell death events, no differences were seen as 
well (data not shown). To rule out that other cell death events which could possibly induced by RUBV 
infection, such as necrosis, we conducted live cell PI staining on uninfected as well as RUBV infected 
hNPCs (m.o.i = 10). The number of PI staining positive cells in RUBV infected hNPCs was comparable 
to uninfected hNPCs at day 7 post infection (Figure.3.3 D). The results clearly suggest that RUBV in-
duced cell death in hNPCs is not the factor in the reduction in the hNPC proliferation rate following infec-
tion.  
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3.3.3 RUBV induces mitotic inhibition (cell senescence) in hNPCs  
To address whether RUBV mediated cell proliferation inhibition in hNPCs resulted from attenuat-
ed proliferative ability or impaired cell cycle progression, we examined expression of the signature prolif-
eration marker Ki-67 in RUBV infected and uninfected hNPCs. Ki-67 was identified recently as a cellular 
marker that is strictly associated with proliferating mammalian cells, including human neural progenitors 
[231]. During interphase, the Ki-67 antigen can be exclusively detected within the cell nucleus, whereas 
in mitosis most of the protein is relocated to the surface of the chromosomes. Ki-67 protein is present dur-
ing all active phases of the cell cycle (G1, S, G2, and mitosis), but is absent from resting cells (G0).To 
investigate whether Ki-67 is actively expressed in RUBV infected cells, hNPCs were double stained with 
anti-RUBV-capsid antibody and anti-Ki-67 antibody so that not only proliferating cells within the whole 
hNPC population, but also within infected cell population, could be identified (Figure 3.4.B). At 2 d.p.i, 
no significant change in percentage of Ki-67 positive cells was noticed. However, at 6 d.p.i, the percent-
age of Ki-67 positive cells was reduced considerably from 70% in uninfected hNPCs to 55% in RUBV 
infected cultures and further to 41% (almost 2-fold reduction) within capsid positive RUBV infected 
hNPCs. This decrease in Ki-67 positive cells upon infection was seen at 10 d.p.i as well (Figure.3.4.A).  
The reduction in Ki67 positive cells correlates with the significantly lower level of Ki67 gene expression 
in RUBV-infected hNPC's, as shown in the previous Chapter (Figure 2.6F) 
Thus, reduced cumulative Ki-67 labeling in RUBV infected hNPCs clearly indicates that RUBV 
inhibits proliferation potential in hNPCs. In addition, Ki-67 was recently defined as a marker for cell se-
nescence; therefore, it is possible that RUBV inhibits hNPC proliferation by inducing those cells into cell 
senescence.   
3.3.4 The ability of RUBV to alter cell adhesion may contribute to the reduction of hNPC proliferation 
A fetal alcohol syndrome study that used this same hNPC model found an increased number of 
floating but live cells observed following ethanol treatment (Rodney Nash, personal communication), in-
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dicating that ethanol-treated hNPCs had altered cell adhesion properties .To test whether RUBV infection 
altered hNPC cell adhesion, the number of floating as well as adherent cells was counted separately in the 
presence or absence of virus. Despite a decrease in total cells following RUBV infection of moi of 10, a 
slight increase in the number of floating cells was observed (Figure.3.5).This suggested that the effect of 
RUBV infection on cell growth may be partially due to an increase in floating cells in the culture. As the 
medium needs to be changed every two days during maintenance, this effect cannot be ignored. To further 
investigate, we compared the cellular distribution of pFAK between RUBV infected cells and uninfected 
cells. pFAK plays an important role in the control of several biological processes, including cell spreading, 
migration, and survival. It has been shown that pFAK also plays a role in regulating hNPC cell adhesion 
[232]. However, no difference was seen upon virus infection (data not shown). Thus, other cell adhesion 
molecules, such as integrin, need to be studied.  
3.3.5 RUBV did not induce inflammatory cytokine responses in hNPCs cultures 
Virus infection is a powerful inducer of type I interferons and other inflammatory cytokines [228, 
233], as many virus components are recognized by pattern recognition receptors. Massive cell death upon 
virus infection can be due to strong innate/ inflammatory cytokine responses (bystander effect)[229, 234]. 
We therefore wanted to investigate if this is the case in RUBV infected hNPCs.  In other words, we 
wished to determine whether the insignificant cell loss in RUBV infected hNPCs was due to a deficient 
cytokine response. To determine the cytokine expression in hNPCs upon RUBV infection, we examined 
the expression at the protein level as well as the RNA level of IL-6 and IFN-beta. During the first four 
days of infection, none of those cytokines had an elevated expression on the RNA level, even in presence 
of robust RUBV replication (Figure.3.6.A). Similar results were seen on the protein level, as confirmed 
by ELISA (data not shown, personal communication with Yumei Zhou). To further prove those observa-
tions, we examined key regulators and signaling molecules (NF-kB p65, pSTAT3 and RIG-I) that regu-
late the expression of these cytokines, and no detectable difference was seen between RUBV infected and 
uninfected cultures during the infection time course (Figure.3.6.B). This was as we expected, as proteins 
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such as pSTAT3also play an important role in regulating hNPCs neuronal differentiation. Abnormal ex-
pression of such proteins would have a drastic effect to the multipotency of hNPCs. Thus, the absence of 
cytokine responses could partially explain why there was no massive reduction of hNPCs population up-
on RUBV infection. 
In summary, herein we showed that RUBV moderately attenuates hNPC proliferation, through cell 
cycle interruption instead of cell death or apoptosis. The level on the population level was moderate prob-
ably due to low percentage of cells infected.  No inflammatory cytokine response, which could affect cell 
viability and proliferation, was seen as well. 
3.4 DISCUSSION 
In the second part of our study, we sought to determine whether and how RUBV affect prolifera-
tion of hNPCs. The first step is to characterize hNPC cell growth in presence of RUBV, as this is the 
foremost and most decisive reflection of cell proliferation. Indeed, less hNPCs cells were present in 
RUBV infected culture compared to the control (~10-20% reduction) after 10 days of infection. However, 
this difference was not statistically significant after a t-test examination. We further addressed this ques-
tion by closely investigated our calculation methodology. It was suggested that in a case of nonsignifi-
cance, the sample size is very important [235]. Since we only repeated the experiment for three-times, it is 
highly possible that the experimental repeats   were not sufficient to generate statistical significance. 
Therefore, a hypothetical fourth experiment using same experimental data as the third repeat was added to 
the data pools. This time we indeed observed a statistical difference (p=0.01 and 0.05 for day 9 and 11 
respectively). Therefore, the non-significance of our result from cell growth is due to lack of experimental 
repeats but not necessarily a lack of biological significance. Also, considering that only 10% of cells in 
the culture are infected, it is highly possible that infected cells had altered proliferation but just because 
there were so few of them, the effect of RUBV infection on hNPC growth was not reflected in a popula-
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tion view. Thus, RUBV attenuation effect to the growth of hNPC is slight at the most from a population 
view and a single-cell-based investigation of infected cells was required for further characterization. 
The reduction in the number of cells present in our infected cultures is in agreement with previous 
findings[61, 62, 65, 67], and can be due to RUBV induced cell death, inhibition of cell cycle progression 
and anoikis which is a specific response to be studied  considering the embryonic source of hNPCs[236, 
237]. Therefore, in our next step, we conducted experiments on individual cells  to investigate if RUBV 
induces each or any of these cellular responses. 
Cell death 
Two types of cell death were previously reported in the brains of CRS abortuses and patients who 
died from PRP, namely apoptosis and necrosis [106, 238]. A common feature of these two types of cell 
death  is chromosomal breakage which can be picked up by PI staining[239]. However, our living cell PI 
analysis over the total population of hNPCs showed no increase upon RUBV infection, indicating RUBV 
did not trigger massive cell death to the hNPCs.  
Studies of RUBV infection to in vitro cell models suggested RUBV induce apoptosis in a caspase-
dependent pathway [239]. We therefore use active-caspase 3 in combination of RUBV-E2 antibody to 
pick up individual infected cells that undergoing apoptosis. A significant reduction in active-caspase 3 
positive populations was seen among RUBV-infected cells compared to the non-infected control, indicat-
ing that RUBV does not induce but instead blocks induction of apoptosis. The immunofluorescence imag-
ing techniques we used to directly pick up single infected cells and apoptotic cells in the population gives 
a more accurate picture of the relationship between virus and cell death responses. We did not stain cells 
with additional necrosis marker to further investigate this cell death event.  This is because during apop-
totic studies, we did not observe swollen cell bodies and chromosomal breakage, which are two hallmarks 
of necrotic cells, in infected cells picked up by RUBV-E2 antibody. 
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In previous studies in our lab, it was shown that while RUBV infection induced apoptosis in adult 
human fibroblasts, it did not do so in fetal human fibroblasts[66, 182],  Frank inhibition  of apoptosis  
during RUBV infection was  previously reported by another group in a study in which it was shown that  
the RUBV capsid protein (C) alone  could inhibit chemical staurosporine (ST) induced  apoptosis [75],  in 
line with the results of our study. In addition, in studies on selected non-human cell lines, although viral 
replication is required to induce apoptosis, it is the non-infected neighboring cells that undergo this effect 
[240]. Other viruses also inhibited induction of apoptosis upon infection in hNPCs. HCMV, which is also 
teratogenic, blocks apoptosis in primary human fibroblast and in hNPCs derived from abortuses [148, 179, 
180].  Highly neurovirolent flaviviruses similarly did not induce cell death in hNPCs: the percentage of 
cells undergoing both apoptotic and necrotic death was not significantly higher in JEV/ WNV infected 
hNPCs after 7 days post infection then in uninfected ones[124, 207]. Expression of HIV gp120 also re-
sults in few apoptotic TUNEL positive cells in murine NPCs [199]. Since NPCs are equipped with certain 
anti-apoptotic factors, like IAP family members (c-IAP1), it has been postulated that it is a factor in the 
resistance to virus induced cell death [146, 241]. In addition, it has been shown that the pattern of c-
oncogenes expression during embryonic development promotes proliferation and inhibits apoptosis in a 
cell-specific and time-specific manner [242, 243].  In studies from our lab, resistance to RUBV-induced 
apoptosis by fetal cells was attributed to the pattern of gene expression in the fetal cells which was anti-
apoptotic [182]  Though some of the anti-apoptotic mechanisms has been elucidated in NPCs that make 
them resilient to apoptotic signals, however, direct evidence of how they evade virus induced cell death is 
still not established. 
Clearly, our results showed RUBV did not induce cell death in hNPCs, either to the population or 
in single-infected cells. Actually, we would expect this result: if cells in the hierarchy of CNS develop-
ment, such as hNPCs, were dead after infection, we would not expect birth defects but rather fetal death. 
As for the mechanism: there is likely  a natural resilience of hNPC's to virus induced cell death, however 
our results indicate a specific anti-apoptotic response on the part of the virus.   
71 
 
Cell cycle arrest 
A key marker identified for proper isolation of proliferating NPCs is Ki-67, which is only ex-
pressed in NPCs undergoing  active cell cycling  [244]. In  single-cell-based examination of Ki-67 ex-
pression in RUBV infected cells, we found  a significant (over 50%) decrease in the percentage of Ki-67 
positive cells in E2-positive cells in infected cultures in comparison with  uninfected cells (either in the 
control or RUBV-infected cultures).  This was further confirmed on the mRNA level by qRT-PCR (see 
Chapter 2). Our EdU incorporation analysis, which reflects level of DNA synthesis by proliferating cells, 
showed slight, but not significant, reduction in EdU incorporation in RUBV infected compared to unin-
fected cultures (this assay was not done by counting E2-positive cells). However, we do not rule out the 
possibility of sample size problems in calculating a statistical significance. In addition, the virus induced 
cell decrease in Ki67 was exaggerated most at day 10 post infection when the effect of RUBV on the 
hNPC growth curve was most pronounced. Therefore, these data implied that RUBV induced cell cycle 
quiescence was the primary factor to the inhibition in cell growth seen in RUBV infected hNPCs. 
Sustained proliferation is a key feature of NPCs and it was recently shown that a number of viruses 
can induce quiescence in these cells by impairing their proliferative ability (see Table 1.3 for a complete 
summary). The proliferation arrest in hNPCs upon HCMV infection is indicative of  a switch from cellu-
lar DNA synthesis to viral DNA synthesis[245]. Evidence from several  labs corroborated that JEV infec-
tion leads to cell cycle arrest at G1—S phase [207]. Quiescence in adult hNPCs following HIV-1 infec-
tion was attributing to the chemokine receptors, CCR3 and CXCR4, which are used by the cells to main-
tain their ability to proliferate [246-248]. Reduced Ki-67 expression has been demonstrated in slow grow-
ing tumors associated with ocular surface squamous neoplasia (OSSN) in presence of HIV infection[249] . 
The proportion of Ki67-positive cells also correlated with tumor stage of progression associated with Ep-
stein-Barr virus-encoded latent membrane protein (LMP1) in nasopharyngeal carcinoma [250].  
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As for RUBV, numerous previous studies suggested that the virus affects cell proliferation by in-
ducing cell cycle arrest (reviewed in [7, 65]) . Growth inhibition is particularly notable in RUBV infected 
primary diploid cells derived from human fetal organs, providing an explanation for underdevelopment of 
organs in congenitally infected children that results in microcephaly as well as  autocrine and bone ab-
normalities [61, 67, 251, 252]. The mechanism of such inhibition is attributed to a) virus association with 
certain cytokinesis regulatory  proteins such as retinoblastoma (RB) and citron-Kinase (CK)[69, 253], b) 
virus induced production of a growth inhibitory factor[64, 68], and/or c) virus disruption of microfila-
ments which play a crucial role in mitosis [89]. The results of our study has suggested a new mechanism 
by which RUBV infection attenuates cell proliferation, namely by directly altering expression of cell cy-
cle regulatory protein. Whether this mechanism is unique to neural precursors or can be generalized to 
other embryonic/fetal cells remains to be tested.  
Anoikis 
Considering hNP1
TM
 cells we used in this study are loosely adherent, we also investigated a non-
typical cytopathic effect that could associate with virus-infection called anoikis. Anoikis is defined is a 
form of programmed cell death which is induced by anchorage-dependent cells detaching from the sur-
rounding extracellular matrix (ECM)[237]. This cytopathic event plays an important role in cancer metas-
tasis and recently has been shown to be associated with tumorogenic viruses such as Epstein-Barr virus, 
KHSV and Hepatits B virus (HBV) [254-256]. In our study, starting from day 5 post infection, there were 
fewer adherent cells in RUBV infected hNPCs compared to uninfected ones. However, the percentage of 
viable cells remained the same as shown by previous PI staining result. Thus, RUBV induces detachment 
of a subpopulation of hNPCs while not killing most of the cells. This type of viral induced cell detach-
ment, although counter to the anoikis hypothesis, was previously demonstrated in SINV infection to 
PBMCs [161]. The day post infection on which we observed reduced adherent cells in infected cultures 
coincident with the reduction of total cell number, suggesting that RUBV induced hNPC detachment may 
partially contribute to attenuated cell growth upon infection. However, we did not observe an alteration in 
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the expression as well as intracellular distribution of focal adhesion kinase (FAK) upon virus infection. It 
is possible that virus directly affects the integrity of integrin or other adhesion molecules. Thus, further 
studies will determine whether the detached cells were infected by RUBV and whether crucial cellular 
adhesion molecule such as integrin was affected upon infection.  
Cytokine profiling 
Previous studies  suggested that CRS is partially due to immune damage mediated  through a by-
stander effect[234]. However, our result showed no up-regulation of classical RUBV induced cytokines 
IL-6 and IFNβ.  This indicated that RUBV did not directly trigger inflammatory or innate immune re-
sponses in hNPCs. The observation was in line with the lack of inflammatory reactions seen in brains of 
CRS infants [106].The vascular lesions present in these brains may be triggered by immune responses 
within endothelial cells as we observed dramatic elevation of IL-6 expression in hMPro even after 3 days 
post infection. Impaired cytokine production and moderate immunosuppression was reported in school-
girls who received a rubella vaccination [257], suggesting RUBV can suppress cytokine responses. A 
posttranscriptional suppression of IL-6 production in human fibroblasts upon HCMV infection has  also 
been reported [258]. Whether the lack of IL6 and IFN induction in hNPCs is virus-specific or cell specific 
thus needs further investigation. 
Induction of inflammatory cytokines by RUBV has been previously demonstrated in vitro in vari-
ous other models: A549 cells infected with RUBV produced enormous amount of IL-6 and IFN-β with 24 
h.p.i; similarly, a drastic elevation of IL-6 expression in hMPro cells was observed after 3 days post 
RUBV infection (Yumei Zhou, et.,al, unpublished data).  In addition, RUBV infected human fetal fibro-
blast showed a burst of IFN and chemokine expression within 24 h.p.i[182]. These findings are in striking 
contrast to the obvious non-inflammatory characteristics of RUBV showed in the hNPCs model. However, 
giving recent mechanistic studies in our lab using other cell models; it is not difficult to explain why in-
flammatory cytokines such as IL-6 and IFN-β were not induced by RUBV. First, using a RUBV harbor-
74 
 
ing Vero cell line 925-IN, we found that although exogenous IFNα suppressed replion RNA and protein 
synthesis, but did not cure the cells[163]. Then, surprisingly, the replicon reappeared within one week of 
suspension of IFNα treatment. Besides, we observed cells that are negative in viral protein synthesis but 
positive for the residence of viral replicon RNA in 925-IN cultures. Those results in together suggested 
that RUBV infection in cell culture is refractory to IFN treatment, the virus can persistent in culture with 
minimum expression / transcription of its genes. In this context, RUBV is able to avoid from being de-
tected by host intracellular pathogen recognition machinery which initiate cytokine responses. Second, in 
characterizing host innate immune responses to RUBV infection in A549 cells, we found that the signal-
ing transduction induced by the virus was postponed and peaked at 48hrs post-infection, indicating that 
RUBV has a degree of intrinsic resistance to cellular IFN response, possibly at the stage of interference 
with the signaling transduction (e.g. IRF3) downstream of RIG-I/MDA5. Such intrinsic resistance may 
also partially explain the non-inflammatory characteristics seen in hNPCs upon RUBV infection. 
In summary, a combination of cell death and mitotic inhibition is reflected in the pathology of CRS, 
which exhibits features of both destruction within specific tissues and growth retardation. In our study, we 
demonstrated that hNPCs are not susceptible to the cytopathogenic effect of RUBV and that a cell cycle 
inhibition may more predominant in these embryonic cells in the early fetus development. A tissue-
specific apoptosis may thus account for the myriad of dysfunctions observed in CRS patients. 
It has been suggest that virus infection early in development adversely affects undifferentiated pre-
cursor cells by inducing apoptosis, leading to underdevelopment[76].  Our results argue against this idea 
in neural precursor cells, which can be infected without undergoing apoptosis. As for the fate of such in-
fected cells in subsequent developmental stages, additional characterization utilizing advanced techniques 
such as laser capture or live-cell antibody labeling is needed so as to track the infected cells in infected 
hNPC cultures also under differentiation. Additionally, chromosomal breakage may need to investigated 
since this has been demonstrated in infected human embryo cells [67]. 
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Figure 3.1 hNPC growing kinetics in presence and absence of RUBV. 
Equal numbers (5×10
5
) of hNPCs (passage 7-10) were seeded in each well of a 24 well plate and mock 
infected or infected with RUBV the next day (m.o.i=10). The culture medium was changed daily.  Total 
cell number in the infected and uninfected cultures was determined at indicated time points through 
11days post infection. This experiment was repeated three times and the error bars indicate SDs. Despite 
the apparent differences in cell numbers at the later time points, these were not statistically significant at a 
95% confidence interval (P<0.05).
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Figure 3.2 Proliferation of hNPC vs A549 after RUBV infection as measured by EdU incorporation 
assay. 
hNPCs and A549 cells were seeded at similar densities  and either left uninfected or infected with RUBV 
(moi = 10) the next day. Cell proliferation and DNA synthesis were analyzed by a non-radioactive EdU 
incorporation assay; the percentage of proliferating, EdU positive cells was quantified by flow cytometry. 
(A) FACS analysis using anAlexa Fluor® 647 Click-iT® EdU Flow Cytometry Assay Kit. At 6 days post 
infection, both hNPCs and A549 cells were treated with EdU for 2 hours and then processed for EdU in-
corporation according to the manufacturer's recommended protocol. The figures show a clear separation 
of proliferating cells (which have incorporated EdU) and non-proliferating cells (which have not). (B) 
Quantification of results shown in (A). (C) Proliferation of hNPCs during an infection time course; EdU 
incorporation was assayed on days 1, 2, 4,6, and 10 postinfection.(D)Proliferation of A549 cells during an 
infection time course; EdU incorporation was assayed on days 1,2,4, and 6 postinfection.  Both experi-
ments were repeated at least twice. Error bars represent SDs. *, statistical significance compared to the 
uninfected control at the same time point deterrmined at a 95% confidence interval (P<0.05).
hNP
RUBV
NC
A549
30
40
50
60
70
80
hNP A549
NC
RUBV
%
E
d
U
p
o
si
ti
v
e 
ce
ll
A. B.
C.
0
20
40
60
80
1 2 4 6 10
%
 E
d
U
 p
o
si
ti
v
e
Days post infection
hNP
NC
RUBV
0
20
40
60
80
1 2 4 6
%
 E
d
U
 p
o
si
ti
v
e
Days post infection
A549
NC
RUBV
D.
*
77 
 
D. 
%
 a
c
ti
v
e
-c
a
sp
a
se
3
Days post infection
0
5
10
15
20
25
30
35
1 2 4 6
NC
RUBV
RUBV-E2 positive
*
NC RUBV
1 d.p.i
2 d.p.i
4 d.p.i
6 d.p.i
DAPI Active-caspase 3 E2 Merge
A.
B.
GAPDH
Active-caspase 3
Pro-caspase 3
0        10     0.1
MOI
C.
D.
0
5
10
15
20
25
30
35
2D 4D 6D 8D 10D
%
 P
I 
p
o
si
ti
v
e
Days post infection
NC
RUBV
78 
 
Figure 3.3 RUBV did not induce apoptosis in infected hNPCs. 
Mock infected and RUBV-infected hNPCs were examined for the expression of active caspase 3, a mark-
er for apoptosis, by immunofluorescence staining. (A) hNPCs were  mock infected  (NC) or infected with 
RUBV at an m.o.i of 10 (RUBV), fixed at 1, 2, 4, and 6 days post- infection, and analyzed by fluores-
cence microscopy. Apoptotic cells were detected with anti-active caspase 3 antibodies (green), RUBV –
infected cells with anti-E2 antibody (red), and nuclei were visualized with Hoechst dye (blue). Individual 
stains are shown for the RUBV infected cells while merged images are shown for the NC. (B)  The per-
centage of active caspase 3positive cells in the mock infected culture, the RUBV-infected culture and 
among E2 positive cells in the RUBV-infected culture was determined.  To make these determinations, 
the experiment was repeated 3 times and at least three fields of view were counted in each experiment. 
Error bars indicated SDs; *, - significance compared to the uninfected control (p < .05) , (C)  Western 
Blot analysis to detect active caspase 3 at 10 dpi in  hNPCs following mock infection or RUBV infection 
at MOIs of 10 and 0.1. The experiment was repeated 3 times and a representative blot is shown. (D) Live 
cell PI staining measuring total cell death events in mock-infected and RUBV infected (moi=10) hNPCs 
at 2, 4, 6, 8 and 10 days post infection. Quantification of the percentage of positive cells present in popu-
lation was done by flow cytometry. The experiment was repeated 3 times and error bars represent SDs.
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Figure 3.4 RUBV induce cell senescence to hNPCs. 
Mock-infected and RUBV-infected hNPCs were examined for the expression of Ki-67, a marker for pro-
liferating hNPC by immunofluorescence staining.  The absence of Ki-67 is also an indicator of senes-
cence.(A) hNPCs were mock infected (NC) or infected with RUBV ( m.o.i = 10) (RUBV) were fixed at 
2,6, and 10 days post infection and analyzed by fluorescence microscopy for Ki-67  (green) and RUBV 
E2 (red);nuclei were visualized with Hoechst dye (blue). A representative image of RUBV-infected cells 
captured on day 6 post infection is shown The arrow denotes a cell positive for E2 but negative for Ki67. 
(B) The percentage of Ki-67 positive cells in the mock-infected and RUBV-infected cultures and among 
E2 positive cells in the RUBV culture was determined.  The experiment was repeated 3 times and in each 
experiment at least 3 fields of view were counted.  Error bars indicate SDs. *, -statistiacal significance 
compared to the uninfected control (P<0.05). 
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Figure 3.5 RUBV infection of hNPCs did not increase the number of "Floaters". 
Equal numbers (5×10
5 cells
) of hNPCs (passage 7-10) were seeded in each well of a 24 well plate and ei-
ther mock infected  (NC) or infected with RUBV  (m.o.i=10) the next day. The culture medium was 
changed daily.  On days 2, 4, 6, 8, and 10 post-infection, the adherent and floating cells in one well of 
each culture were collected and counted. The experiment was repeated three times and the, error bar indi-
cates (SDs).ns, no statistical significance compared to the mock infected control at a 95% confidence in-
terval (P<0.05). 
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Figure 3.6 RUBV did not induce inflammatory responses in hNPCs. 
(A) RNA isolated from mock-infected  and RUBV infected (moi=10) hNPCs at days 1,2, and 4 post in-
fection was used to perform real-time qRT-PCR to detect the r viral E2 gene E2 and mRNAs for the in-
flammatory  cytokines IL-6 and IFN-beta. Each experiment were done in triplicate and repeated at least 
twice, and representative data from one experiment are shown. The gene expression levels were normal-
ized to GAPDH mRNA in the same sample and are shown as fold change over the amount of RNA in the 
mock-infected control at same time point. Error bars indicate SDs. *, statistical significance compared to 
the control (P<0.05). (B) Western Blot analysis of expression of three inflammatory signaling proteins 
during early infection.  Each experiment was performed at least twice. A representative blot is shown. 
GAPDH: loading control. 
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CHAPTER 4 : CHARACERIZATION OF THE EFFECT OF RUBV INFECTION ON HUMAN 
NEURAL PROGENITOR CELL DIFFERENTIATION INTO NEURONS AND GLIAL CELLS   
4.1 INTRODUCTION 
Multi-sensory impairment (MPI) is a typical clinical feature of CRS [259]. Hearing loss is often 
accompanied by eye defects, indicating sensory neurons that are shared by both systems can be affected 
by RUBV infection. In rare cases, CRS infants can develop severe CNS degenerative disease such as 
mental retardation and progressive rubella panencephalitis (PRP), suggesting that RUBV has the capacity 
to impact the development of the host neural system. In addition, other viral teratogens (e.g. HCMV, 
CVB, JEV) that cause similar congenital defects as RUBV were shown to disrupt hNPC differentiation in 
vitro, further supporting the possibility of RUBV induced abnormalities in hNPCs, including its differen-
tiation [260].  
The human CNS is mainly composed of two types of cells: neurons and glial cells. Neurons are the 
cells that establish communications transmit signals and administrate various actions throughout the body; 
while glial cells provide support and nutrition, maintain homeostasis, form myelin, and participate in 
pathogen clearance in the nervous system. The total number of neurons and glial cells are almost the same 
within in brain areas and glial cells play important roles in maintaining CNS integrity. Therefore, it is 
worthwhile to investigate whether and how RUBV infection impacts the differentiation of hNPCs into 
both cell lineages. Additionally, this is the first time that RUBV infection has been studied for its effect 
on the differentiation of a human cell line. 
To test whether RUBV affects the differentiation of hNPCs into neurons and/or glial cells, hNPCs 
undergoing neuronal and glial differentiation were analyzed for their response to virus infection, which 
was introduced at different points of the differentiation process, including both the induction and commit-
ted phases. Cell morphology and expression of selected stemness markers were analyzed by immunofluo-
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rescence microscopy. Genome expression profiling analysis was carried out on RUBV infected hNPCs at 
the end of the differentiation process to further investigate detailed cell markers or pathways that could be 
impacted by the virus. Interestingly, the virus had a marginal effect to the induction of cell differentiation 
into both cell types. To explain that observation, we investigated the susceptibility of differentiated cells 
to RUBV infection and we found that extracellular production of RUBV was significantly reduced upon 
the initiation of differentiation and that differentiated cells no longer expressed virus antigen. Therefore, 
the effect of RUBV infection on hNPCs differentiation was marginal at most and that this is mostly due to 
lack of infectivity of RUBV in those differentiated cells. 
4.2 MATERIAL AND METHODS 
4.2.1 Cell culture and differentiation 
Proliferating hNPCs were cultured and passaged as described in Chapter 2, passage 6-10 cells were 
used in following studies. For hNPC differentiation:  
(1) For spontaneous differentiation, which yields mostly neurons, hNPCs were grown for 14-21 
days in neural expansion medium lacking bFGF to promote random differentiation. Briefly, mid-passage 
hNPCs were seeded in 60 mm plates coated with Matrigel at a density of 1×10
6
 cells/plate. Differentiation 
was initiated after the cell reached 70%-80% confluency by replacing the AB2 complete neural expansion 
medium with differentiation medium (AB2 complete neural expansion medium without bFGF). Differen-
tiation conditions were maintained for 3 weeks, during which the medium was changed every 2-3 days. 
For study of the effect of RUBV on hNPC differentiation, cells were similarly seeded onto 60mm plates, 
infected with an m.o.i of 10 with RUBV the next day and then recovered in AB2 complete neural expan-
sion medium for 2 days before differentiation was initiated. Cells were passaged every 7 days or as need-
ed (when cells reached 100% confluency) during differentiation. 
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(2) For astroglial differentiation that yield mostly astrocytes and oligodendrocytes, hNPCs were 
grown for 14 days in neurobasal medium supplemented with 1x B27 (define), 1x Pen-Strep, 2mM L-
glutamine, (all from Gibco, Invitrogen), 20mg/ml bFGF and 10ng/ml ciliary neurotrophic factor (CNTF, 
Millipore), as previously described[137]. Briefly, mid-passage hNPCs were seeded in 60mm poly-L-
ornithine (20µg/ml, Sigma) and laminin (5 µg/ml, Sigma) coated plates at a density of 1×10
6
 cell/plate. 
Differentiation was initiated after cells reaching 70%-80% confluency by replacing the neural expansion 
medium with differentiation medium (as described above). Differentiation conditions were maintained for 
2 weeks, during which medium was changed every 2-3 days. For study of the effect of RUBV infection 
on hNPC differentiation, cells were similarly seeded onto 60mm plates, infected with RUBV at a an m.o.i. 
of 10 the next day and then recovered in AB2 complete neural expansion medium for 2 days before dif-
ferentiation was initiated. Cells were passaged every 7 days or as needed (when cells reached 100% con-
fluency) during differentiation. 
For optimal astroglial differentiation, hNPCs were grown on poly-L-ornithine and laminin coated 
plates. For poly-L-ornithine/laminin coating: The growth substrates poly-l-lysine and laminin were pur-
chased from Sigma–Aldrich. The culture dish was first coated with a solution of 50 μg/ml poly-l-lysine in 
sterile water for 1 hr (37 °C), rinsed once with sterile water, air dried and coated with a solution of 20 
μg/ml laminin in sterile phosphate-buffered saline (PBS) for 1 hr(37 °C) or overnight (4°C), rinsed twice 
with PBS before use or directly put into 4°C for storage 
For RUBV infection at later stage, briefly, hNPCs that have been cultured in differentiation medi-
um for 14 days were infected with RUBV at moi of 10. After 1 hr, the virus inoculum was removed and 
cells were refeed with differentiation medium. The infected cultures were analyzed two day post infection 
by immunofluorescence staining for virus antigen and culture medium was used to titer extracellular virus 
production. 
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4.2.2 Monitoring the stage of differentiation and the loss of multipotency by flow cytometry 
Flow cytometry was performed during hNPC differentiation to monitor multipotency changes. For 
spontaneous differentiation, cells were collected for analysis each week during the three week differentia-
tion process. For astroglial differentiation, cells at the end of the differentiation (week 2) were subjected 
to flow cytometry analysis. Flow cytometry was carried out as described in Chapter 2. For this experiment 
the following antibodies were used: anti-Nestin (conjugated with PE); anti-SOX2 (conjugated with FITC); 
anti-Ki-67 (conjugated with V450), all from BD Bioscience, 5µl for each sample. 
4.2.3 Cell differentiation marker expression profiling by qRT-PCR 
RNA was isolated from cells at either 21 days of differentiation (spontaneous) or 14 days of differ-
entiation (astroglial) followed by quantification and cDNA synthesis following protocols described in 
Chapter 2.In order to acquire the hNPCs differentiation status as well as multipotency changes, several 
genes were probed (see Table 4.1 and 4.2 for target gene list and primers). Those target genes covered 
markers of hNPC multipotency and all three lineages of terminally differentiated neuronal cells, namely 
neurons, astrocytes and oligodendrocytes. PCR was performed in ABI Prism 7500 system and data was 
acquired using SDS 2.2.1 software (Applied Biosystems). Gene expression data (done in triplicate) were 
acquired and ABI Prism 7500 software and ABI data assist (both from Applied Biosystems) were used to 
estimate relative fold change values using the ∆∆Ct quantitation method. We compared gene expression 
in differentiated cells (both mock and RUBV infected) and normalized this to gene expression levels in 
undifferentiated hNPCs. Endogenous GAPDH was used for normalization and calibrated gene expression 
for each sample against undifferentiated hNPCs. Statistical analysis was performed as previously de-
scribed [135] and briefly discussed under data procurement and statistical analysis below. Means were 
compared and grouped using Student test at 5% level of significance. 
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4.2.4 Immunofluorescence staining of differentiated hNPCs 
Cells were grown on coverslips, fixed in 4% paraformaldehyde and stained with anti-Nestin (1:450; 
Neuromics), anti-neuron specific β-tubulin III (Tuj1) (1:1000; Abcam); anti-A2B5 (1:100; Abcam); anti-
GFAP (1:300; Abcam); anti-MOG (1:100; Abcam); anti-RUBV E2 (1:100; Eptomics)and anti-RUBV 
capsid (1:100; Eptomics). Immunofluorecence staining and image acquisition waere carried out as de-
scribed in Chapter 2.  
Cell Profiler software was used for image processing and quantification. Pipeline set up was con-
ducted as described in Chapter 3. For morphology/cell phenotype analysis of differentiated neurons, at 
least three random fields of view (each with more than 20 cells) from two different experiments of Tuj-1 
immunostained cells were used. Briefly, the DAPI stained images were used for identification of nuclei 
before identification of differentiated neurons using Tuj1 stained images. “Measurement-Neuron” pipe-
line was utilized to acquire both the number of differentiated neurons as well as their average shape pa-
rameters (trunks and branches). After recovery of the image, that parameter was obtained and results were 
compared between differentiated cells in presence or absence of RUBV. For quantifications of differenti-
ated astroglial, A2B5 was used as the phenotype marker. Positive stained cells were quantified as de-
scribed in Chapter 3. The percentage of A2B5 positive cells were compared between astroglial differenti-
ated cells in the presence or absence of RUBV. Each experiment was repeated at least twice for statistical 
analysis. 
4.2.5 Viral susceptibility studies 
For assessment of susceptibility of hNPCs to RUBV infection during the differentiation, (1) To test 
extracellular production of virus during differentiation course compared to the undifferentiated control: 
culture medium of undifferentiated and differentiated hNPCs infected with RUBV were collected at indi-
cated day post infection. Extracellular production of virus during the differentiation time course was test-
ed by standard plaque assay (see chapter 2). (2) To examine the expression of virus antigen in differenti-
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ated cells: at 14 days after initiation of differentiation, infected cultures were stained with lineage specific 
markers (Tuj-1 for neurons and A2B5 for astroglia) together with antibodies for virus antigen (E2 or Cap-
sid) by standard immunofluorescence assay (described in chapter 2). (3) To examine susceptibility of dif-
ferentiated cells to RUBV infection: Uninfected hNPC cultures differentiated for 14 days were infected 
with RUBV at a m.o.i of 10, expression of virus antigen was tested 2 days later. Culture medium was also 
collected and tested for extracellular production of the virus by plaque assay. Control undifferentiated 
hNPCs were similarly infected and tested for the production of the virus at same d.p.i. 
4.3 RESULT 
To investigate whether RUBV infection impairs the differentiation of hNPCs, hNPCs were infected 
with RUBV at the initiation of cell differentiation (to test whether RUBV impairs the induction of differ-
entiation), or at a later stage of cell differentiation (to test whether RUBV impairs the function of hNPCs 
that already committed to differentiation). Two differentiation pathways were examined in this study: 
hNPCs differentiated into neurons (neuronal differentiation or neurogenesis) and hNPCs differentiated 
into astroglial cells (glial differentiation or gliogenesis). 
4.3.1 Effect of RUBV infection on hNPCs neurogenesis 
hNPCs are capable of differentiating into neurons 
To mimic the neurogenesis process, we utilized the “spontaneous differentiation strategy” accord-
ing to the company's (ArunA Biomedical) protocol which indicated would yield mostly neurons (Figure. 
4.1.A).Immunofluorescence demonstrated that more than 90% of cells in the undifferentiated cultures 
expressed the neuroepithelial stem cell marker Nestin (Figure.4.1.B left).Upon growth factor bFGF with-
drawal, the cells stopped proliferating and differentiation was initiated. During differentiation, cells were 
passaged as necessary, usually every 7 days. The cells that had lost differentiation potential or were una-
ble to further differentiate would be gradually selected out from the culture plate by cell detaching (most-
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ly progenitor cells). Cells grown on Matrigel-coated plates would eventually become neurons and exhibit 
distinguishing phenotype that contrasts with undifferentiated hNPCs on the basis of morphology and cell 
marker expression. By the end of the differentiation process, around 40% of cells were differentiated, as 
determined by elongated neurite outgrowth as well as Tuj-1 (β-tubulin III) positive immunostaining (Fig-
ure.4.1.B). Expression of stemness markers, such as Nestin and SOX2, decreased during differentiation as 
cells gradually lose their multipotency (cells positive for Nestin expression decreased from 92.9%±3.31% 
to 54%±3.54%; cells positive for SOX2 expression decreased from 87.6%±4.21% to 50.9%±5%, Fig-
ure.4.1.C). Using this differentiation strategy, very few cells had the morphology typical of oligodendro-
cytes and astrocytes, and expressions of astroglial lineage marker (Gfap, Mbp, etc.) genes were not de-
tectable by quantitative real-time PCR (data not shown). 
RUBV infection did not significantly impair the induction of hNPCs’ neuronal differentiation 
To investigate whether and how RUBV infection impacts the induction of hNPC neuronal differen-
tiation, proliferating hNPC cultures were infected with RUBV (moi = 10) two days prior to the initiation 
of spontaneous differentiation. Cells were maintained for 3 weeks following differentiation and passaged 
as necessary (Figure.4.1.A). As a control, hNPCs were similarly infected and passaged, but not subjected 
to differentiation. 
To evaluate the effect of RUBV infection on neurogenesis, hNPCs that had undergone differentia-
tion for 21 days (at the end of differentiation) were fixed and immunostained with an antibody directed 
against the neuronal marker Tuj-1 (Figure.4.2.A and B). Gross examination did not reveal major morpho-
logical differences between the uninfected and RUBV infected cultures. Tuj-1 positive cells were hetero-
geneous, occasionally exhibiting no neurites or short neurites, but most exhibited long neurites The exten-
sive neurite outgrowth indicated that neurons had acquired a more mature morphology. Alteration in neu-
rite length or branching was not detectable when comparing the uninfected to virus-infected cells at this 
time point, indicating that RUBV infection did not interfere with the induction of neurogenesis. The enu-
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meration of Tuj-1 positive cells showed an average of 44±1.2 neurons per field in non-infected culture, 
whereas 51±2.1 neurons were present in RUBV infected cultures (Figure.4.2.C). Thus, numerous neu-
rons had been generated in both non-infected and RUBV infected cultures and a ~7% increase occurred in 
infected culture, which was not statistically significant. This increase in neuron numbers could due to loss 
of proliferating hNPCs upon RUBV infection, which was demonstrated in Chapter 3. As hNPCs naturally 
require sufficient room for robust generation of neurons, the loss of hNPCs during differentiation due to 
infection could yield more room, therefore supporting outgrowth and production of more neurons at the 
local site of infection. No difference was observed between the entire population of hNPCs in the pres-
ence or absence of RUBV at the protein level of Tuj-1, NF-M (another neuronal lineage marker) and key 
regulators of cell differentiation such as NF-kB and pERK (Figure.4.2.D). Therefore, RUBV infection at 
the induction of spontaneous differentiation had a marginal effect on the overall generation of neurons. 
We then investigated if RUBV infection caused any changes during the differentiation process. 
First, the expression of neural stem markers, Nestin and Sox-2 as well as the proliferation marker Ki-67 
was examined and quantified at every passage by flow cytometry to determine if there was any changes 
of cell multipotency during differentiation  in all four experimental groups (undifferentiated, undifferenti-
ated infected with RUBV, differentiated, differentiated infected with RUBV) (Figure.4.3.A). As expected, 
all three markers were down regulated during differentiation, Nestin by 40%, Sox-2 by 50% and Ki-67 by 
40%, indication of loss of cell stemness. Compared to controls, RUBV infected hNPCs exhibited growth 
attenuation as a further reduction in Ki-67 expression was seen in both undifferentiated as well as differ-
entiated cells. This was consistent with what was previously observed in the proliferation study in Chap-
ter 3. Despite that, a similar percentage of reduction in Nestin and Sox-2 expression was observed in both 
RUBV-infected and uninfected cultures, revealing that virus infection does not alter hNPCs in their ca-
pacity to lose their multipotency and commence a differentiation program. 
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To further evaluate the temporal profile of expression of lineage-specific genes and transcription 
factors involved in neuronal differentiation, real-time qPCR was performed using RNA isolated from cell 
cultures 4 days to 21 days post initiation of differentiation (Figure. 4.3 B and C). At 21 days post infec-
tion, which corresponds to the end of the experiment, a significant increase in the mRNA levels of neu-
ronal lineage marker Tuj-1 (beta-Tubulin-III), NF-M and Olig2 were observed when comparing differen-
tiated groups to the undifferentiated control (20 fold for Tuj-1, 45 fold for NF-M and 12 fold for Olig2. 
respectively). However, no alteration was found between uninfected and RUBV-infected cells that had 
undergone differentiation, which was also supported by the immunofluorescence results. There were no 
detectable changes in the mRNA levels of others markers that represent astroglial lineages, including 
MOG，MBP, Gfap, NG2 (for a detailed description of each marker, see Table 4.2), further confirming 
that no astroglial lineage cells were present in the differentiated culture at this time (Figure. 4.3.B). On the 
other hand, RUBV affected lineage marker expression at the mRNA level at an early time point of differ-
entiation. Olig2 and NF-M mRNA showed increased expression at 4 days of differentiation in control 
hNPCs and was significantly (p=0.021 and 0.043 respectively) decreased in case of differentiated RUBV 
infected hNPCs at the same time point. (Figure.4.3.C) 
RUBV infection did not impair hNPCs that had already committed to neuronal differentiation 
We next investigated if RUBV could impact hNPCs that had already committed to neuronal differ-
entiation. hNPCs at 14 days after spontaneous differentiation were infected with RUBV at a m.o.i of 10. 
Cells were collected 2-3 days after infection and evaluated for morphology changes, cell marker expres-
sion, as well as CPE that would possibly be induced upon virus infection. At this time point, RUBV infec-
tion did not induce any morphology changes, cell marker alterations, or CPE events to the differentiated 
culture compared to the uninfected control that had been differentiated for same number of days(data not 
shown). Therefore, hNPCs already committed to neuronal differentiation were not sensitive or responsive 
to RUBV infection in terms of the differentiation program. 
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hNPCs under spontaneous differentiation are less susceptible to RUBV infection 
Clearly, RUBV infection did not significantly alter hNPC neuronal differentiation. Whether this 
could be explained by a lack of permissiveness to the RUBV infection of cells differentiated into neurons 
was thus evaluated (refer to Figure. 4.4 A for experimental design).  The evidence that extracellular virus 
yield, as assessed by the viral titer, was decreased by 10 fold during the differentiation process supported 
this hypothesis (Figure.4.4.B). Virus replication, as determined by quantification of genomic RNA, was 
significantly decreased during the differentiation process, further supporting our hypothesis that hNPCs 
differentiating into neuronal lineage did not support RUBV replication (Figure.4.4.C).More importantly, 
we found that during differentiation, progenitor cells were infected, as shown by E2 immunostaining, but 
not those that showed more mature neuron morphology,  14 days after the induction of differentiation 
(Figure.4.4.D, left panel). In addition, the non permissivity of neurons to RUBV infection was confirmed 
by directly infecting a “neuron enriched” culture where hNPCs had already differentiated for 14 days. 
Cells susceptible to RUBV infection were evaluated by double staining the culture for E2 and Tuj-1 two 
days after infection. Again, only progenitor cells instead of differentiated neurons exhibited E2 positive 
staining, demonstrating that the virus could only replicate in hNPCs but not differentiated cells (Fig-
ure.4.4.D, right panel). Finally, a 10 fold decrease in virus titer was seen in the differentiated cultures 
compared to undifferentiated hNPCs infected for the same period of time (Figure.4.4.E). 
4.3.2 Effect of RUBV infection on hNPC gliogenesis 
hNPCs are capable of differentiating into astroglial lineages 
To determine whether RUBV infection could influence hNPC glial differentiation, we first opti-
mized the differentiation protocol to yield astrocytes and oligodendrocytes in addition to neurons. When 
we initiated this study, there were no established protocols for hNPC astro-glial differentiation. Protocols 
used in most other studies yielded a very low percentage of glial lineages (<10%). The current protocol 
we utilized in this part of study is illustrated in Figure. 4.5.A: Astroglial differentiation was carried out as 
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an optimization of a previously suggested method, adding both CNTF and bFGF to promote the propaga-
tion of astroglial cells during the  regular expansion of the hNPCs[137]. During differentiation, cells 
grown on poly-L-ornithine and laminin coated plates were passaged as necessary, usually every 5-6 days. 
Under this protocol, ~10% of the cells would eventually become astroglial lineage cells, showing a dis-
tinguishing phenotype from undifferentiated hNPCs on the basis of morphology and cell marker expres-
sion. The differentiated cells have a signature spongy nucleus as well as an obviously different morpholo-
gy (eg. Star/branched shape) than its neighboring progenitor cells, as demonstrated by tubulin/Hoechest 
staining (Figure.4.5.C). Immunostaining of those cells showed that they were positive for the astroglial 
marker A2B5 while negative for progenitor marker Nestin, confirming that they represented an authentic 
astroglial lineage and not undifferentiated progenitor cells (Figure.4.5.B). Expression of stemness markers 
such as Nestin and SOX2 did not decrease significantly (Nestin from 92%±3.2% to 89%±2% of the 
cells; SOX2 from 84%±1.2% to 79.7%±3.2% of the cells, data not shown), as only a low percentage of 
cells were terminally differentiated. Under this differentiation protocol, very few cells had the typical 
morphology of neurons and the neuronal lineage marker (Tuj-1) gene was not detectable by quantitative 
real-time PCR (data not shown). 
RUBV does not impair the induction of hNPC astroglial differentiation, but limits the differentia-
tion of neurons under these conditions 
Previous studies showed that RUBV infection of oligodedrocytes triggered demyelization[108]. 
We wondered if this would be the case in hNPC induced to become astroglial cells as these cells undergo 
extensive myelination during differentiation. To investigate whether and how RUBV infection impacts 
the induction of hNPC astroglial differentiation, proliferating hNPCs were infected with RUBV (MOI = 
10) two days prior to the initiation of their differentiation. The cells were allowed to differentiate for 2 
weeks and passaged as necessary (Figure.4.5.A). As a control, hNPCs were similarly infected and pas-
saged but left undifferentiated. 
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Immunostaining revealed that a number of astroglial lineage cells were formed 14 days after the 
onset of differentiation in both uninfected and RUBV infected cultures. The size of astroglial cells in 
RUBV infected cultures were generally larger than that in uninfected cultures, probably due to the addi-
tional room available on the plate in RUBV infected  culture due to the decreased cell number. Besides 
the size of astroglial cells, no morphological differences were observed between the two cultures (Fig-
ure.4.6.A). This suggested that astroglial differentiation occurred normally the in infected culture. This 
idea was further confirmed by the enumeration of cells, which showed that a similar number of astroglial 
cells was generated in infected (4.6±0.2 per field) and uninfected cultures (3.9±0.5 per field) (Fig-
ure.4.6.B). We also noticed a number of neurons formed during astroglial differentiation, which was iden-
tified by a strong signal of Tubulin staining (Figure.4.6.A). To our surprise, under this differentiation pro-
tocol, it seemed that RUBV infection significantly impaired the propagation of such cells. No neurons 
were found in RUBV infected cultures after 14 days of differentiation. Enumeration of cells demonstrated 
that numbers of neurons in RUBV infected cultures (0.3±0.2 per field) was significantly lower than in 
uninfected cultures (2.3±0.3 per field) (data not shown). 
In addition, we evaluated the changes of hNPC multipotency and proliferation marker expression 
upon RUBV infection (Figure.4.7.A). As a low percentage of cells were terminally differentiated, it was 
not surprising to see few changes in the global expression of multipotency/stemness markers. Similar per-
centages of Nestin and SOX2 positive cells were obtained before and after 14 days of differentiation 
(Nestin from 92%±3.2% to 89%±2% of the cells; SOX2 from 84%±1.2% to 79.7%±3.2% of the 
cells).Thus RUBV infection did not alter the multipotency of the overall hNPC population, as no detecta-
ble changes were observed in the expression of Nestin and SOX2 between uninfected and RUBV infected 
cells in either undifferentiated or differentiated groups. The percentage of Ki-67 positive cells, a marker 
for cell proliferation, was down-regulated by RUBV in undifferentiated and differentiated groups as seen 
previously. However, the difference was not as pronounced as seen in proliferating hNPCs or during neu-
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ronal differentiation. Therefore, the effect of RUBV on hNPCs multipotency during astroglial differentia-
tion conditions was marginal at most. 
Finally, to further evaluate the temporal profile of the expression of lineage specific genes and 
transcription factors involved in astroglial differentiation, real-time qPCR was performed using RNA iso-
lated from cell cultures 14 days after the initiation of differentiation (Figure. 4.7.B). The profiling provid-
ed ample information for the differentiated population. A drastic increase in the mRNA expression of as-
troglial lineage marker NG2 (Neuron Glial Antigen 2, a marker for early astroglial lineage cells) and Ol-
ig2 (a marker for early neurons and type 2 oligodendrocytes) was observed in differentiated cells com-
pared to the undifferentiated control, indicating successful generation of astroglial lineages. A moderate 
increase in NF-M indicated presence of neurons in differentiated culture. Expression of mature oligoden-
drocytes marker, MBP, was modestly up-regulated, indicating differentiated cells at this time point were 
at a less mature stage. RUBV infection, on the other hand, up-regulated the expression of two astroglial 
lineage markers, NG2 and Olig2, compared to the uninfected control that had undergone the same differ-
entiation protocol. This was possibly due to an enlargement of the cell body instead of increased cell 
number of differentiated cells (as seen in Figure.4.6.A). Expression of NF-M was down-regulated by 
RUBV infection, which further confirmed our immunostaining observations. 
hNPCs under astroglial differentiation are less susceptible to RUBV infection 
Apparently, RUBV infection exhibits least influence on hNPC astroglial differentiation. We evalu-
ated whether this could be explained by an increase in the permissiveness to RUBV infection in cells dif-
ferentiated into astroglial lineage (refer Figure 4.4 A for experiment design and annotation). The evidence 
that extracellular virus yield, as assessed by the viral titer, was decreased by 10 fold during the differen-
tiation process did not support this hypothesis (Figure.4.8.B). Virus replication, as determined by quanti-
fication of genomic RNA, is significantly decreased during the differentiation process, further demon-
strating the loss of RUBV permissiveness during astroglial differentiation (Figure.4.8.C).More important-
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ly, we found that during differentiation progenitor cells were themselves infected, but not those showing 
astroglial lineage morphology, as shown by E2 immunostaining 14 days after the induction of differentia-
tion (Figure.4.8.D). Finally, the lack of permissivity of astroglial differentiated cells to RUBV infection 
was confirmed by directly infecting an enriched culture where hNPCs had already differentiated for 14 
days. Cells susceptible to RUBV infection were evaluated by double staining the culture for E2 and A2B5 
two days after infection. Again, only progenitor cells instead of differentiated glial cells stained positive 
for E2, demonstrating that the virus could replicate in hNPCs but not differentiated cells. A ~10 fold de-
crease in virus titer was seen compared differentiated cultures two days after infection compared to undif-
ferentiated hNPCs infected for some period of time (Figure.4.8.E). However, how RUBV affected differ-
entiating hNPCs under astroglial differentiation conditions remain to be elucidated. 
Therefore, RUBV did not severely impact hNPCs neurogenesis and gliogenesis. Besides that, 
RUBV seems to exhibit an effect only on undifferentiated or progenitor cells in cultures but those under-
going differentiation, indicating that the major type of cells impacted by were the progenitors. The obser-
vation of enhanced differentiation after virus infection, if there was any, could possibly be achieved by 
depletion of precursor cells. This was plausible because in both types of differentiation, cells required ad-
ditional space to achieve optimal differentiation such as neurite outgrowth and demyelination. The evi-
dence of lack permissiveness of differentiated cells to RUBV infection further supports this idea.  
4.4 DISCUSION 
NPCs are multipotent cells, which can give rise to both neuronal and glial lineages upon commit-
ment induced by specific intrinsic and extrinsic cues. The process of neurogenesis and gliogenesis are 
intricately orchestrated and a number of viruses affect the differentiation into the proper lineages (see Ta-
ble 1.3 for detail). As for RUBV, it has long been proposed that the virus inhibits differentiation of  cells 
involved in organogenesis [168]. Taking advantage of the infectability and differentiatability of hNPCs, 
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we investigated if RUBV infected affect nervous system development by upsetting the delicate process of 
hNPC differentiation. 
Neuronal differentiation 
We first sought to determine if RUBV affects hNPC differentiation into neuronal lineages. Our re-
sults demonstrated that RUBV did not block the overall differentiation of hNPCs, as a similar decrease in 
the expression of neural stem cell markers, Nestin and Sox-2 was observed in uninfected and RUBV in-
fected cultures This is also confirmed by the lack of alterations in the expression of lineage specific mark-
ers Tuj-1, NF-M and Olig2 that was seen at both the protein level and the RNA level between RUBV in-
fected and un-infected cultures after 3 weeks of spontaneous differentiation. Indeed, we observed an im-
paired/delayed neuronal differentiation at an early time point of differentiation (4 days after initiation of 
differentiation) evident by decreased expression of Olig2 and NF-M, however, these differences were di-
minished during the differentiation process. One possible explanation is that hNPCs were blocked in un-
differentiated stage; cells engaged along the neuronal pathway were not affected by the presence of the 
virus. Thus, infected hNPCs were selected out before their differentiation, the room that depleted hNPCs 
provided in the infected culture thus allowed additional differentiation of hNPCs into neuronal cells 
which catch up the delay seen at 4 days after the induction of differentiation. This notion is further sup-
ported by the non-permissiveness of differentiated cells to RUBV infection and the lack of gross differ-
ences in the number and morphology of neuronal cells between the uninfected and infected cultures. Fur-
thermore, proliferation of infected cells (as illustrated by Ki-67 expression) was not as attenuated during 
differentiation than among undifferentiated cells, indicating that RUBV infection primarily impacts pre-
cursor cells. 
In fact, it has been repeatedly shown in previous studies that fully differentiated neurons in culture 
were not affected by RUBV infection (see Table 1.2 for detail). In both rat and human cultures, neuronal 
cells were rarely infected by RUBV. Although cytopathic effect was reported in one in vitro study, it was 
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concluded that it resulted from toxic factors released from damaged glial cells [79]. In vivo, a complete 
loss of Purkinje cells (GABAergic) was reported  in PRP patients[261]. This observation is similarly ex-
plained by glial cell triggered immune-mediated damage. Taking these results together with ours, it is in-
dicated that the effect of RUBV on neurons, if there is any, is restricted to precursor cells instead of de-
veloping or developed neurons.  
Comparatively, most teratogenic viruses impair neurogenesis of hNPCs, but using quite diverse 
mechanisms (see Table 1.3 for detail). BDV does not cause any damages to undifferentiated hNPCs, but 
induces high-level apoptosis to cells undergoing neurogenesis.  Coxsackie virus B3 (CVB3) induces mas-
sive cell death in hNPCs and therefore prevents further differentiation of the cells [204]. HCMV impacts 
undifferentiated hNPCs directly by causing a premature differentiation of the cells [149]. Although the 
ability of HCMV to induce neuron formation declines after 3-4 days of differentiation [150], this is not 
because lack of permissiveness of virus in differentiated cells as virus antigen is present in fully differen-
tiated neurons. Therefore, this observation is caused by neurons becoming refractory to the effect of the 
virus instead of changes of tropism. However, it must be noted that most of these teratogenic viruses do 
not induce slow progressive diseases as RUBV does in the case of PRP. Therefore, our finding that 
RUBV does not have a direct effect on the neuronal population may also contribute to the explanation of 
why PRP patients appear healthy and normal during the long-incubation period.   
Astroglial differentiation 
We also investigated if RUBV infection affects gliogenesis of hNPCs by inducing such differentia-
tion in presence of RUBV. The positive staining for glial specific marker A2B5 and obviously different 
cell morphology of the differentiated cells confirmed that hNPCs were undergoing gliogenesis. At the end 
of the differentiation process, significant up-regulation in the expression of glial markers NG2 and Olig2 
was observed in infected cultures compared to the uninfected ones, and this was accompanied by a cyto-
plasmic swelling of a few astroglial cells. These observations suggested that RUBV infection has the po-
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tential to trigger gliosis of the differentiating hNPCs. Since NG2 and Olig2 are both oligodendrocytes 
precursor markers, specific up regulation of those two genes in infected culture indicating that RUBV 
infection preferentially impacted oligodendrocyte lineages. Whether this preference is related to the dif-
ferentiation protocol we utilized needs to be further investigated. Also, one unsettled point is that RUBV 
does not alter the expression of Nestin and SOX2, markers that essentially represent the stage prior to dif-
ferentiation. One explanation is that RUBV, although causing changes in morphology of glial cells did 
not necessarily alter the composition of cell population, as evident by enumeration of cells (undiff/ diff 
cell ratio). Thus, RUBV does not necessarily change the expression of these stemness markers in most of 
the cells but instead induces overexpression of glial specific proteins within individual cell. Alternatively, 
there were very few swollen cells (1/100 cells) present in the population, any changes caused by RUBV 
therefore are on a minimal number of cells.  
Several previous studies suggested that RUBV infection causes damage to astroglial lineages in 
brain and in in vitro cell cultures [36, 65, 101] (Table 1.3).However, in our culture, we did not observe 
increased cell death nor demyelination but swelling of a few differentiated cells. Cytoplasmic swelling of 
glial cells following virus infection was previously reported for HIV-1 and canine distemper virus (CDV) 
[262, 263] and suggested a mechanism for virus persistence and sustained replication in the CNS. Cell 
swelling has also been associated with hypoxia and cell-cell fusion during Sendai virus infection[264]. 
Thus, it is possible that RUBV triggers a similar type of cell damage. Since virus antigen could not be 
detected in differentiated cells, how RUBV infection triggered this abnormal phenotype of cells remains 
unknown. However, it must be noted that in our experimental settings, astroglial lineages do not reach a 
fully mature stage, as shown by morphological immaturity as well as lack of expression of fully mature 
glial cell markers such as GFAP and MBP. Therefore, future studies should focus on whether those as-
troglial lineage cells can regain their permissiveness to RUBV (or a reactivation of RUBV replication) 
after they acquired a mature phenotype and also whether the abnormalities of  those glial cells could  fur-
ther  lead to  demyelination as well as cell death during  their maturation. Also, we observed a specific 
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depletion of “neuron-like cells” in RUBV infected culture undergoing gliogenesis and further characteri-
zation of the lineage of such cell types is needed.  
Multiple factors can contribute to brain damages and demyelination is seen in CRS and PRP brains. 
As reviewed by Stohlman and Hinton, "demyelination induced by virus infection can result from 1): a 
direct viral infection of oligodendrocytes resulting in cell death; 2) a persistent viral infection, resulting in 
the loss of normal cellular homeostasis and subsequent oligodendroglial death; 3) a cytokine storm medi-
ated by virus infection of cells other than oligodendrocytes; or 4) infection initiating activation of  im-
mune responses specific for either oligodendroglia or their myelin component" [265]. RUBV infection of  
mature rat oligodendrocytes,  triggering cell death, has been demonstrated previously, along with the ob-
servation of subsequent myelin removal [78]. A molecular mimicry between a RUBV antigen and MOG 
has also been proposed to explain the relevance of virus-specific oligoclonal IgG detected in CRS and 
PRP patients and its role in demyelination [266]. In this proposed mechanism, antibodies are confused 
between MOG and RUBV antigen, thus, the virus infection of CNS can sensitize to subsequent autoim-
mune demyelination. However, a general point to remember is that the ways in which the CNS can re-
spond to virus infections are limited: the neurons themselves may undergo lysis, demyelination, or spon-
giform degeneration and the inflammatory response is mainly expressed by the appearance of lympho-
cytes and activation of microglia, the macrophages of the CNS. Thus, in absence of microglial cells 
(which are derived from other hematopoietic stem cells) in our culture, it is hard to verify the molecular 
mimicry idea. But still, we were able to detect abnormalities in differentiating glial lineages which may 
serve as a preliminary to  demyelination events and we did not rule out that a persistent infection of 
RUBV in hNPCs may  contribute to demyelination at a later time in  infected individuals. 
Throughout the differentiation study (both neuronal and glial), we found that RUBV infection af-
fected the expression of Olig2 in both neuronal and glial differentiation processes. Oligodendrocyte tran-
scription factor 2 (Olig2) is a bHLH transcription factor essential for the selection of both the motor neu-
ron and oligodendrocyte pathways  and directing the choice of neural progenitors to either proliferate or 
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differentiate during  early development.Olig2 also plays important role in reactive gliosis and neuronal 
repair in vivo. SNPs in the Olig2 gene have been associated with schizophrenia [267-270]. The activity of 
Olig2 in cell fate determination as well as in sustained hNPC proliferation is regulated by phosphorylation 
state of this protein: phosphorylation at S147 directs the formation of Olig2 homodimers that promote the 
expression of motor neuron-specific genes and silence others while dephosphorylation at same site ena-
bles Olig2 to form heterodimers with bHLH proteins such as Ngn2 and induce oligodendrocyte progeni-
tor specific genes.  In hNPCs, the phosphorylation of a triple serine motif at the N terminus is necessary 
for Olig2 enhancement of proliferation [267]. In our study, expression of Olig2 mRNA was significantly 
altered in both neuronal and glial differentiation, suggesting Olig2 is a critical cellular target for RUBV in 
differentiating hNPCs. This impact was not seen in undifferentiated hNPCs, indicating RUBV primarily 
affect Olig2’s expression in cell fate determination. Our finding of RUBV impact on a key transcription 
factor for early embryonic development is in congruence with the idea that the virus is most teratogenic 
during first trimester of pregnancy. And we foresee a possible mechanism by which RUBV affecting Ol-
ig2 expression contributes to the progression of CRS associated neurological abnormalities. 
Permissiveness changes during differentiation 
One important factor that affects the outcome of cell differentiation during infection is the cell's 
permissiveness or susceptibility to the virus during the process. In our study, both differentiated neuronal 
and astroglial cells lost their permissiveness to RUBV infection. In both types of cell culture, a decrease 
in extracellular virus production as well as in intracellular viral genomes was noticed compared to undif-
ferentiated hNPCs that were similarly infected The loss of virus load was further attributed to loss of virus 
replication in the differentiated cells in the culture as we did not detect any virus antigen in those cells, 
even after direct infection of cultures enriched in differentiated cells. It is possible that differentiated cell 
have intrinsic factors (receptor shifts, defensive machinery) that prevent infection or restricted the virus to 
an inactive/silenced form with minimum virus genome present in the cytoplasm. Therefore, further inves-
tigation is needed to detect the presence of viral RNA or transcripts in single cells undergoing differentia-
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tion. Finally, viral RNA was still readily detectable at the end of differentiation process, indicating failure 
of the culture in toto to clear RUBV during differentiation. Thus, in current experimental setting, we 
showed that 1), RUBV loses its replication in hNPCs undergoing differentiation; 2) hNPCs failed to elim-
inate viruses under a differentiation culture environment. 
Our permissiveness study result correlates well with the situation in CRS: during fetal development 
CNS cells become fully differentiated and lose their permissiveness for RUBV infection; this correlates 
with the decreased incidence of fetal infections with the progress of pregnancy. The lack of permissive-
ness for RUBV infection of neuron cells seen in our study was consistent with most of the in vitro studies 
using mixed neuronal/glial cell culture for RUBV infection. However, the lack of permissiveness in as-
troglial lineage does not agree with several of these studies (Table 1.2). Both rat and human brain cell 
cultures demonstrate permissiveness of glial cells for RUBV infection. Even in the only available studies 
using human brain cells, astrocyte and microglia were  the two type of cells that supported robust RUBV 
replication,  instead of neuron and oligodendrocytes [108]. This could possibly be explained by a lack of 
mature astroglial lineages in our current differentiation protocols  Immature cells may also gain permis-
siveness to RUBV at later stages of differentiation after the derivation of specific astrocyte and oligoden-
drocyte lineages, however, an optimized differentiation protocol is required to achieve the terminal differ-
entiation.  Otherwise, differences in observations could simply be strain specific as the viruses used in the 
two studies were different. 
Reduced virus replication in hNPCs undergoing  differentiation was seen in studies using other vi-
ruses: JEV viral load was significantly higher in undifferentiated NPCs than in those upon differentiation, 
although the virus infection altered migration and differentiation of the neurospheres [207]. VZV, on the 
other hand, established a nonproductive replication in pure populations of terminally differentiated human 
neurons [192]. As noted before, it is possible that RUBV may persist in differentiated hNPCs in an inac-
tive form. “Silenced” viral genome expression was previously reported by our lab in a study of RUBV 
resistance to  IFN using cell lines stably transfected with RUBV replicon[163]. Also, reactivation of virus 
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replication has previously seen in HIV-1 and JC virus (JCV) during differentiation of NPCs into astro-
cytes[200, 212]. In both cases, the virus exerts prominent impact to the terminal differentiation into astro-
cytes. Therefore, we do not rule out the possibility of a reactivation of RUBV replication in terminally 
differentiated astroglial cells. However, such studies  require the detection of the presence of virus ge-
nome in  individual hNPCs undergoing  differentiation and also the ability to produce a terminally differ-
entiated glial cell culture to verify our  reactivation hypothesis,  which we could not achieve using our 
currently available protocols,  
In summary, the failure of RUBV to replicate in differentiated hNPCs as seen in our study correlat-
ed well with the time period for fetal infections with congenital manifestations, which is first trimester of 
pregnancy. After this period of time, the brain structure is established, most cells are differentiated and 
therefore fetuses are less susceptible to RUBV infection[132].  In addition, the permissiveness study also 
established that the major population being impacted by RUBV is progenitor/precursor cells. Further 
studies will be needed to determine the intrinsic cell programs that eliminate permissiveness to virus in-
fection in differentiated cells. 
A comparison with another classical teratogen—HCMV 
HCMV is the most significant infectious cause of congenital anomalies in the CNS caused by in-
trauterine infection in humans nowadays; it is therefore a model virus to study congenital virus infection 
on CNS development. As reviewed by Tsutsui, numerous studies have engaged in the study of suscepti-
bility of embryonic and fetal cells to HCMV and the effect of the infection on brain development of fetus-
es[147]. We therefore contrast our result in this study with those summarized from HCMV studies to give 
a more comprehensive understanding of teratogenesis of RUBV infection. (See Table 1.1 for other refer-
ences). 
1) RUBV and HCMV share similar cell tropisms. Both HCMV and RUBV demonstrated more ro-
bust replication in glial cells than in neurons in in vitro cell models, indicating that both viruses may di-
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rectly hijack astroglial lineages that balance nervous system homeostasis. In addition, both viruses infect 
hNPCs as their teratogenic nature. HCMV efficiently infect hNPCs while RUBV only establishes a non-
productive replication in those cells, possibly explaining the results of congenital infections by both vi-
ruses to CNS: HCMV cause malformations of brain while RUBV does not.  
2) RUBV and HCMV affect CNS cell proliferation, but by different mechanisms. HCMV infection 
is primarily cytolytic, as evident in both hNPCs and those differentiated into glial lineages. The non-
cytolytic effect of the virus on neuronal lineages was attributed to intrinsic factor C/EBPβ, which sup-
presses CMV promoter activity [188]. RUBV, on the other hand, induces cell cycle arrest in hNPCs. But 
obviously both viruses deplete the neural precursor pool so as to achieve its long term effect to brain de-
velopment.  
3) HCMV has a profound impact on hNPC differentiation. In HCMV the virus inhibited glial dif-
ferentiation of hNPCs by lytic infection, presumably causing brain malformations, while neuronal cells 
tended to be infected persistently, presumably causing brain dysfunctions. Meanwhile, hNPCs popula-
tion’s undewent severe depletions, making brain repair impossible. This is obviously not the case for 
RUBV: the virus tends to establish a persistent infection in hNPCs, even in those cells under differentia-
tion. Any lytic/ necrotic effect to glial lineages may happen at a later stage of differentiation but obviously 
not at the initiation process. The effect of virus infection to the brain development depends more on vas-
cular damages.  
Therefore, although HCMV and RUBV are teratogenic, they affect the development of CNS prob-
ably by quite different mechanisms.
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Table 4.1 List of target genes and primers used in gene expression profiling study 
Gene name Primer Sequence Size(bp) 
Oct3/4 Sense:5′-GACAGGGGGAGGGGAGGAGCTAGG-3′Antisence:5′-CTTCCCTCCAACCAGTTGCCCCAAAC-3′ 144   
Nestin Sense: 5′- CAGCTGGCGCACCTCAAGATG-3′       Antisence: 5′-AGGGAAGTTGGGCTCAGGACTGG-3′ 209 
SOX2 Sense:5′-AGTCTCCAAGCG ACGAAA AA-3        Antisence: 5′-GCA AGA AGC CTC TCC TTG AA-3′ 141  
Pax-6 Sense: 5′-AACAGACACAGCCCTCACAAACA-3′           Antisense: 5′-CGGGAACTTGAACTGGAACTGAC-3′ 275    
Musashi-1 Sense: 5′-GGCTTCGTCACTTTCATGGACCAGGCG-3′   Antisense 5′-GGGAACTGGTAGGTGTAAC-3′ 542 
Olig2 Sense: 5′- CAGAAGCGCTGATGGTCATA-3′         Antisense: 5′- TCGGCAGTTTTGGGTTATTC-3′ 208    
MAP2 Sense: 5′- TGCCATCTTGGTGCCGA-3′             Antisense:5′- CTTGACATTACCACCTCCAGGT-3′ 367/460 
Tuj-1 Sense: 5′-ACTTTATCTTCGGTCAGAGTG-3′        Antisense: 5′- CTCACGACATCCAGGACTGA-3 97 
GFAP Sense: 5′-ACATCGAGATCGCCACCTAC-3′         Antisense: 5′-ACATCACATCCTTGTGCTCC-3′         219 
Ki-67 Sense: 5′-ACGAGACGCCTGGTTACTATC- 3′       Antisense: 5′-GCTCATCAATAACAGACCCATTTAC-3′ 226               
MOG Sense: 5′-CAT ATC TCC TGG GAA GAA CGC-3′    Antisense: 5′-GTA GCT CTT CAA GGA ATT GCC-3′ 500 
MBP Sense: 5′-CTGGGCAGCTGTTAGAGTCC-3′        Antisense: 5′- CTGTGGTTTGGAAACGAGGT-3′ 275 
Tuj-1 Sense: 5′-CAACAGCACGGCCATCCAGG-3′        Antisense: 5′-CTTGGGGCCCTGGGCCTCCGA-3′ 244 
NG2 Sense: 5′- ACTGGCTAGGGGTGTCAATG-3′        Antisense: 5′-TCCTCAAGGTCCTGCTGAGT-3′ 271 
NF-M Sense: 5′- AAGCCAATCAGACCAGAATA-3′           Antisense: 5′-GCAGCGATTTCTATATCCAG-3′ 366 
RUBV-E1 Sense: 5′- CAACACGCCGCACGGACAAC -3′                     Antisense: 5′-CAGGTCGCGCATACACCTCA-3′ 328 
105 
 
Table 4.2 Description of markers used in this study 
Name Lineage specification Brief summary Reference 
Oct3/4 Totipotent ES cells Transcription factor that is expressed in embryonic stem (ES) cells and germ cells, and its ex-
pression is required to sustain cell self-renewal and pluripotency. 
[271] 
Nestin Neural 
stem/progenitor cells 
Intermediate filament structural protein expressed in primitive neural tissue [272] 
Sox2 Pluripotent to mul-
tipotent stem cells 
Transcription factors with diverse roles in development. Functions in specifying the first three 
lineages present at implantation and inregulating proliferation and differentiation in the devel-
oping nervous system. 
[271] 
Pax6 Neural 
stem/progenitor cells 
Transcription factor expressed as ES cell differentiates into neuroepithelium [273] 
Musashi-1 Neural 
stem/progenitor cells 
Musashi1, a neural RNA-binding protein, plays an important role in regulating cell differentia-
tion in precursor cells. Human neuralepithlial cells (NEP) derived from neural rosettes isolated 
from fetus and from ESCs are psotive for both Nestin and Musashi-1 
[271, 274] 
Olig2 Motor neuron and 
Oligodendrocyte 
Oligodendrocyte transcription factor 2 (Olig2) are bHLH transcription factors expressed in the 
progenitor domain of the spinal cord. Olig2 is required for oligodendrocyte and motor neuron 
specification in the spinal cord. It is also well known for its role in sustaining replication in 
early development. SNPs in Olig2 have been associated with schizophrenia. Olig2 also plays a 
role in reactive gliosis and neuronal repair. 
[267-270] 
Map2 Neuron Microtubule-associated protein-2 (Map2) Dendrite-specific MAP; protein found specifically 
in dendritic branching of neuron 
[275] 
Tuj-1 Neuron Class III β-tubulin (Tuj-1) is a microtubule element expressed exclusively in neurons, and is a 
popular identifier specific for neurons in nervous tissue. 
[276] 
NF-M Neuron Neurofilaments medium subunit (NF-M) is intermediate filament that are major components 
of the neuronal cytoskeleton.The level of neurofilament gene expression seems to directly 
control axonal diameter, which in turn controls how fast electrical signals travel down the ax-
on.Mutant mice with neurofilament abnormalities have phenotypes resembling amyotrophic 
lateral sclerosis 
[277, 278] 
A2B5 Glial progenitors A2B5 is a surface antigen expressed on several gangliosides that remain as yet uncharacter-
ized. It has been used as a glia progenitor marker. Expression of A2B5 is down-regulated as 
the cell differentiates into the nature oligodendrocytes. 
[136, 218] 
NG2 Oligodendrocyte pro-
genitors 
Neuron/glia-type 2 antigen (NG2) is a type I integral membrane proteoglycan found on oli-
godendrocyte precursor cells, macrophages and melanoma cells. It binds multiple components 
of the ECM. NG2 glia are homogeneously present in the grey and white matter. In white mat-
ter, they are found along unmyelinated axons as well as myelinated axons, engulfing nodes of 
[279-281] 
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Ranvier. 
MOG Mature oligodendro-
cyte 
Myelin Oligdodendrocyte Glycoprotein (MOG) is an Ig superfamily member found exclusive-
ly in myelinating oligodendrocytes in the central nervous system. Multiple isoforms of human 
MOG exist. Though its molecular function is not elucidated yet, MOG seem play an role in 
demyelinating disease, such as MS and Rubella induced mental retardation. MOG is the only 
known receptor for Rubella. 
[10, 282] 
MBP Mature oligodendro-
cyte 
Myelin basic protein (MBP) is one of the major proteins of CNS myelin and constitutent of 
myelin sheath of oligodendrocytes and Schwann cells in nervous system. Knockout mice defi-
cient in MBP showed a progressive disorder characterized by tremors, seizures and early 
death. Interest in MBP has centered on its role in multiple sclerosis (MS). A”molecular mimic-
ry” hypothesis of MS has been suggested in which T cells are essentially confusing MBP with 
human herpesvirus-6 (HHV-6). 
[283, 284] 
Ki-67 Proliferating cells Ki-67 is a nuclear protein that belongs to a molecular group comprised of mitotic chromo-
some-associated proteins. It is contextually expressed in all cells that are not in the Go phase 
of the cell cycle. Thus, Ki-67 qualifies as a cell proliferation marker. Functionally, Ki-67 is 
known to interact with Hklp2, a protein that promotes centrosome separation and spindle bipo-
larity. It also directly interacts with NIFK, and apparently binds to UBF, thus playing a role in 
rRNA synthesis. 
[231, 285] 
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Figure 4.1 hNPC spontaneous differentiation is primarily into neurons. 
(A)Scheme of hNPC differentiation protocol: Following seeding, hNPC's were left uninfected or infected 
with RUBV (MOI= 10) on the next day. After two days of recovery in expansion medium, differentiation 
was initiated by growth factor withdrawal (control, undifferentiated cells were maintained in expansion 
medium with growth factor. Cells were passaged twice during the three-week differentiation process, at 
which time analyses were performed.  Four experimental conditions were thus generated as shown: dif-
ferentiated cells (Diff), RUBV-infected differentiated cells (RUBV Diff), undifferentiated cells (Undiff), 
and RUBV-infected undifferentiated cells (RUBV Undiff). (B) Immunofluorescence staining of undiffer-
entiated and differentiated hNPCs  by antibodies against Nestin (red)(a protein indicative of multipotency) 
and Tuj-1 (β-tubulin-III, green)(a protein indicative of neuronal differentiation), Hoechst stain (blue) de-
notes nuclei. Note the neurites cell extensions in the differentiated cells. Bars: 10µm. (C) Expression of 
stemness (multipotency) markers Nestin and SOX2 analyzed by flow cytometry. The experiment was re-
peated 3 times. Error bars indicate SDs. *: statistical difference from the undifferentiated control at a 95% 
confidence interval (P<0.05). 
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Figure 4.2 Effect of RUBV infection on spontaneous differentiation of hNPCs. 
(A)hNPCs, either uninfected or infected with RUBV were induced to  differentiate and analyzed by fluo-
rescence microscopy 21 days post differentiation. Cells were stained for Nestin (red) or -Tuj-1 antibody 
(green); nuclei were visualized with Hoechst dye (blue). Merged images are shown. Bars: 10µm. (B) 
Morphology comparison of diff and diff RUBV culture. (C) The percentage of   Tuj-1 positive in each 
culture was determined. The experiment was repeated 3 times and in each experiment, at least 3 fields of 
view were counted. Error bars indicate SDs ns, no statistical significance compared to the uninfected  
control  at a 95% confidence interval (P<0.05).(D) Western Blot analysis of  expression of  neuronal 
markers, neurofilament-M (NF-M) and Tuj-1, and key regulators of differentiation, pERK and NF-kB p65 
at the end of  differentiation course. Each experiment was performed at least twice. A representative blot 
is shown. GAPDH: loading control. 
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Figure 4.3  RUBV infection did not impair hNPC neurogenesis. 
(A) Expression of the stemness markers Nestin and SOX2 as well as the proliferation marker Ki-67 in 
each of the four experimental groups was analyzed by flow cytometry at each week during the spontane-
ous differentiation protocol. Each data point is the average from three experiments, each a duplicate titra-
tion. Error bars indicate SDs. *, statistical significance (P<0.05) in comparison with the Undiff con-
trol(B,C) RNA isolated from each of the four  experimental groups either  4 days (C) or at the end of  the 
differentiation protocol (B)  were used for a  real-time qRT-PCR of several  stemness and differentiation-
specific genes. Each experiment was done in triplicate and repeated at least twice, and representative data 
from one experiment are shown. The gene expression levels were normalized to GAPDH mRNA in the 
same sample and are shown as fold change over the amount in the Undiff at same time point. Error bars 
represent standard deviations. *, statistical significance (P<0.05) in comparison with the Undiff control 
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Figure 4.4 Lack of permissivity to the RUBV infection of hNPCs under spontaneous differentiation. 
(A)Illustration of permissiveness experiment design   The RUBV Undiff and RUBV Diff are as described 
in Fig. 1. In addition, Undiff or Diff cells were infected with RUBV 14 days post differentiation and virus 
titer and the presence of virus infected cells were assayed two days later.  These two groups were desig-
nated (Diff 14D_RUBV 2D) and (Undiff 14D_RUBV 2D), respectively. (B) Virus titer from RUBV in-
fected hNPCs under differentiation vs the RUBV infected undifferentiated control. *, statistical signifi-
cance (P<0.05) compared to virus titer from undifferentiated hNPCs at same time point. (C) The amount 
of the viral genomic RNA was analyzed by real-time qRT-PCR in Undiff, RUBV Undiff, and RUBV Diff 
cells at the indicated days post differentiation. **, statistically highly significant (p<0.01) in comparison 
with RUBV Undiff on the same day post differentiation. (D)  Left: RUBV Diff cells were fixed after 14 
days of differentiation and immunostained with antibodies directed against viral antigen E2 (red) and Tuj-
1 (green). Nuclei were stained with DAPI (blue). The white arrow indicates infected cells and the bolded 
arrow indicates neurons. Bars: 10µm. Right: Diff hNPCs at day 14 post differentiation were infected with 
RUBV (MOI = 10) and two days after infection the: culture was fixed and immunostained for E2 (red) 
and Tuj-1 (green), arrow indications are the same as in the left panel. Bars, 10µm. (E) Comparison of vi-
rus titer from hNPCs infected with RUBV (MOI = 10) following differentiation for 14 days and undiffer-
entiated hNPCs maintained for 14 days (medium was harvested 2 days post-infection.  Error bars indicate 
SDs. The experiment was conducted twice. *, statistical significance in comparison to the undifferentiated 
culture (P<0.05) 
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Figure 4.5 Differentiation of hNPCs into astroglial cells. 
(A)Scheme of hNPC astroglial differentiation protocol: Following seeding, hNPC's were left uninfected 
or infected with RUBV (MOI= 10) on the next day. After two days of recovery in expansion medium, 
differentiation was initiated by adding cell growth factor CNTF (control, undifferentiated cells were 
maintained in expansion medium without this growth factor). Cells were passaged twice   during the two-
week differentiation process, at which time analyses were performed.  Four experimental conditions were 
thus generated as shown: differentiated cells (Diff), RUBV-infected differentiated cells (RUBV Diff), 
undifferentiated cells (Undiff), and RUBV-infected undifferentiated cells (RUBV Undiff)(B) Immunoflu-
orescence labeling of hNPCs  after astroglial differentiation by antibodies against the stemness marker 
Nestin (red) and astroglial marker A2B5 (green), Hoechst stain (blue) denote nuclei. Pictures of two rep-
resentative cells were shown. Bars: 10µm.  (C) Immunofluorescence labeling of a representative cell after 
astroglial differentiation by antibodies against Tubulin (green), Hoechst stain (blue) denotes nuclei. Pic-
tures of one representative cell were shown. Note that the cell has a different shape than undifferentiated 
hNPCs.  Bars: 10µm.  
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Figure 4.6 Effect of RUBV infection on hNPCs astroglial differentiation. 
(A,B) hNPCs were left uninfected Diff or infected with RUBV at an  m.o.i of 10 (RUBV Diff), differenti-
ated  as described in Figure 4.5, and processed  at 14 days after differentiation for  analysis by fluores-
cence microscopy. A2B5, an astroglial marker was detected with anti-A2B5 antibody (red), Tubulin with 
anti-Tubulin antibody (green), and nuclei with Hoechst dye (blue). Merged images are shown in A. Bars: 
10µm.  (B)  The mean number of A2B5 positive cells per field of view was determined.  The experiment 
was repeated 3 times and at least 3 fields of view were examined in each experiment     Error bars indicate 
SDs. ns, no statistical significance (p>.05) 
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Figure 4.7 Effect of RUBV infection of gene expression during hNPC astroglial differentiation. 
(A)Percentage of cells expressing the stemness markers Nestin and SOX2 as well as the proliferation 
marker Ki-67 was measured in each of the four experiment group by flow cytometry at the end of the dif-
ferentiation protocol. Each data point is the average of duplicate titrations from three independent exper-
iments. Error bars indicate SDs .ns, no statistical significance in comparison with the Undiff control 
(p>0.05).(B) RNA isolated from the  four experimental groups at the end of  the differentiation protocol  
was  used to perfrom real-time qRT-PCR to quantitate expression of several stemness and differentiation 
genes. Each experiment was done in triplicate and repeated at least twice, and representative data from 
one experiment are shown. The gene expression levels were normalized to GAPDH mRNA in the same 
sample and are shown as fold change over the amount of RNA present in the Undiff control at same time 
point. Error bars indicate SDs; *, statistical significance (p<0.05) in comparison to the Undiff control. **, 
highly statistical significance (P<0.01 in comparison with the Diff control.)
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Figure 4.8 Lack of permissivity to RUBV infection of hNPCs following astroglial differentiation.. 
(A) Virus titer in culture fluid from RUBV Diff hNPCs vs culture fluid from RUBV Undiff at indicated 
days of the astroglial differentiation protocol.   The means of 3 independent experiments are shown; error 
bars indicate SDs; *, statistical significance (P<0.05) between the two cultures. (B) The expression of the 
viral genomic RNA was assayed by real-time qRT-PCR in Undiff, RUBV Undiff, and RUBV Diff at the 
indicated time points post-differentiation.  The experiment was repeated 3 times, error bars indicate SDs, 
**, highly statistical significance compared to RUBV Undiff control on the same day post differentiation. 
(C) After completion of the differentiation protocol (14 days), RUBV Diff cells were immunostained with 
antibodies directed against viral antigen E2 (red) and A2B5, an astroglial marker (green). Nuclei were 
stained with DAPI (blue). Bolded arrow show aastroglial lineage cell. Bars: 10µm. (D) Comparison of 
virus produced following infection of Undiff and Diff hNPCs after completion of the astroglial differenti-
ation protocol.  Cells were infected after 14 days of differentiation and medium was collected and titered 
2 days post-infection.  This experiment was conducted three times, error bars indicate SDs, *, statistical 
significance (P<0.05). 
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CHAPTER 5 : SINDBIS VIRUS INFECTION INDUCES APOPTOSIS AND TRIGGERS PREM-
ATURE DIFFERENTIATION OF HUMAN NEURAL PROGENITORS 
5.1 INTRODUCTION 
In this last research chapter, we investigated the effect of SINV on hNPCs to contrast the difference 
between its effect on hNPCs with RUBV to determine whether the observations on RUBV infection of 
hNPCs are general among viruses or unique to RUBV.  SINV was chosen because it is also a member of 
the Togaviridae family. SINV causes rash and fever in humans and age-dependent encephalitis in mice, 
therefore it serves as a model to study viral encephalitis induced by viruses in the Togaviridae family [3, 
4]. In addition, SINV is widely used as a vector for the delivery of genes into selected stem cells; however, 
the toxicity as well as other side effects of such viral vectors has rarely been discussed. In a recent study, 
a SINV vector expressing HIV gp120 was used to infected hNPCs and showed a lytic infection while oth-
ers using wild-type HIV did not[120, 286]. Therefore, it is worthwhile this virus to compare and contrast 
its effect to that of RUBV on hNPCs.  
Not unsurprisingly, as a known neurotropic virus, SINV induced a lytic replication cycle in hNPCs 
with CPE observed at 24h.p.i. and few cells remained adherent at 48h.p.i. In contrast to RUBV, SINV 
replicated and disseminated effectively as virus titer increased by 100 fold in hNPC cells and the percent-
age of infected cells reached over 85% at later time points. SINV attenuated cell proliferation by trigger-
ing apoptosis instead of inducing cell mitotic inhibition, a mechanism different than RUBV. Under close 
scrutiny, this could due to the virus induction of strong inflammatory responses as key regulators of such 
pathways are highly induced upon virus infection. Interestingly, the virus also seems to induce a prema-
ture differentiation of hNPCs at early times, which could due to abnormal expression of key regulators, 
such as pSTAT3 during the inflammatory responses. The SINV infection of hNPCs clearly contrasts with 
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that of RUBV infection in that a slow virus such as RUBV affects maturation and function of the brain in 
a different way than a quick neurotropic virus such as SINV. 
5.2 MATERIAL AND METHODS 
5.2.1 Cell culture 
hNP1™ Neural Progenitor cells (hNPC’s) (ArunA Biomedical) derived from the WA09 hESCs 
were cultured in Matrigel™ (BD Bioscience) coated tissue culture dishes as described in Chpater 2. For 
experiments in this part of the study, passage 7 to 10 cells were used.  
Baby hamster kidney (BHK-21) cells for preparing SINV stock were obtained from the American 
Type Culture Collection (ATCC) and grown and maintained at 35°C in Dulbecco's Modified Eagle Medi-
um (D-MEM, Cellgro) with 5% fetal bovine serum (FBS), as described previously[287]. 
5.2.2 Virus stock preparation and infection 
The Sindbis virus (SINV, HR strain) used in this study was a laboratory strain routinely used in the 
Frey laboratory. For making SINV stock, BHK cells at 80% confluence were infected with SINV at an 
m.o.i of 0.1. At 2 dpi the development of cytopathic effects (CPE) was present in nearly 100% of the cells 
and at that time the supernatant was collected and stored at -80°C. Cell free virus stock was prepared by 
centrifugation of the medium at 2000 rpm and collection of the supernatant. Each batch of virus stock was 
titered by plaque assay. Medium for mock infection was similarly prepared from uninfected BHK cells. 
To infect NPCs: cells were seeded in 2×10
6
 cell/cm
2
 (a high density) and changed with complete neural 
expansion medium the next day. For the infection, SINV stock was added directly to the plate at m.o.i of 
1pfu/cell. Infected plates underwent analysis through 2 dpi without additional medium changing. 
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5.2.3 SINV growth curve characterization 
To characterize SINV growth kinetics, hNP1 cells at 60-70% confluence were infected with SINV 
at an m.o.i of 1 and medium was collected at 4, 8, 12, 24, and 48 hours post infection. The amount of in-
fectious SINV produced was titered by plaque assay. For plaque assay, serial ten-fold dilutions of SINV 
were inoculated onto semi-confluent Vero cell monolayers. After adsorption (1hr, 35°C), the inocula were  
removed and the cells were overlaid with MEM containing 0.7% agarose (Miles) and incubated for 2 days 
at 35°C, as described in Chapter 2. at which time the plaques were visualized by crystal violet staining. 
5.2.4 Live-cell morphology changes 
Cell morphology changes were monitored on an inverted Nikon TMS-F microscope (using a 20× 
objective). Uninfected and infected cells were monitored in parallel to compare changes in cell morphol-
ogy and the presence of CPE. 
5.2.5 Immunofluorecent assay (IFA) 
Standard immunofluorescence was performed as described in Chapter 2. Primary antibodies used 
were directed against nestin (a neural stem marker; 1:450; Neuromics), SINV-NSP (a SINV antigen 
against SINV non-structural protein NSP1:100,Eptomics), active-caspase 3 (1:500; Cell signaling) and β-
tubulin (cytoskeleton marker, 1:200, Abcam). Secondary antibodies were anti-rabbit/mouse Alexa Fluor 
488 and anti-rabbit/mouse Alexa Fluor 594 (1:2000-4000; Molecular Probes-Invitrogen Life Technolo-
gies). Fluorescence images were acquired on a Zeiss Axioplan epifluorescence wide-field microscope and 
processed with AxioVision software. For image quantification, at least three fields of view under each 
experimental condition were analyzed. CellProfiler software was used for the automatic image processing 
and quantification, as described in Chapter 2.  
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5.2.6 Proliferation assay 
For the assessment of the effect of SINV on hNPC differentiation, hNPCs were seeded onto 60 
mm
2
 plates in a density of 2×10
6
 cells/plate and infected with SINV at an m.o.i of 1. Mock infected and 
SINV infected samples were collected at 12, 24 and 48 hours post infection and subjected to the following 
analyses: (1) EdU incorporation assay for assessment of cell cycle and proliferation (2) Active-caspase 3 
staining for apoptosis  induction. (3) Living cell PI staining for detection of cell death events. All tech-
niques were done as described in Chapter 3. 
5.2.7 Flow cytometry 
The percentage of cells expressing virus antigens or lineage specific markers was determined by 
flow cytometry. hNPCs were harvested and washed twice with 2%FBS/PBS staining buffer and then 
fixed by BD Cytofix/Cytoperm solution according to the manufacturer’s instructions (BD Bioscience) in 
aliquots of 100,000 cells in replicate for each antigen. Each aliquot was stained with one or two of the 
selected cell marker antibodies for 1 hr on ice. Antibodies used were: anti active Caspase 3(conjugated 
with V450, BD Pharmingen) and anti-nestin (conjugated with PE, BD Pharmingen). Cells were then 
washed twice with staining buffer and labeled with secondary antibody, if appropriate. Flow cytometry 
was performed using a BD LSR Fortessa or FACS Canto, both from BD Bioscience. Forward and side-
scatter plots were used to exclude dead cells and debris from the histogram analysis. Data analysis was 
performed using FACS Diva software (BD Bioscience). The percentage of cells expressing fluorescence 
intensity greater than the control cells was calculated using the FlowJo program (Tree Star, Inc., Ashland, 
Oregon). 
5.2.8 Western Blot 
Western Blot analysis was performed on cell lysates of hNPCs either mock infected or SINV in-
fected (moi = 1) at 4, 12, 24, 36, 48 hours post infections, using protocols described in Chapter 2. Primary 
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antibodies used were anti-GAPDH (1:5000; Abcam), anti-NF-kB p65 (1:200; Santa Cruz); anti-phospho-
STAT3 (1:200; Cell signaling), anti-phospho-IRF3 (1:1000; Eptomics); anti-Nestin (1:500; Neuromics); 
anti-neuro-filament M (NF-M; 1:500; Neuromics); anti-Tuj1 (1:1000; Abcam); anti-PCNA (1:1000, Santa 
Cruz) and anti-cleaved-caspase 3 (1:1000; Cell Signaling). 
5.3 RESULTS 
5.3.1 hNPCs are fully permissive to SINV infection 
To determine the permissiveness of hNPCs to SINV infection, we plated them onto Matrigel-
coated plates and infected them with SINV at an m.o.i of 1. The capacity of the virus to infect, to replicate, 
and to disseminate in hNPCs then was evaluated by immunofluorescence at 4, 8,12,24, and 48 hours fol-
lowing infection using an antibody directed toward the viral nonstructural proteins, SINV-NSP. In addi-
tion, we also used an antibody against tubulin to monitor cell morphology changes during the infection 
(Figure.5.1.A). At 4 hours following infection, a number of cells, albeit a small number, stained positive 
for SINV-NSP, revealing their permissiveness to SINV infection. No significant changes in cell 
shape/morphology were detected at this point. The observation of cultures from 4 to 24 hours after infec-
tion showed that while only 3.8%±0.32% of the cells were expressing virus antigen  at 4h.p.i, a large 
proportion of cells, 86.8%±0.8%, did so  by 24h.p.i (Figure.5.1.B), thus demonstrating that the virus rep-
licates in hNPCs and disseminates in a very efficient manner. CPE (i.e. presence of floaters, elongation of 
adherenct cell bodies) was detected at 24 hours post infection and at 48 hours few cells remain attached to 
the plate compared to the uninfected control. The percentage of infected cells no longer increased at 48 
h.p.i, probably due to the massive loss of proliferating hNPCs upon SINV infection. Interestingly, an 
elongated cell morphology was noticed in infected cells at this time point, indicating that SINV may in-
duce premature differentiation of hNPCs. The extracellular virus yield was examined as a measurement of 
SINV replication efficiency (Figure.5.1.C). Virus titer increased by 100 fold from 4 h.p.i (10
3 
pfu/ml) to 
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24 h.p.i (10
5 
pfu/ml), at which time the virus had disseminated throughout most of the culture. The viral 
titer achieved by SINV in hNPCs is 2-3 log lower than those seen in BHK cells (10
7
 or 10
8
pfu/cell)[288].  
5.3.2 SINV inhibits hNPCs proliferation by inducing apoptosis but not cell cycle arrest 
Since SINV infection led to massive cell loss, we investigated whether the diminished hNPC popu-
lation was due to SINV induced cell death or cell cycle arrest. The effect of SINV on hNPC proliferation 
was quantitatively analyzed by EdU incorporation, which demonstrated significantly reduced cell growth 
in the infected cultures (Figure.5.2.A). At 12 h.p.i, no significant change in EdU labeling was noticed, 
however, at 24 h.p.i, this reduced drastically from 74.7%±3.2%in uninfected control cells to 33.4%±
1.25% in SINV infected hNPCs. This negative effect on cell proliferation was not demonstrated until 24 
hours after infection, in correlation with virus replication kinetics. 
To investigate the induction of apoptosis upon SINV infection, at 24 h.p.i mock infected and SINV 
infected cells were fixed, stained for active-caspase 3 and analyzed by flow cytometry.  Compared to un-
infected cells, a 2-fold increase in the percentage of active-caspase 3 positive cells in the SINV infected 
culture was observed (uninfected: 17.5%±0.25% positive vs. SINV infected: 35%±0.33% positive) 
(Figure.5.2.B). To further characterize apoptotic events in hNPCs upon SINV infection, the expression of 
active-caspase 3 was monitored at the protein level by Western Blot throughout the infection time course 
(Figure.5.2.C). Expression of active-caspase 3 was significantly elevated at 24-48h.p.i, consistent with 
our observations of CPE. This result clearly showed that SINV induces apoptosis as a means of cell death 
in hNPCs. 
To address whether SINV mediated growth inhibition in hNPCs results from attenuated cell cycle 
progression, cell lysates from 4 to 48 h.p.i were used to probe the expression of proliferation cell nuclear 
antigen (PCNA) by Western Blot (Figure.5.2.C). PCNA is an accessory factor for DNA polymerase δ in 
eukaryotic cells and therefore is only expressed in proliferating cells which have robust DNA synthesis. 
Infections of hNPCs with SINV did not result in significant loss in the expression of PCNA, especially at 
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24 h.p.i when strong apoptosis was induced. The reduction seen at 48 h.p.i could possibly be due to mas-
sive reduction in cell number, as illustrated by the expression of the internal control, GAPDH. 
Thus, SINV limited hNPCs proliferation primarily by inducing cell death/apoptosis instead of trig-
gering cell cycle arrest.  
5.3.3 Proliferating hNPCs lost cellular multipotency/stemness upon SINV infection 
As hNPCs exhibited a neuron-like elongated cell shape at the end of SINV infection time course, 
we wanted to investigate whether SINV induces premature differentiation or loss of cellular multipotency 
upon infection. The percentage of Nestin positive cells was analyzed at 24 hours after SINV infection 
(Figure.5.2.B). SINV infection decreased Nestin positive cells by 30% compared to the uninfected control 
(91%±1.3% of uninfected vs.62.2%±3.33% of SINV infected were positive). Expression of Nestin was 
also monitored on the protein level by Western Blot (Figure.5.2.C). A similar decrease in Nestin expres-
sion was noticed, clearly suggested that proliferating hNPCs lost their multipotency/stemness during 
SINV infection. Reduction of Nestin levels was not seen until 24 h.p.i, which is the time point SINV 
reached its highest infection rate, indicating that alteration in cell multipotency was also correlated with 
virus replication. To investigate if a premature differentiation was initiated, we probed the cells against 
lineage specific markers such as Tuj-1, A2B5 and NF-M, however, none of these markers showed a posi-
tive staining compared to uninfected hNPCs at 48 h.p.i (data not shown). It is possible that the time 
course of t his experiment was too short for infected hNPCs to exhibit differentiated cell markers at the 
protein level. On the other hand, it is also possible that SINV infection impaired hNPC differentiation 
potential. 
5.3.4 SINV modulates multiple cell signaling pathways of hNPCs during infection 
Finally, we wanted to investigate the mechanism behind SINV modulation of hNPCs morphology, 
proliferation and multipotency/stemness. Expression of multiple signaling molecules (NF-kB p65, 
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pSTAT3, pIRF3 and pERK1/2) on crucial regulation pathways during SINV infection course were ana-
lyzed by Western Blot (Figure.5.2.D). The expression of active phosphorylated (Y705) STAT3 (pSTAT3) 
was down-regulated by SINV at 24h.p.i, suggesting a negative regulation of JAK/STAT pathway upon 
infection. pSTAT3 is required for normal hNPC differentiation, and the reduction in this protein possibly 
led to impaired differentiation potential[289]. Expression of Phospho-p44/42 MAPK (pERK1/2) was sim-
ilarly down-regulated by SINV at 24h.p.i. The MAPK pathway regulates multiple phosphorylation events 
including those involved in cell proliferation. Robust expression of pERK1/2 was shown to be pro-
survival[290]. Therefore, it is highly possible that SINV impairs hNPC proliferation by repressing 
pERK1/2 expression and therefore the regulation of MAPK pathway. Expression of NF-kB p65 and 
phospho-interferon regulation factor 3 (pIRF3) were not significantly altered upon SINV infection. As 
both proteins serve as signaling molecules in IL-6 and IFN induction, it was plausible to suggest SINV 
did not induce high expression of cytokines and therefore the inflammatory response.   
5.4 DISCUSSION 
In this last part of our study, we addressed the susceptibility of hNPCs and their cellular responses 
to SINV infection. Although SINV does not produce  CNS anomalies in humans, there are still multiple 
reasons why we studied  infection of this virus in to hNPCs: (1), SINV is a model alphavirus that produc-
es age-dependent encephalitis in mice, providing a  parallel reference for viral induced human CNS de-
generative disease  and, most importantly, the study of neurological aspects of infection by  its close rela-
tive RUBV [291, 292]. (2), SINV has been used to infection rat neural progenitors and these results  pro-
vide the closest relevant references to our studies, considering SINV and RUBV are classified in To-
gaviridae[161]. (3), SINV is a common test analyte in the class of viral agents for various in vitro models 
[161]. hESC-derived hNPCs are rarely used in viral pathogenesis studies and another goal of our studies 
is to assess the  feasibility of hNPCs as a model to study viral infection. We have shown that RUBV is a 
poor inducer of cytokine responses in  hNPCs ; we therefore utilized SINV as a complementary agent to  
evaluate the cell signaling profile  of hNPCs e. (4), SINV-based vectors have  been widely employed  in 
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stem cell infections and tumor therapies in humans , however, little is known about the toxicity of the vec-
tor itself. Therefore in the current study, we evaluated the potential effect of using SINV as a vector in the 
studies of human cells as well as in  therapies for  cancer[293].  
Here, for the first time for a member of the Alphavirus genus y, we report that SINV can infect 
hNPCs and significantly attenuate cell proliferation. The virus induces robust cell death and abruptly ter-
minates hNPCs multipotency. The results of our studies could shed light on multiple aspects discussed 
above.  
hNPC is highly susceptible to SINV infection 
We have shown that hNPCs are fully permissive for SINV infection. The virus is able to establish 
productive replication and dissemination in culture since over 90% of cells were infected at the time peak 
virus titer was achieved, which corresponds to its neurotropic nature. Highly-efficient cell entry of SINV 
is probably due to the abundant availability of the cell surface receptor laminin on hNPCs, which has been 
shown as a receptor for SINV in mammalian cells [294]. SINV infection of human cell has not been ex-
tensively studied; however, there are several reports that human brain cells are susceptible to SINV infec-
tion. In a comparison of oncolytic potential with eight other viruses, SINV was shown infect nearly 100% 
of human glioblastoma cells (U-87MG) and induce apoptosis immediately upon its entry[293]. The 
spread of SINV has also been demonstrated in human brain microvascular endothelial cells (HBMECs), 
where the virus infection renders cells hypersensitive to the inflammatory inducer Bradykinin [162]. Here 
we also demonstrated sufficient virus replication of SINV in hNPCs and its potential to deplete the said 
cell pool. Therefore, it is intriguing why the virus is not neurovirulent in the human CNS. SINV has also 
been shown to replicate in human peripheral mononuclear cells (PBMC), decreasing cell adhesion [161]. 
Thus, it is highly possible that the virus is eliminated by  immune system before  entering the CNS as the 
virus was shown enter the brain through the hematogenous route in a mouse  model [3]. 
SINV triggered apoptosis of hNPCs 
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Several viruses actively induce apoptosis at late stages of infection, thus allowing the dissemination 
of progeny viruses, while avoiding host inflammatory and immune responses[295]. In a mouse model, 
NPCs are very susceptible to SINV induced apoptosis as cell death was detected as early as one day post 
infection [161]. It has been recently shown that certain viruses like CVB3 and CMV can either induce 
apoptosis in hNPCs thus achieve optimal viral dissemination[204, 221].  Consistent with these reports, we 
observed a strong induction of apoptosis in SINV infected hNPCs, as illustrated by an increase in the ac-
tive-caspase 3 positive cell population and protein expression at late stage of infection. Further validation 
of proliferation damage in hNPCs with progressive infection was obtained by EdU incorporation analysis, 
which clearly demonstrated that SINV impacted cell metabolism since there was a significant decrease in 
EdU uptake compared the uninfected control. Interestingly, we did not observe any reduction of cell cycle 
progression in hNPCs as the relative expression of PCNA was consistent even at a later time points of 
infection, indicating that cell cycle arrest does not contribute to the reduced NPC population following 
infection. This is in sharp contrast to the situation of JEV and RUBV infection of hNPCs in which both 
viruses attenuate cell proliferation by inducing cell cycle arrest. As mentioned in Chapter 3 discussion, 
inhibition of apoptosis is also a mechanism by which the virus sustains its replication in the infected cell. 
Thus, our studies with SINV and RUBV illustrated the difference of hNPCs response to different patho-
gens. Considering similarities between human NPCs and murine NPCs in their response to SINV infec-
tion, our study also emphasized virus induced apoptosis as a possible mechanism of diminishing the NPC 
pool following infection in the pathogenesis of encephalitis. 
SINV decrease expression of Nestin in hNPCs 
Next, we sought to determine if SINV impacted differentiation of hNPCs. However, as the virus 
almost depleted the hNPC pools in 2 days, it is thus impossible to initiate any type of differentiation in 
presence of the virus. But still, we were able to detect  a significant reduction of stemness marker Nestin 
expression in proliferating hNPCs after infection, indicating the virus infection triggered premature dif-
ferentiation of the cells or at least, abnormal neural precursor development. Reduced Nestin expression 
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has been highlighted in a recent relevant study: the researchers reported that a Sindbis virus vector ex-
pressing HIV envelope protein (SIN-HIVenv) could impair murine neural stem cell survival and expres-
sion of Nestin [120]. The role of HIVenv in damaging NPCs was  ruled out by other groups as it was  re-
ported that few apoptosis or TUNEL positive NPCs were detected following exposure of the  cells to ei-
ther a high concentration of gp120 or in the subgranular zone (SGZ) of gp120 transgenic mice[146, 199]. 
Thus, it is the SINV vector that disturbs Nestin expression observed in the   neural stem cells. Taking 
these studies together with ours, we showed that SINV impacts the multipotency of NPCs and therefore 
the proper development of CNS. Further studies should focus on determining if the reduced expression of 
Nestin is directly triggered by SINV or by a bystander effect and to characterize the cell lineage to which 
hNPCs tend to differentiate after SINV infection.  
SINV upset the dedicated balance of hNPCs cell signaling 
In last part of our study, we took advantage of the strong cell responses that SINV triggered to in-
vestigate cell signaling profile of hNPCs, which regulates their response to diverse pathogens.  
The JAK/STAT pathway plays a pivotal role in balancing hNPCs lineage specific differentiation. 
Activation of phosphorylated (Y705) STAT3 and the accumulation of this form inside cells is required for 
normal astrocyte differentiation[289]. The reduced pSTAT3 level in SINV infected hNPCs indicates that 
the virus probably impaired cell specific differentiation into this cell type. In addition, the pSTAT3 is also 
associated with expression of cytokines such as IL-6 in the developing CNS[296], thus, the pSTAT3 re-
duction could also be  a mechanism by which  SINV avoids inflammatory  responses in NPCs. Reduced 
pSTAT3 expression has also been reported in JEV infection of hNPCs[205]. 
Extracellular signal-regulated kinases (ERK1/2) participates in modulation of genes that regulate 
multiple cell events in neural progenitors: proliferation, differentiation, cell fate, and synaptic 
plasticity[297]. The protein also has been shown to regulate apoptosis in a pAKT independent manner in 
hNPCs[290]. In our study, w observed that SINV infection induced the phosphorylation of both ERK at 
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early time points p.i. and this phosphorylation was decreased later on, suggesting a  virus interplay with 
cellular apoptosis signaling with progression of infection, possibly to achieve  optimal replication and 
dissemination in culture. Consistent with our study, such changes of ERK1/2 expression upon SINV in-
fection was also reported in HMBCs [161]. Not uncommon, this important control center of cellular re-
sponses is differently employed to support the replication of several important human pathogenic RNA 
viruses including influenza virus, Ebola virus, hepatitis C virus and SARS coronavirus[298]. 
NF-kB is another central signaling molecule in hNPCs: in vivo, the protein regulates neural plas-
ticity, learning, memory, neuroprotection and neurodegeneration; in vitro, this molecule controls the pro-
liferation, migration, differentiation of hNPCs [299]. More importantly, NF-kB plays a central role in cel-
lular stress responses and in inflammation by controlling the expression of a network of inducers and ef-
fectors; in this way it defines the response  to a specific pathogen[300]. Suprisingly, our results showed 
that expression was not affected by SINV infection, an indication of lack of an inflammatory response 
during infection. In addition, the pro-apoptotic role of NF-kB may be compensated for by the significant 
decrease of pERK1/2/. Finally, the binding site of NF-kB is down stream of pSTAT3 on the target differ-
entiation regulator gene promoter, therefore, a modulation of NF-kB besides STAT3 maybe redundant for 
the virus. 
Interferon regulatory gene 3 (IRF3) mediates Type I-IFN induction and signaling. Type-I IFN sig-
naling was enhanced during hNPCs differentiation, suggesting maturation of the innate immune system 
during fetal development[301]. However, in our study, we did not observe any changes of IRF3 induction 
upon virus infection, implying a lack of IFN responses to SINV infection; but on the other hand, we may 
have simply verified the immaturity of innate immune system in hNPCs. The neuronal differentiation-
dependent Type I IFN activity and SINV susceptibility provides a plausible explanation for clinical ob-
servation that several neurotropic arbovirus infection are particularly severe in pediatric patients where 
immature neurons or NPCs  may be more susceptible to virus-induced damage due to reduced innate im-
mune responses, even in the setting of adequate systemic or local type I IFN production-[291]. 
133 
 
Conclusion 
Back to our original questions for this part of study: here we showed that (a) SINV establishes a 
productive infection to hNPCs induces massive apoptosis/ cell death and altered cell stem cell marker ex-
pression. This is in combination with the virus' ability to avoid cell inflammatory responses by upsetting 
specific cell signaling pathways and taking advantage of the hNPCs’ intrinsic immaturity in innate im-
mune system.  In the particular, the latter may contribute to the age dependence of neurological disease 
seen in the SINV-mouse model, (b) the robust and versatile signaling, proliferation and other cell re-
sponses of hNPCs to virus infection demonstrated that it is a good model for study pathogenesis of terato-
gens or other neurovirulent pathogens. (c) We are adding hNPCs as a novel type of human cells that are 
susceptible to SINV infection and have proved its cytopathic effect in stem cell lineages. Therefore, extra 
care should carry out when utilizing SINV vector for human disease gene therapy and stem cell infection.  
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Figure 5.1 hNPCs are highly susceptible to SINV infection. 
hNPCs were infected with SINV at an  m.o.i. of 1(A) At 4, 8,12,24, and 48 hours after infection, cells 
were immunostained with antibodies against tubulin (green) and the SINV nonstructural proteins (NAP, 
red).  Nuclei were counterstained with DAPI (blue). Bars: 10um. (B) Medium collected at the same time 
points was titered for infectious virus. Each data point is the average of duplicate titration from three ex-
periments. Error bars indicate SDs. (C) Based on SINV_NSP immunostaining as shown in figure 5.1, the 
percentage of infected hNPCs was determined at each time point. The results are the means of two inde-
pendent experiments; at least 200 cells from three different fields were counted at each time point.  Error 
bars indicate SDs. 
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Figure 5.2 Effect of SINV infection on hNPCs proliferation and undifferentiated phenotype. 
hNPCs were mock infected or infected with SINV (MOI = 1) (A) Cell proliferation was  analyzed by 
flow cytometry using an EdU incorporation assay. (B) At 48 hours after infection, expression of the stem-
ness marker Nestin as well as the apoptotic marker active caspase 3 was analyzed by flow cytometry. In 
both A and B, the experiments were repeated at least twice, two titrations per experiment. Error bars indi-
cate  SDs. *, statistical significance (P<0.05) compared to the mock infected control at same time point  
(C) Western Blot analysis of the expression of Nestin, active caspase 3 and proliferating cell marker 
PCNA during the infection time course. Each experiment was performed at least twice. A representative 
blot is shown. GAPDH: loading control. (D)Western Blot analyses of the expression of key innate im-
mune response regulators during SINV infection. The expression of cellular proteins that regulate key 
event during differentiation as well as early inflammation responses were analyzed during infection time 
course. Each experiment was performed at least twice. A representative blot was shown. GAPDH: load-
ing control.
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CHAPTER 6 : GENERAL CONCLUSION, SIGNIFICANCE AND FUTURE DIRECTION 
6.1 GENERAL CONCLUSIONS AND SIGNIFICANCE 
6.1.1 Working model for CRS and RUBV induced neurological diseases 
The overarching goal of this dissertation was to elucidate the mechanism underlying the develop-
ment of neurological abnormalities in CRS. Since the primary time in gestation when RUBV exhibits pro-
found teratogenicity (i.e, the first trimester) coincides with organogenesis in the developing fetus, the fa-
vored hypothesis is that alterations induced in infected fetal stem/progenitor cells ultimately affect organ 
development. The attractiveness of this hypothesis increased, especially in CNS complications, consider-
ing the recently developed “schizophrenia hypothesis” which stated that schizophrenia results from a dis-
ruption in programmed maturation of the brain in prenatal and early neonatal life [109]. Meanwhile, 
RUBV specific antibody can be detected in the CNS of infants with CRS for a prolonged time after birth 
and in PRP with onset of disease in the second-decade of life in individuals with CRS, indicating the in-
fectious process continues within in brain even after birth and that virus persistence may play an im-
portant role for the pathogenesis of RUBV-associated neurological diseases. Our model is that hNPCs are 
the major cell type that RUBV impacts in the developing of CNS. The cells support RUBV replication 
and persistence and therefore it serves as a reservoir for long-term  viral residence in brain  RUBV limits 
hNPCs cell doubling potential and deactivates the genetic program of cell death in infected cells, albeit in 
a small number of cells. Overall, however, this explains the general features of CRS-induced disease, 
namely reduced cell number and aberrations, but not to the extent that fetal death occurs, Since hNPCs 
still function in adult brain, it is highly possible that the depletion of hNPCs over the years would signifi-
cantly hamper the local brain tissue repair and regeneration ability and thus contribute partially to the later 
onset neurological diseases, such as autism or schizophrenia. Our model is also proposed in conjunction 
with the studies in this dissertation, which found that viral persistency may play an important role for the 
disease development: the non-productive replication of RUBV in hNPCs may serve as a mechanism to 
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avoid local cytokine/inflammatory responses in brain at early embryonic development. However, with the 
progressive maturity of adaptive immune response and increased humoral competency, virus can be de-
tected and therefore trigger massive immune responses that contribute to CRS late-onset diseases. The 
neuronal and glial cell damages could possibly be triggered by viral mediated demyelination (molecular 
mimicry between viral envelope protein and MOG) and cytokine mediated local necrosis. Our results may 
complement the clonal hypothesis by Simons (REF), which posits that viral persistence in congenital ru-
bella could be explained by the effect of many interacting factors: the intracellular location of RUBV may 
avoid the activity of specific antibodies; the impossibility of activating the genetic program of cell death 
by at least part of the infected cells during embryogenesis; the slower growth rate and limited doubling 
potential observed in clones of infected cells. 
6.1.2 hESC derived neural progenitors as a model to study viral teratogenesis 
Numerous attempts have been made to establish a model of RUBV and other teratogenic viruses 
both in vitro and in vivo. Overall, definitive conclusions cannot be drawn for mechanisms of teratogenesis 
of RUBV since none of the previous studies was performed in a human lineage that mimics early stages 
of fetal development. hNPCs derived from  hESCs presumably mimic the in utero progression from the 
pluripotent cells of the inner cell mass to differentiated neuronal phenotype. Thus, the first advantage of 
using such cells to study RUBV and other viral teratogens is that they well reflect the most important de-
velopmental events during first trimester of pregnancy the time period in which the fetus is most vulnera-
ble to the malformations. Indeed, in our study, the results of RUBV infection of hNPCs are consistent 
with earlier in vitro and in vivo CRS studies in brain suggesting that hNPCs provide a reliable model for 
RUBV-induced teratogenesis research. Another advantage we can obviously point out after all these ex-
periments is that: hESC derived hNPCs have uniform performance over proliferation and differentiation,  
However, this is hard to achieve in hNPCs isolated from abortuses; the performance of the cells largely 
depend on the gestational age of fetus and genetic background. Finally, the diverse cell responses  of 
hNPCs to different virus infections (SINV and RUBV in our study and VZV by Goldstein) supports that 
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hESC-derived progenitor cultures have potential broad application for detailed pathogenesis studies with 
RUBV and other clinically important teratogenic viruses.  
Taken together, our work demonstrates the utility of hESCs derived culture systems as a platform 
to study the interactions between embryonic development, virus infection and pathogenesis in CNS. Fu-
ture work should focus on broadening the genetic background of the cells, which can be achieved by em-
ploying other hESC lines and reprogramming cells of interested individuals (see NIH hESCs cell line reg-
istry for a complete list of hESC lines eligible for NIH funding). Also, additional work has to be done by 
stem cell biologists to further explore the multipotency of those progenitor cells such as to characterize 
specific lineages that can be derived from progenitor cells. Thus, moving to more efficient protocols for 
complete terminal differentiation of hNPCs would be a great step-forward in the field.  
6.1.3 Significance 
The work described in this dissertation adds to the expanding breath of knowledge concerning the 
CNS disorders associated with RUBV infection. It is important to continue this work, as important paral-
lels could be drawn between RUBV and other teratogenic/ neurotropic viruses in the pathogenesis of var-
ious brain anomalies. In comparison and contrast with another neurotropic virus, SINV, our study also 
illustrated how multiple factors come together to influence the final outcome of an infection in same type 
of cells therefore the neuropathological manifestations. It is intriguing that RUBV, although inducinng a 
wide spectrum of neurological disease throughout life of congenitally infected individuals is not particu-
larly neurovirulent to the brain. As similarly seen in VZV, this represents a category of neuropathologen-
esis associated with teratogenic viruses that requires further exploration. RUBV infected hNPCs could 
further serves as a model of chronic viral infections in perinatal/postnatal period which via disruptions of 
NPCs growth and neurogenesis, which might lead to the onset of neurovahavioral abnormalities. 
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6.2 FUTURE DIRECTIONS 
Although strides have been reported in this dissertation to understand the basis of RUBV terato-
genesis, more work need to be done to address the problem. We were able to demonstrate a limited repli-
cation of RUBV in hNPCs. However, little is known about the mechanism behind this phenomenon. The 
outcome of virus infection to a specific cell type is a combined result of virus-host interactions. Therefore, 
future studies should first focus on identifying cellular factors that restrict RUBV entry and/or limit viral 
replication. To this end, differences in global gene expression between the RUBV infected and uninfected 
hNPCs should be assayed and thus specific information as to mechanisms involved in the inability of 
RUBV to enter and replicate in hNPCs may be obtained. This experimental model may provide insight 
into the mechanisms and host factors required for the specificity of productive RUBV infection. In addi-
tion, it is also necessary to explore viral components that are subjected to this restriction. The exact step 
during RUBV cycle that is restricted by hNPCs will be first determined, for example: RUBV genome will 
be introduced into hNPCs directly by transfection to determine if viral entry is the case.   
Further investigation of the fate of infected hNPCs would be another extension of this study. Par-
ticularly, it would be interesting if we can capture and track the infection on a single cell basis. In this 
regards, state-of-the-art techniques may employed including laser-capture, living cell antigen staining, etc. 
Whether those infected cells retained this differentiation after RUBV goes persistent or gradually be se-
lected out ould thus be determined. In addition to that, it would also be interesting to investigate RUBV 
infection in terminally differentiated human neuronal and glial cell lines such as U87-MG and M059J to 
get a more comprehensive evaluation of RUBV replication in brain.   
Finally, to provide additional support to our final model, we would first expand the virus strains 
used to include clinical isolates and the cells used to include those from different genetic backgrounds. It 
is of critical importance of investigate the ability of RUBV   to infect pluripotent hESCs to see if RUBV-
induced teratogenesis includes infection of cells at a stage earlier than the precursor stage.
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Figure 6.1 Proposed model for RUBV teratogenesis in the central nervous system.
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